



National Surgical Antibiotic Prophylaxis Guideline (Singapore)

Developed by
The National Surgical Antibiotic Prophylaxis (SAP) Guideline Development Workgroup
of the National Antimicrobial Stewardship Expert Panel (NASEP)

Version 1.0

Published on 01 SEP 2022



Academy of
Medicine,
Singapore



College of
Anaesthesiologists,
Singapore



Chapter of Infectious
Disease Physicians
College of
Physicians,
Singapore



College of
Surgeons,
Singapore



National Centre for
Infectious Diseases



Contents

Acknowledgements	3
List of Abbreviations	5
Section 1: Introduction	6
Section 2: Guideline Statement	7
Section 3: Practice Points	8
Section 4: Recommendations for Surgical Antibiotic Prophylaxis	12
4.1. BREAST SURGERY	12
4.2. CARDIOTHORACIC AND VASCULAR SURGERY	14
4.3. GASTROINTESTINAL SURGERY	15
4.4. HEPATOBILIARY SURGERY	17
4.5. OBSTETRICS AND GYNAECOLOGY	19
4.6. ORTHOPAEDIC/SPINE SURGERY	21
4.7. OTORHINOLARYNGOLOGY	22
4.8. NEUROSURGERY	24
4.9. UROLOGICAL PROCEDURES	25
Section 5: Monitoring and Surveillance	29
Appendix A: Evidence Grading (Tabulation of Guidelines and Literature)	30
BREAST SURGERY	32
CARDIOTHORACIC AND VASCULAR PROCEDURES	35
GASTROINTESTINAL PROCEDURES	45
HEPATOBILIARY PROCEDURES	51
OBSTETRICS AND GYNAECOLOGY	58
ORTHOPAEDIC/SPINAL PROCEDURES	89
OTORHINOLARYNGOLOGY	96
NEUROSURGERY	107
UROLOGY	113
References	133

Acknowledgements

This Guideline was developed by the National Surgical Antibiotic Prophylaxis Guideline Development Workgroup of the NASEP, in consultation with the National Antimicrobial Resistance Control Committee (NARCC); the Chapter of Infectious Disease Physicians, College of Physicians, Singapore; College of Anaesthesiologists, Singapore; and College of Surgeons, Singapore under the Academy of Medicine, Singapore; and the National Centre for Infectious Diseases (NCID), Singapore.

We thank the following for their valuable contribution to this Guideline:

National Surgical Antibiotic Prophylaxis (SAP) Guideline Development Workgroup Panel:

Dr Jyoti Somani, Senior Consultant, Division of Infectious Diseases, Department of Medicine, National University Hospital (Workgroup Panel Lead); **Ms Chung Wei Teng, Gladys**, Senior Clinical Pharmacist, National University Hospital (Workgroup Panel Co-lead).

Changi General Hospital - **Dr Humaira Shafi**, Senior Consultant, Infectious Diseases; **Dr Jonathan Seah**, Senior Principal Clinical Pharmacist; **Dr Lee Wai Peng**, Consultant, Breast Surgery; **Dr Vincent Tay**, Associate Consultant, Plastic and Reconstructive Surgery; **Dr Noelle Lim**, Chief & Senior Consultant, Anaesthesia & Surgical Intensive Care

Khoo Teck Puat Hospital - **Dr Parthasarathy Purnima**, Senior Consultant, Department of General Medicine (Infectious Diseases); Director, ASP Program; **Mr Taweechai Patun**, Senior Clinical Pharmacist; **Dr Venkatesan Kumaresh**, Senior Consultant, Department of Anaesthesia; Director, Surgical Intensive Care Unit; **Dr Lau Weida**, Consultant, Department of Urology

KK Women's and Children's Hospital - **Dr Kam Kai-Qian**, Consultant, Department of Paediatric Medicine, Infectious Disease Service; **Dr Valerie Seah Xue Fen**, Principal Clinical Pharmacist; **Dr Rina Ong Yue Ling**, Principal Clinical Pharmacist; **Dr Shahul Hameed Mohamed Siraj**, Senior Staff Physician, Department of Minimally Invasive Surgery, Division of Obstetrics and Gynaecology

National University Hospital - **Dr Jyoti Somani**, Senior Consultant, Division of Infectious Diseases, Department of Medicine; **Ms Chung Wei Teng, Gladys**, Senior Clinical Pharmacist; **Dr Iyer Shridhar**, Senior Consultant & Head, Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery; **Dr Ng Li Shia**, Consultant, Department of Ortholaryngology - Head & Neck Surgery (ENT); **Dr Yanni Tan**, Consultant, Department of Anaesthesia

Ng Teng Fong General Hospital - **Dr Lin Li**, Senior Consultant, Infectious Diseases; **Mr Robin Choo Sing Meng**, Senior Clinical Pharmacist; **Dr Han Zhe**, Principal Clinical Pharmacist; **Adj. Asst. Prof. Low Shiong Wen**, Head of Division & Senior Consultant, Neurosurgery; **Dr Choo Wee-Sen**, Consultant, Anaesthesia

Sengkang General Hospital - **Dr Loh Jiashen**, Consultant, Department of Infectious Diseases (*Dec 2019-Dec 2020*); **Dr Pushpalatha Lingegowda**, Senior Consultant, Infectious Diseases, Department of General Medicine (*w.e.f. Dec 2020*); **Ms Cheryl Lim Li Ling**, Principal Clinical Pharmacist; **Mr Lim Fang Kang**, Senior Pharmacist; **Dr Huang Yilun**, Consultant, Department of Orthopaedic Surgery; **Dr Chau Keen Chong**, Senior Resident Physician, Department of Anaesthesiology

Singapore General Hospital - **Dr Jasmine Chung Shimin**, Director, Antimicrobial Stewardship Unit; Senior Consultant, Infectious Diseases; **Dr Nathalie Grace Sy Chua**, Specialist Pharmacist; **Prof Tan Teing Ee**, Head & Senior Consultant, Department of Cardiothoracic Surgery, National Heart Centre Singapore; **Prof Tan Seck Guan**, Senior Consultant, Vascular Surgery; **Dr Tay Yoong Chuan**, Director, Ambulatory Surgery Centre; Senior Consultant, Division of Anaesthesiology and Perioperative Medicine

Tan Tock Seng Hospital - **Dr Lee Tau Hong**, Consultant, Infectious Diseases; **Dr Ng Tat Ming**, Principal Pharmacist (Specialist); **Ms Yap Min Yi**, Senior Pharmacist (Clinical); **Dr How Kwang Yeong**, Consultant, General Surgery; **Adj Asst Prof Mandy Lim Pei Pei**, Senior Consultant, Intensive Care and Pain Medicine

External Reviewers:

Dr Nelson Chua Ping Ping, Specialist in Anaesthesiology & Intensive Care Medicine, Raffles Hospital; **Dr Leyland Chuang Lee Ren**, Co-Chairman Infection Control Committee and Specialist in Infectious Diseases, Raffles Hospital; **Dr Roy Kan Kum Chuen**, Specialist in Anaesthesiology & Intensive Care Medicine, Raffles Hospital; **Dr Asok Kurup**, Chairman, Chapter of Infectious Disease Physicians, College of Physicians, Singapore; Infectious Disease Physicians, Infectious Diseases Care Pte Ltd, Mount Elizabeth Medical Centre; **Dr Lee I Wuen**, Medical Director & Specialist in Obstetrics & Gynaecology, Raffles Hospital; **Dr Sheila Loh Kia Ee**, Specialist in Obstetrics & Gynaecology, Raffles Hospital; **Prof Paul Anantharajah Tambyah**, Senior Consultant, Division of Infectious Diseases, Department of Medicine, National University Hospital; Member, Chapter of Infectious Disease Physicians, College of Physician, Singapore; **Dr Shawn Vasoo**, Senior Consultant and Clinical Director; Head, Infectious Disease Research Laboratory, National Centre for Infectious Diseases

College of Anaesthesiologists, Dr Nelson Chua, President

College of Surgeons: Chapter of Cardiothoracic Surgeons, Dr Kenny Sin Yoong Kong, Chairman; **Chapter of General Surgeons**, Dr Aung Myint Oo @ Ye Jian Guo, Chairman; **Chapter of Hand Surgeons**, Dr Anthony Foo Tun Lin, Chairman; **Chapter of Neurosurgeons**, Dr Ng Yew Poh Vincent, Chairman; **Chapter of Orthopaedic Surgeons**, Dr Tay Keng Jin Darren, Chairman; **Chapter of Otorhinolaryngologists**, Dr Mok Kan Hwei, Paul, Chairman; **Chapter of Paediatric Surgeons**, Dr Loh Hong Pheng Amos, Chairman; **Chapter of Plastic, Reconstructive and Aesthetic Surgeons**, Dr Dr Kang Chun-Wui Gavin, Chairman; **Chapter of Urologists**, Dr Edmund Chiong, Chairman

Endorsed By:

Chapter of Infectious Disease Physicians, College of Physicians, Singapore

College of Anaesthesiologists, Singapore

College of Surgeons, Singapore

Academy of Medicine, Singapore

National Centre for Infectious Diseases (NCID), Singapore

Supported By:

Antimicrobial Resistance Coordinating Office (AMRCO), NCID

Citation Suggestion:

National Surgical Antibiotic Prophylaxis Guideline (Singapore). 2022.

<https://www.ncid.sg/Health-Professionals/Documents/NationalSAPGuidelineSingapore.pdf>

Enquiries:

Enquiries regarding this Guideline should be addressed to NASEP Secretariat at narcc_sec@ncid.sg

List of Abbreviations

ASHP	American Society of Health-System Pharmacists
BD	<i>Bis in die</i> (Latin), 2 times a day
BMI	Body Mass Index
CDC	Centers for Disease Control and Prevention, USA
C-section	Caesarean section
CSF	Cerebrospinal Fluid
ERCP	Endoscopic Retrograde Cholangio-Pancreatography
EVD	External Ventricular Drain
HSG	Hysterosalpingography
ICP	Intracranial Pressure
IDSA	Infectious Diseases Society of America
IM	Intramuscular
IUD	Intra-Uterine Device
IV	Intravenous
MBP	Mechanical Bowel Preparation
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
PCNL	Percutaneous Nephrolithotomy
PID	Pelvic Inflammatory Disease
PO	Per Oral (Oral Administration)
QDS	<i>Quater die sumendum</i> (Latin), 4 times a day
SAP	Surgical Antibiotic Prophylaxis
SHEA	Society for Healthcare Epidemiology of America
SIS	Surgical Infection Society
SSI	Surgical Site Infections
TDS	<i>Ter die sumendum</i> (Latin), 3 times a day
UTI	Urinary Tract Infection

Section 1: Introduction

Surgical Antibiotic Prophylaxis (SAP) refers to the administration of antimicrobials just prior to clean and clean-contaminated surgeries to prevent post-operative surgical site infections (SSI). An optimal SAP should be highly effective in preventing SSI. An ideal prophylactic antimicrobial regimen is (1) effective against the pathogens most likely to contaminate the surgical site, generally skin flora, (2) given in an appropriate dosage and at a time that achieves highest tissue concentration upon skin incision, (3) safe, and (4) administered for the shortest effective period to minimise adverse effects, the development of antimicrobial resistance, and costs.¹ Antimicrobials should be re-dosed if surgery is prolonged or there is significant blood loss to ensure adequate serum and tissue concentrations throughout the entire procedure.

Institutional SAP guidelines are in place at all public hospitals in Singapore but variations exist amongst them and adherence to these guidelines are not reported nationally. Point prevalence surveys on antimicrobial utilisation conducted by Singapore public hospitals in 2019 showed that the prophylactic use of antimicrobials for surgeries accounted for 10% of all antimicrobial agents prescribed. Of concern, 64% of these prophylactic antimicrobials were administered for more than 24 hours.

Current evidence indicates that SAP has no benefit when given beyond 24 hours, and may be associated with harm.^{1–3} SAP continued beyond 24 hours has been shown to be associated with increased risk of acute kidney injury and *Clostridioides difficile* infections.⁴ Unnecessarily long durations of SAP may also increase selective pressure favouring the emergence of multi-drug resistant organisms.⁵

SAP should be regarded as one of the components of an effective policy for the control of healthcare-associated infection (HAI). Based on the first national point prevalence survey conducted in public hospitals in Singapore, SSI were the second most common healthcare-associated infection after pneumonia, accounting for 17.3% of HAI.⁶

The establishment of the national SAP guideline for hospitals in Singapore may reduce the rate of SSI, while also reducing adverse events from prolonged courses of SAP, which would promote patient safety and address the problem of antimicrobial resistance.⁵

This Guideline provides SAP recommendations for elective, clean and clean-contaminated procedures in the following nine (9) surgical disciplines:

- i. Breast
- ii. Cardiothoracic and vascular
- iii. Gastrointestinal
- iv. Hepatobiliary
- v. Obstetrics and gynaecology
- vi. Orthopaedic/ spine
- vii. Otorhinolaryngology
- viii. Neurosurgery
- ix. Urology

Section 2: Guideline Statement

This National SAP Guideline (Singapore) provides evidence-based recommendations for the rational use of antibiotic prophylaxis – including recommended agent(s), dose, timing and duration for patients undergoing the more common surgical procedures.

This Guideline aims to align best practices nationally and provide a framework for audit and surveillance.

SAP is one of the important pillars in the prevention of SSI. The Workgroup Panel recognises the importance of other non-antimicrobial factors but discussion of these factors lies outside the scope of this Guideline.

The recommendations in this Guideline apply to elective clean and clean-contaminated procedures in the adult population.

- Clean: an incision in which no inflammation is encountered in a surgical procedure, without a break in sterile technique, and during which the respiratory, alimentary or genitourinary tracts are not entered.
- Clean-contaminated: an incision through which the respiratory, alimentary or genitourinary tract is entered under controlled conditions but with no contamination encountered.⁷

Individual healthcare institutions should also consider local resistance patterns of organisms and overall SSI rates at their respective sites when adopting these recommendations.

This Guideline does not cover the following:

- Treatment of infection in patients undergoing emergency surgery for contaminated or dirty wounds
- Antimicrobial prophylaxis for prevention of infective endocarditis
- Antimicrobial prophylaxis in patients with prosthetic implants undergoing dental surgery or other surgery that may cause bacteraemia
- Use of antiseptic for prevention of wound infection after elective surgery
- Administration of topical antibiotics in wound

This Guideline reflects current knowledge of antimicrobial prophylaxis in surgery. Given the dynamic nature of scientific information and technology, the Guideline will be subjected to periodic review, updating, and revisions as necessary.

Section 3: Practice Points

- SAP with the right antibiotic, dose and timing, has been found to be of benefit for most clean-contaminated, as well as in certain clean procedures where there are severe consequences of infection (for example, placement of prosthesis or implant).¹ SAP may not be required in clean, uncomplicated procedures not involving the placement of prosthesis or implants.
- Most SSI are caused by skin flora or from flora that may be found at the site of the organ being operated on (for example, gram-negative and anaerobic bowel flora for surgeries traversing the colon).
- Antimicrobial treatment is indicated for contaminated or infected wounds, and is not considered as surgical prophylaxis.

3.1. Antibiotic Choice

- The antimicrobial agent selected must cover the expected pathogen for the operative site and concentrate in high levels at the site prior to incision.
- Narrow-spectrum antimicrobial agents are preferred.
 - The association of some antimicrobial agents (third-generation cephalosporins, fluoroquinolones, clindamycin) with the increased risk of *C. difficile* infections and the development of multi-drug resistant colonisation or infections should be taken into consideration.^{8,9}
- The choice of the antimicrobial agent should take into account the local resistance patterns.
- The recommended antimicrobial prophylaxis for specific surgical procedures, along with alternatives for patients with severe penicillin allergy, are provided in **Section 4: Recommendations for Surgical Antibiotic Prophylaxis**

3.2. Administration Timing

- The optimal time for administration of most pre-operative doses is 30 to 60 minutes before surgical incision. The antibiotic should be infused completely prior to the incision.
- Specific agents (fluoroquinolones and vancomycin) which require longer infusion time, should be administered at least 1 hour before the incision.^{1,10,11} For emergency procedures when vancomycin cannot be infused due to limited time, teicoplanin is an effective option. Teicoplanin may be administered over 3 to 5 minutes or as a 30-minute infusion.^{12,13}

3.3. Methicillin-resistant *Staphylococcus aureus* (MRSA) Risk and Antimicrobial Coverage

- Screening and selective decolonisation of patients positive for MRSA have shown to prevent SSI.^{14–19} The Workgroup Panel recommends screening and decolonisation for patients who will be undergoing high-risk surgeries (cardiac, orthopaedic and neurosurgery with implant). Decolonisation without screening is not recommended as widespread use of mupirocin has been shown to promote resistance.¹⁴

- Vancomycin prophylaxis should be considered for patients with known MRSA colonisation or recent MRSA infection. This is recommended for (but not limited to) patients undergoing high risk surgeries.¹
- As vancomycin is less effective than cefazolin for preventing SSI caused by methicillin-susceptible *Staphylococcus aureus* (MSSA), consider adding cefazolin to vancomycin for prophylaxis in MRSA colonised patients.¹ This combination was shown to have lower SSI rates^{20–23}, though some studies showed a slightly higher risk of acute kidney injury.²⁴ The Workgroup Panel recommends the use of this combination in MRSA colonised patients, who undergo cardiac or orthopaedic (involving implants) procedures.

3.4. Antibiotic Dosing and Re-dosing Intervals

The recommended re-dosing intervals for commonly used antimicrobial agents are provided in Table 1.

Table 1: Recommended doses and re-dosing interval

Antibiotic	Adult dose	Re-dosing interval
IV cefazolin	2g or (3g if > 120kg)	Every 4 hours [†]
IV ceftriaxone	2g	Every 12 hours
IV metronidazole	500mg	Every 8-12 hours
IV clindamycin	600-900mg	Every 4-6 hours
IV vancomycin	15-20mg/kg	Every 8-12 hours [†]
IV/IM gentamicin	3-5mg/kg	NA
IV amoxicillin-clavulanic acid	1.2g	Every 4 hours [†]
IV/PO ciprofloxacin	400mg (IV), 500mg (PO)	Every 8-12 hours [†]
IV aztreonam	2g	Every 4 hours [†]

[†]Recommended doses and re-dosing intervals are based on normal renal function. Renal dose adjustment may be required.

- For aminoglycosides, once-daily dosing is recommended.
 - Gentamicin dosing regimens have been compared for prophylaxis in colorectal surgery. A single gentamicin dose of 5mg/kg was found to be more effective in SSI prevention than multiple doses of 1.5mg/kg given 8 hourly.²⁵
 - A large retrospective cohort study of surgical patients (n=1590) showed that the use of once-daily gentamicin was safe, with similar nephrotoxicity risk between gentamicin (2.5%) vs control (1.8%), $p=0.17$.²⁶
- Intra-operative re-dosing is required when:^{1,11,27–30}
 - The duration of the procedure exceeds two half-lives of the drug, or
 - There is excessive intra-operative blood loss (i.e., > 1500mL), or
 - There are extensive burns.
- Therapeutic drug monitoring for vancomycin and aminoglycosides is not required due to the short duration of prophylaxis. If these antibiotics are continued beyond the recommended duration for surgical prophylaxis, therapeutic drug monitoring should be initiated according to institutional guidelines.

3.5. Dosing in Obese Patients

- Obesity has been linked to an increased risk of SSI.^{31,32}
- For cefazolin, the recommended dose if weight is > 120kg is 3g instead of the usual 2g.¹
- For aminoglycosides use in obese patients (actual body weight is 20% above the ideal body weight), the dose is calculated based on patient's adjusted body weight (formula provided below).^{1,33,34}

<p style="text-align: center;">Adjusted body weight</p> <p style="text-align: center;">= Ideal body weight + 0.4 x (Total body weight – Ideal body weight)</p> <p>where</p> <p style="padding-left: 40px;">Ideal body weight (male) is 50 + 2.3 x (height in inches - 60)</p> <p style="padding-left: 40px;">Ideal body weight (female) is 45.5 + 2.3 x (height in inches - 60)</p> <p style="padding-left: 40px;">(1 inch = 2.54cm)</p>

- For vancomycin, it should be dosed at 15-20 mg/kg of actual body weight, with the first dose capped at 3g per dose.^{1,33,35–38}

3.6. Patients with Beta-lactam Allergy

- Beta-lactams, including cephalosporins, are the mainstay of SAP and have the highest efficacy. Studies have shown that patients with reported beta-lactam allergy have an increased odds of SSI, attributed to the receipt of second-line antimicrobial agents.^{39,40} Thus, patients with a history of beta-lactam allergy should have a detailed antibiotic and allergy assessment to determine if a true allergy exists, and to exclude any non-immunological adverse reaction (for example, diarrhoea, vomiting, non-specific rash).
- Patients with severe penicillin allergy should not receive a beta-lactam for surgical prophylaxis. These include patients with severe IgE-mediated reactions (i.e., anaphylaxis, urticaria, bronchospasm and angioedema), or non-IgE-mediated reactions (Steven-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome). Alternatives to beta-lactam antimicrobials are provided in **Section 4: Recommendations for Surgical Antibiotic Prophylaxis**.
- In patients with uncomplicated non-IgE-mediated allergic reaction to penicillin (i.e., maculopapular rash), cephalosporins (i.e., cefazolin or 3rd generation cephalosporins) can be considered after discussion with the patient and allergy team (if available). Cefazolin, in particular, has a unique R1 side chain that is distinct from other cephalosporins and beta-lactams, and its side chain cross-reactivity with other beta-lactams is not expected.^{41,42}

3.7. Patients receiving Therapeutic Antimicrobial for an Active Infection before Surgery

- If the antimicrobial agent used to treat the current infection is deemed appropriate for surgical prophylaxis, an extra dose should be administered within 60 minutes before the surgical incision.
- If the current antimicrobial agent is insufficient for surgical prophylaxis, additional cover per surgical prophylaxis guidelines is recommended.

- The need for re-dosing should be individualised and evaluated on a case-by-case basis.

3.8. Patients with prior Colonisation or Infection with Multi-drug Resistant Pathogens

- The causative link between carriage of multi-drug resistant organisms and the resultant SSI caused by these pathogens has not been established. Whether prophylaxis should be expanded to cover for these pathogens depends on many factors, including the host, the pathogen and its antimicrobial susceptibility profile, the procedure and the proximity of the reservoir of pathogen to the operative site.¹ These patients should be evaluated on a case-by-case basis.

3.9. Consideration for Formal Infectious Diseases Consultation

- Formal infectious diseases consultation should be considered for the following patients:
 - Patients who have contraindications to both the first and second line antibiotic prophylaxis regimen (i.e., complex allergy history, impaired renal function, etc.)
 - Patients with a recent history of colonisation and/or infection with multi-drug resistant organisms and who are undergoing high-risk procedures

3.10. Duration

- The duration of antimicrobial prophylaxis should not exceed 24 hours for most procedures.
 - A recent systematic review of 83 randomised controlled trials across various surgical subspecialties found no additional benefit from extending duration of prophylaxis as compared to immediate discontinuation. A pre-specified subgroup analysis in this study also showed that when best practice standards (defined as first dose within an hour of incision and appropriate re-dosing) were applied, prolonged antibiotic prophylaxis had no effect on the risk of SSI.⁴³
- In clean and clean-contaminated procedures, additional prophylactic antimicrobial agents should not be administered after the surgical incision is closed, even in the presence of a drain. This recommendation also applies to patients on systemic corticosteroids or other immunosuppressive therapy.^{1,33}
- Antibiotic is not required prior to insertion and removal of indwelling urinary catheters around elective procedures.
- Prolonged SAP beyond 24 hours has been shown to be associated with acute kidney injury and *C. difficile* infections.⁴ Such practice may also increase selective pressure favouring the emergence of multi-drug resistant organisms.⁵

Section 4: Recommendations for Surgical Antibiotic Prophylaxis

- Doses recommended are based on normal renal function. Renal dose adjustment may be required.
- The recommended duration of antimicrobial prophylaxis was graded according to the strength of the consolidated evidence. For procedures in which antimicrobial prophylaxis are not recommended, the strength of evidence represents the support against prophylaxis. The description of evidence base and grading of recommendation can be found in **Appendix A: Evidence Grading** (Tabulation of Guidelines and Literature).
- Refer to Section 3.6. for the definition of severe penicillin allergy.

4.1. BREAST SURGERY

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Breast cancer surgery without oncoplastic/reconstruction surgery	Not recommended <u>For patients with risk factors:</u> IV cefazolin 2g	Not recommended <u>For patients with risk factors:</u> IV clindamycin 600 - 900mg or IV vancomycin 15-20mg/kg	Single dose	Risk factors: 1. Post neo-adjuvant chemotherapy 2. Immunocompromised individuals	Level 1- (Grade B) 1,44,45
Breast cancer surgery with oncoplastic/reconstruction surgery	IV cefazolin 2g Followed by, 1-2g q8h	IV clindamycin 600 - 900mg Followed by, 600mg q8h or IV vancomycin 15-20mg/kg Followed by, 15mg/kg q12h	Up to 24 hours		Level 1+ (Grade A) 1,44-50
Breast lump excision biopsy Wire localisation excision biopsy	Not recommended	Not recommended	NA	If prophylactic antibiotic is used, it should not exceed single dose. Please refer to above choices if prophylactic antibiotic is used	Level 1- (Grade B) 1,44

Table 2: Recommended prophylaxis for breast surgeries

4.2. CARDIOTHORACIC AND VASCULAR SURGERY

Table 3: Recommended prophylaxis for cardiothoracic and vascular surgeries

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Cardiac (aortic dissection, CABG, TEVAR, valve repair or replacement, LVAD placement, permanent pacemaker/defibrillator insertion)	IV cefazolin 2g Followed by, 1-2g q8h <u>MRSA colonised:</u> IV cefazolin 2g + IV vancomycin 15-20mg/kg** Followed by, IV cefazolin 1-2g q8h + IV vancomycin 15mg/kg q12h	IV vancomycin 15-20mg/kg** Followed by, 15mg/kg q12h	24-48 hours	**IV vancomycin dose of 20mg/kg pre-operatively may be preferred to achieve sufficient tissue concentrations at the time of surgery ³⁶ At onset of bypass: May consider additional 1-2g of IV cefazolin via cardiopulmonary bypass circuit ⁵¹⁻⁵⁴	Level 1+ (Grade A) 1,55-63,5,4,64,65
Thoracic (decortication, lobectomy, thymectomy, VATS)	IV cefazolin 2g <u>MRSA colonised:</u> IV vancomycin 15-20mg/kg	IV clindamycin 600-900mg or IV vancomycin 15-20mg/kg	Single Dose		Level 1- (Grade B) 1,58,66-74
Vascular (artery or vein repair, AVF or AVG creation, excision, jump graft, aortic stent graft)	IV cefazolin 2g Followed by, 1-2g q8h <u>MRSA colonised:</u> IV vancomycin 15-20mg/kg Followed by, 15mg/kg q12h	IV clindamycin 600-900mg Followed by, 600mg q8h or IV vancomycin 15-20mg/kg Followed by, 15mg/kg q12h	Up to 24 hours		Level 1- (Grade B) 1,58,75-83
Cardiac or Vascular (angioplasty, stent insertion)	Not recommended	Not recommended	NA		Level 3 (Grade D) 1,58,75,84-87

*CABG: coronary artery bypass grafting; TEVAR: thoracic endovascular aortic repair; LVAD: left ventricular assist device; VATS: video-assisted thoracoscopic surgery; AVF: arteriovenous fistula; AVG: arteriovenous graft

4.3. GASTROINTESTINAL SURGERY

Table 4: Recommended prophylaxis for gastrointestinal surgeries

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Appendectomy	IV cefazolin 2g + IV metronidazole 500mg or IV ceftriaxone 2g + IV metronidazole 500mg or IV amoxicillin-clavulanic acid 1.2g	IV gentamicin 5mg/kg + IV metronidazole 500mg or IV gentamicin 5mg/kg + IV clindamycin 600-900mg^	Single dose		Level 1+ (Grade A) 1,88,89
Gastroduodenal and oesophageal	IV cefazolin 2g or IV ceftriaxone 2g or IV amoxicillin-clavulanic acid 1.2g	IV gentamicin 5mg/kg +/- IV clindamycin 600-900mg	Single dose		Level 1+ (Grade A) 1,58,90–94
Small bowel	IV cefazolin 2g + IV metronidazole 500mg or IV ceftriaxone 2g + IV metronidazole 500mg or IV amoxicillin-clavulanic acid 1.2g	IV gentamicin 5mg/kg + IV metronidazole 500mg or IV gentamicin 5mg/kg + IV clindamycin 600-900mg^	Single dose		Level 1+ (Grade B) 1,33
Colorectal	IV cefazolin 2g + IV metronidazole 500mg or	IV gentamicin 5mg/kg + IV metronidazole 500mg or	Single dose		Level 1++ (Grade A) 1,25,95–97

		IV ceftriaxone 2g + IV metronidazole 500mg or IV amoxicillin-clavulanic acid 1.2g	IV gentamicin 5mg/kg + IV clindamycin 600-900mg^			
		To be used only in conjunction with mechanical bowel preparation (MBP) (if given): PO neomycin sulfate 1g + PO erythromycin base 1g or PO neomycin sulfate 1g + PO metronidazole 1g		Three doses in conjunction with MBP over approximately 10 hours the day before operation (e.g. between 1pm to 11pm)	Need for MBP + PO prophylaxis to be decided by individual institution	Level 1++ (Grade B) 1,98–100
Hernia repair	Hernioplasty (i.e., with mesh placement)	IV cefazolin 2g	IV vancomycin 15mg/kg	Single dose	Recommendations for prophylaxis mainly derived from studies on inguinal/femoral hernia repairs. Mixed outcomes for other types of hernias and studies were often of poor quality.	Level 1++ (Grade B) 101–107
	Herniorrhaphy (i.e., no mesh placement)	Not recommended	Not recommended	NA		Level 1++ (Grade A) 58,102,103

^Note: Clindamycin resistance has been increasing in *Bacteroides* species. Metronidazole may be preferred if the procedure transverses the lower gastrointestinal tract.

4.4. HEPATOBILIARY SURGERY

Table 5: Recommended prophylaxis for hepatobiliary surgeries

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Biliary tract surgery	IV cefazolin 2g or IV ceftriaxone 2g or IV amoxicillin-clavulanic acid 1.2g	IV clindamycin 600-900mg or IV vancomycin 15-20mg/kg + IV gentamicin 5mg/kg or IV aztreonam 2g	Single dose	It is reasonable to give a single dose of prophylaxis to patient undergoing laparoscopic cholecystectomy although evidence showed that antibiotic is not required for low-risk patients. This is because some of these risk factors cannot be determined prior to surgery.	Level 1+ (Grade A) 1,108–111
Hepatectomy	IV cefazolin 2g, Followed by, 1-2g 8h or IV ceftriaxone 2g once	IV clindamycin 600-900mg or IV vancomycin 15-20mg/kg + IV gentamicin 5mg/kg or IV aztreonam 2g	Up to 24 hours	If procedure is expected to involve the lower gastrointestinal tract, consider adding anaerobic coverage	Level 1+ (Grade A) 112–116
Splenectomy or left sided pancreatic surgery	IV cefazolin 2g	IV vancomycin 15-20mg/kg	Single dose	There is no need to extend antibiotic duration for patients who are not immunised. Administer the appropriate immunisations	GPP
Whipple's operation (no recent biliary intervention/stenting)	IV cefazolin 2g, Followed by, 1-2g 8h or IV ceftriaxone 2g once	IV clindamycin 600-900mg or IV vancomycin 15-20mg/kg +	Up to 24 hours	For patients with recent biliary intervention/stenting, there is a higher incidence of bacterobilia with ESBL-	Level 2+ (Grade C) 1,117–122

	or IV amoxicillin-clavulanic acid 1.2g Followed by, 1.2g 8h	IV gentamicin 5mg/kg or IV aztreonam 2g		producing organisms. Antibiotic should be tailored according to in-house antibiogram or recent bile/ blood cultures from the patient	
Endoscopic retrograde cholangio- pancreatography (ERCP)	Not recommended except in cases of incomplete biliary drainage or obstructive biliary tract disease IV cefazolin 2g or IV ceftriaxone 2g	Not recommended except in cases of incomplete biliary drainage or obstructive biliary tract disease IV gentamicin 5mg/kg	Single dose	Antibiotic prophylaxis for ERCP was shown to increase the proportion of resistant bacteria ^{123–125}	Level 1+ (Grade A) <small>126–130</small>

4.5. OBSTETRICS AND GYNAECOLOGY

Table 6: Recommended prophylaxis for obstetrics and gynaecology surgeries

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Caesarean section (C-section)	IV cefazolin 2g	IV clindamycin 900mg	Single dose	Continuation of antimicrobial prophylaxis (up to 2 days) may be considered for patients with major risk factors for surgical infections, e.g., obesity (Body mass index (BMI) ≥ 30)	Level 1- (Grade B) 1,131–162
Normal vaginal delivery (Non-operative/instrumental)	Not recommended	Not recommended	NA	Antibiotic prophylaxis may be considered in the setting of a third- or fourth-degree perineal laceration Group B Streptococcus (GBS) and preterm premature rupture of membranes (PPROM) prophylaxis are excluded in this guideline.	Level 1- (Grade B) 135,163–178
Normal vaginal delivery (Operative/instrumental)	IV amoxicillin-clavulanic acid 1.2g	IV clindamycin 900mg	Single dose after delivery		
Hysterectomy Abdominal/ vaginal/ laparoscopic	IV cefazolin 2g + IV metronidazole 500mg	IV clindamycin 900mg + IV gentamicin 5mg/kg	Single dose		Level 2- (Grade C) 1,134,179–202
Hysteroscopy	Not recommended	Not recommended	NA	Risk of infection is very low, antibiotic prophylaxis generally not necessary unless high risk e.g.: dilated fallopian tubes, history of pelvic inflammatory disease (PID), tubal damage or abnormal tubal architecture (associated with risk of post-operative PID/ endometritis). If	Level 1- (Grade B) 1,134,179–182,203–213
Hysterosalpingography (HSG)	Not recommended	Not recommended	NA		Level 2- (Grade C) 134,179,180,214

				evidence of endometritis/ infection found at point of procedure, treat accordingly	
Endometrial biopsy, cervical tissue excision, cervical cone procedures	Not recommended	Not recommended	NA	NA	Level 2- (Grade C) 134,179,180,212,215–219
Intra-uterine device (IUD) insertion	Not recommended	Not recommended	NA	Consider sexually transmitted infections (STI) screen in high-risk populations and advise to complete treatment prior procedure.	Level 1+, (Grade A) 134,179,180,220–227

4.6. ORTHOPAEDIC/SPINE SURGERY

Table 7: Recommended prophylaxis for orthopaedic/spine surgeries

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Clean orthopaedic, non-spinal procedure with no implantation (arthroscopy, tendon repair surgery)	Not recommended <u>For patients with risk factors</u> IV cefazolin 2g <u>MRSA colonised:</u> IV cefazolin 2g +/- IV vancomycin 15-20mg/kg	Not recommended <u>For patients with risk factors</u> IV vancomycin 15-20mg/kg or IV clindamycin 600-900mg	Single dose	Risk factors include dermatological conditions, predicted prolonged operative time, malnutrition, immunosuppressant use and poorly controlled diabetes mellitus ^{58,228,229}	1- (Grade B) 1,58,230,231
Clean orthopaedic surgery with implants Wrist arthroplasty	IV cefazolin 2g Followed by, 1-2g q8h <u>MRSA colonised:</u> IV cefazolin 2g + IV vancomycin 15-20mg/kg Followed by, IV cefazolin 1-2g q8h + IV vancomycin 15mg/kg q12h	IV vancomycin 15-20mg/kg Followed by, 15mg/kg q12h or IV clindamycin 600-900mg Followed by, 600mg q8h	Up to 24 hours		1++ (Grade A) 1,58,230,33,232–240
Spine surgery (with and without implants)	IV cefazolin 2g Followed by, 1-2g q8h <u>MRSA colonised:</u> IV cefazolin 2g + IV vancomycin 15-20mg/kg Followed by, IV cefazolin 1-2g q8h + IV vancomycin 15mg/kg q12h	IV vancomycin 15-20mg/kg Followed by, 15mg/kg q12h or IV clindamycin 600-900mg Followed by, 600mg q8h	Up to 24 hours		1++ (Grade A) 1,2,58,241–247

4.7. OTORHINOLARYNGOLOGY

Table 8: Recommended prophylaxis for otorhinolaryngology procedures

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Comments	Level of Evidence (Grade)
Clean head and neck (thyroidectomy, parotidectomy, salivary gland excisions)	Not recommended	Not recommended	NA		1+ (Grade A) 1,248–251
Clean-contaminated head and neck Neck dissection procedures	IV amoxicillin-clavulanic acid 1.2g q8h or IV cefazolin 2g q8h + IV metronidazole 500mg q8h	IV clindamycin 600-900mg q8h +/- IV gentamicin 5mg/kg once*	Up to 24 hours	Prolonged course of oral antibiotics has not been shown to reduce post-operative infections and may increase the risk of complications	1+ (Grade A) 1,248,252–266 For neck dissection: 2+ (Grade C) 267–269
Clean otologic procedures	Not recommended	Not recommended	NA		1+ (Grade A) 248,270–273
Clean-contaminated otologic procedures	IV amoxicillin-clavulanic acid 1.2g q8h or IV cefazolin 2g q8h + IV metronidazole 500mg q8h	IV clindamycin 600-900mg q8h +/- IV gentamicin 5mg/kg once*	Up to 24 hours		1- (Grade B) 248,270–273
Specific Procedures					
Tonsillectomy	Not recommended	Not recommended	NA		1+ (Grade A) 1,248,274,275
Simple Septorhinoplasty	Not recommended	Not recommended	NA	Infection rates are very low, especially when	1- (Grade B)

				nasal packing/splint use ≤ 48 hours	248,276–279
Complex Septorhinoplasty	IV amoxicillin-clavulanic acid 1.2g q8h or IV cefazolin 2g q8h + IV metronidazole 500mg q8h	IV clindamycin 600-900mg q8h +/- IV gentamicin 5mg/kg once*	Up to 24 hours		1- (Grade B) 248,276–279
Endoscopic sinus surgery	IV amoxicillin-clavulanic acid 1.2g or IV cefazolin 2g + IV metronidazole 500mg	IV clindamycin 600-900mg +/- IV gentamicin 5mg/kg*	Single dose	Post-operative antibiotics should not be given if there is no mucous seen intra-operatively	1- (Grade B) 1,248,280–283

*Note: The addition of gentamicin may be appropriate when there is an increased likelihood of gram-negative contamination of surgical site.

4.8. NEUROSURGERY

Table 9: Recommended prophylaxis for neurosurgery

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Comments	Level of Evidence (Grade)
Clean wounds [Elective craniotomy, external ventricular drain (EVD), intracranial pressure (ICP) monitors]	IV cefazolin 2g <u>MRSA colonised:</u> IV vancomycin 15-20mg/kg	IV vancomycin 15 - 20mg/kg or IV clindamycin 600-900mg	Single dose*		1+ (Grade A) 1,284–287 For EVD and ICP: 2++ (Grade B) 288–293
Clean wounds with foreign body or instrumentation [cerebrospinal fluid (CSF) shunting procedures]	IV cefazolin 2g <u>MRSA colonised:</u> IV vancomycin 15-20mg/kg	IV vancomycin 15 - 20mg/kg or IV clindamycin 600-900mg	Single dose*		1+ (Grade A) 1,284,294–296

*Note: While single-dose prophylaxis is usually sufficient, the duration of prophylaxis for all procedures should be less than 24 hours.

4.9. UROLOGICAL PROCEDURES

Note:

- If antibiotic prophylaxis is indicated and there is a pre-operative urinary culture, the antibiotic choice should be tailored accordingly.
- Institutions should review their local resistance patterns to select the most optimal antibiotic prophylaxis. Generally, amoxicillin-clavulanic acid is recommended as an option for patients with renal impairment. Ceftriaxone may be used in patients with uncomplicated non-IgE mediated penicillin allergy and renal impairment. The association of third-generation cephalosporins and fluoroquinolones with the increased risk of *C. difficile* infections and the development of multi-drug resistant colonisation should be taken into consideration.^{8,9}
- Other aminoglycosides (i.e., amikacin) may be an alternative to gentamicin. The choice of the antimicrobial agent should take into account the local resistance patterns. Caution is recommended in the use of aminoglycosides for patients at risk for acute renal failure (i.e., urinary tract obstruction or requiring nephrectomy).

Table 10: Recommended prophylaxis for urological procedures

Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
Lower Urinary Tract Instrumentation					
Cystourethroscopy					
-With or without minor manipulation, and without significant break in mucosal barriers	Not recommended, except in those with risk factors, to manage as transurethral cases (refer below)	Not recommended, except in those with risk factors, to manage as transurethral cases (refer below)	NA	If urine culture shows no growth prior to the procedure, antimicrobial prophylaxis is not necessary	1+ (Grade A) 297–299
-With significant break in mucosal barriers/ significant manipulation	To manage as transurethral cases (refer below)			Risk factors: poor functional status/frailty, anatomic anomalies of urinary tract, chronic steroid use, immunocompromising condition or recent systemic chemotherapy, poorly controlled diabetes mellitus, prior severe urosepsis	
Transurethral cases and minimally invasive	IV/IM gentamicin 3-5mg/kg or	IV/IM gentamicin 3-5mg/kg or	Single dose		1+ (Grade B)

surgical therapy (MIST) to the prostate	IV amoxicillin-clavulanic acid 1.2g or IV ceftriaxone 2g	PO ciprofloxacin 500 mg/IV 400 mg^^			1,58,297,299,300
Transrectal prostate biopsy	PO ciprofloxacin 500 mg + IV/IM gentamicin 3-5 mg/kg or IV amoxicillin-clavulanic acid 1.2g/ PO 625mg + IV/IM gentamicin 3-5 mg/kg or IV ceftriaxone 2g	PO ciprofloxacin 500 mg + IV/IM gentamicin 3-5 mg/kg	Up to 48 hours	For PO ciprofloxacin, dose 1-2 hours before the procedure For PO amoxicillin-clavulanic acid, dose 24 hours before the procedure	1+ (Grade A) 1,297,299,301–306
Transperineal procedures e.g. Prostate brachytherapy, transperineal prostate biopsy	Not recommended	Not recommended	NA	Prophylaxis may be recommended in patients with risk factors (chronic steroid use, immunocompromising condition or recent systemic chemotherapy, poorly controlled diabetes mellitus), prior severe urosepsis or post-biopsy infection. (Antibiotic choice: PO cephalosporins or amoxicillin-clavulanic acid 2 hours before the procedure)	2+ (Grade C) 297,307–309
Upper Urinary Tract Instrumentation					
Percutaneous renal surgery, e.g. percutaneous	IV cefazolin 2g + IV gentamicin 3-5mg/kg or	IV gentamicin 3-5mg/kg + IV clindamycin 600-900mg or IV gentamicin 3-5mg/kg +	Single dose		1+ (Grade A) 58,297,299,310

nephrolithotomy (PCNL)	IV amoxicillin-clavulanic acid 1.2g or IV ceftriaxone 2g	IV vancomycin 15-20mg/kg			
Ureteroscopy (including laser lithotripsy)	IV gentamicin 3-5mg/kg or IV amoxicillin-clavulanic acid 1.2g or IV ceftriaxone 2g	IV gentamicin 3-5mg/kg or PO ciprofloxacin 500 mg/ IV 400 mg^^	Single dose		1 ⁺ (Grade A) 58,297,299,310,311
Open, Laparoscopic Or Robotic Surgery					
Urethroplasty; Reconstruction anterior urethra, stricture repair, including urethrectomy; Controlled entry into the urinary tract e.g. renal surgery, nephrectomy, ureterectomy, pyeloplasty, radical prostatectomy; partial cystectomy	IV cefazolin 2g + IV gentamicin 3-5mg/kg or IV amoxicillin-clavulanic acid 1.2g or IV ceftriaxone 2g	IV gentamicin 3-5mg/kg + IV clindamycin 600-900mg or IV gentamicin 3-5mg/kg + IV vancomycin 15-20mg/kg	Single dose	Consider pre-operative urine cultures and treat accordingly For buccal mucosal graft, consider adding anaerobic coverage	2 ⁺ (Grade B) 297,310,311
Urinary diversion involving small or large bowel	IV cefazolin 2g + IV gentamicin 3-5mg/kg + IV metronidazole 500mg or IV amoxicillin-clavulanic acid 1.2g	IV gentamicin 3-5mg/kg + IV metronidazole 500 mg or IV gentamicin 3-5mg/kg + IV clindamycin 600-900mg	Single dose	Metronidazole may be optional for small bowel surgery.	2 ⁻ (Grade C) 297,312

	or IV ceftriaxone 2g + IV metronidazole 500mg				
Implanted prosthetic devices: AUS, IPP, sacral neuromodulators	IV cefazolin 2g + IV gentamicin 3-5mg/kg or IV amoxicillin-clavulanic acid 1.2g or IV ceftriaxone 2g <u>MRSA colonized:</u> IV vancomycin 15-20mg/kg	IV vancomycin 15-20mg/kg + IV aztreonam 2g or IV clindamycin 600-900mg + IV gentamicin 3-5mg/kg	Single dose		4 (GPP) 1,58,297
Others					
Urodynamic study Penile surgery Shock-wave lithotripsy**	Not recommended except in those with risk factors (see cystourethroscopy section)	NA	NA	**For shock-wave lithotripsy, consider antibiotic prophylaxis (single dose IV gentamicin or IV ceftriaxone) only if high risk of infection e.g. infected stones, recent instrumentation, nephrostomy tubes, positive urine culture, or history of recent urinary tract infection/sepsis	1+ (Grade A) 1,297,299,313

*AUS: Artificial urinary sphincter; IPP: Intravesical prostatic protrusion

^^ Due to the high local resistance of gram-negative organisms to quinolones, this is only recommended if the organism is shown to be sensitive in the pre-operative urine culture.

Section 5: Monitoring and Surveillance

The Workgroup Panel recommends the following indicators for monitoring and audit:

Process measures:

- The choice, dosage, and route of administration of antimicrobial agent is consistent with national guideline.
- The first dose of prophylaxis is given at the right time in relation to the incision time.
- Re-dosing of antimicrobial agent is consistent with the national guideline.
- The duration of prophylaxis is consistent with the national guidelines.

Data on the choice and duration of SAP in public hospitals are collected annually through the Antimicrobial Utilisation-Point Prevalence Survey (AMU-PPS). The above additional process measures may be incorporated into the AMU-PPS to provide useful information to improve antimicrobial stewardship initiatives.

Appendix A: Evidence Grading (Tabulation of Guidelines and Literature)

Approach

The Workgroup Panel adopted the ADAPTE methodology framework³¹⁴ with modifications in the development of the Guideline. Members of the Workgroup Panel aimed to ensure validity, reliability, and applicability of the Guideline for the local setting. The draft document for each surgical procedure was circulated and reviewed by the Workgroup Panel, together with anaesthesia and surgical representatives from the public acute hospitals.

Evidence Base and Grading of Recommendation

The primary literature published through December 2020 were identified by searches of PubMed® and the Cochrane Database of Systematic Reviews. The studies from the literature search, together with published international guidelines [e.g., American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), National Institute for Health and Care Excellence (NICE) and the US Centers for Disease Control and Prevention (CDC)] were reviewed in detail. Particular attention was paid to the study design, with greatest credence given to systematic reviews, meta-analyses and randomised, controlled, double-blinded studies.

The recommended duration of antimicrobial prophylaxis was graded according to the strength of consolidated evidence, applying scoring system of the MOH Clinical Practice Guidelines. For the procedures in which antimicrobial prophylaxis is not recommended, the strength of evidence represents the support against prophylaxis. The strength of evidence does not apply to the choice of antimicrobial agent or dosage regimen. Studies supporting the recommended duration were classified as follows:

Table A-1: Levels of evidence

Level	Type of Evidence
1⁺⁺	High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias
1⁺	Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1⁻	Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2⁺⁺	High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2⁺	Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2⁻	Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3	Non-analytic studies, e.g. case reports, case series
4	Expert opinion

Table A-2: Grades of recommendation

Grade	Recommendation
A	At least one meta-analysis, systematic review of RCTs, or RCT rated as 1 ⁺⁺ and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1 ⁺ , directly applicable to the target population, and demonstrating overall consistency of results

B	A body of evidence including studies rated as 2 ⁺⁺ , directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1 ⁺⁺ or 1 ⁺
C	A body of evidence including studies rated as 2 ⁺ , directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2 ⁺⁺
D	Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2 ⁺
GPP (good practice points)	Recommended best practice based on the clinical experience of the guideline development group

BREAST SURGERY

Guidelines

Table A-3: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence (Grade)
ASHP, IDSA, SIS, and SHEA ¹	Plastic surgery and breast procedures (Clean with risk factors or clean-contaminated)	Cefazolin, ampicillin-sulbactam	IV clindamycin or IV vancomycin ± gram-negative cover (aztreonam, gentamicin, fluoroquinolone) if gram-negative infections highly suspected	≤ 24 hours (regardless of presence of indwelling catheters or drains)	Antimicrobial prophylaxis does not significantly decrease the risk of infection for clean procedures (including reduction mammoplasty, lumpectomy, mastectomy, axillary node dissection)	Grade C (graded based on the need for prophylaxis)
ASBrS ⁴⁴	Breast Surgery	First-generation cephalosporin (unless the patient is allergic or has a history of prior infection with MRSA)	Not stated	≤ 24 hours	<p>1. Indicated for mastectomy, with or without any type of axillary dissection or reconstruction</p> <p>2. May be used for partial mastectomy for cancer, with or without sentinel lymph node biopsy or axillary dissection</p> <p>3. May be used for simple surgical excisional biopsy, especially if specific patient or clinical risk factors for SSI are present</p>	Not graded
ASPS ⁴⁶	Implant-based reconstruction after mastectomy	Not stated	Not stated	≤ 24 hours (unless a drain is present)	Unless a drain is present, antibiotics should be discontinued within 24 hours of the completion of the procedure. If a drain is present, the role of antibiotics is less clear and should be left to physician judgement	Level 4 (Grade D)

***ASBrS**: The American Society of Breast Surgeons; **ASPS**: American Society of Plastic Surgeons

Literature

Table A-4: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
45	Systematic review (Cochrane 2019)	11 RCTs 2,867 patients	Surgery for breast cancer Pre- (within 24 hours prior to surgery) or peri-operative antibiotics (given between commencement of induction of surgery and the patient leaving the recovery room)	Pre-operative prophylactic antibiotics probably reduced the incidence of SSI for patients undergoing breast cancer surgery without reconstruction (pooled risk ratio (RR) 0.67, 95% CI 0.53 to 0.85)	Antibiotic regimens used varied across studies, which encompassed a variety of surgeries. Most studies had a single prophylactic antibiotic dose	1+	A
47	Systematic review (Phillips 2016)	5 clinical studies and 2 systematic reviews	Implant-based breast reconstruction Antibiotic prophylaxis of varying durations	The literature does not support prolonged (>24 hours) post-operative antibiotic use in autologous breast reconstruction. The authors' opinion is that at least 24 hours of antibiotic prophylaxis is warranted following mastectomy with expander or implant-based reconstruction. Level I evidence suggests that 24 hours is not inferior to prolonged antibiotics, and therefore limiting post-operative antibiotic use to 24 hours is recommended Patient-centered antibiotic prophylaxis based on a risk-assessment model may be a more effective alternative	The study states conflicting information from medical literature on duration, and concludes that further studies are needed	1-	B
48	Systematic review and meta-analysis (Wang 2016)	4 cohort studies, 1 RCT	Immediate prosthetic breast reconstruction Prolonged prophylactic antibiotics (>24 hours) vs antibiotics within 24 hours	>24 hours vs 24 hours Surgical-site infections: 14% vs 19% Pooled relative risk of implant loss was 1.17 (95% CI 0.39 to 3.6) with less than 24 hours of antibiotics, not statistically significant	Significant heterogeneity between studies	1-	B
49	Non-inferiority RCT USA	112 patients	Tissue-expander-based immediate breast reconstruction.	SSI: 24 hours (12/62) vs >24 hours (11/50) (19.4% vs 22.0%, $p=0.82$)		1+	A

	(Phillips 2016)		All received cefazolin (or clindamycin if allergic). Compared 24 hours of IV antibiotic post-operative vs continuing oral antibiotics until all drains removed	Less patients in 24-hour group had implant loss		
50	Cohort study USA (Drury 2016)	1036 patients	Autologous breast reconstruction Prolonged prophylactic antibiotics (>24 hours) vs antibiotics <24 hours	SSI: Prolonged vs 24 hours (2.92% vs 5.01%, $p=0.109$)	2+	C

CARDIOTHORACIC AND VASCULAR PROCEDURES

Cardiac Surgeries

Guidelines

Table A-5: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
ASHP, IDSA, SIS, SHEA ¹	Cardiac surgeries	IV cefazolin or IV cefuroxime <u>If MRSA colonised:</u> IV Vancomycin ± gram-negative cover (aztreonam, aminoglycoside, fluoroquinolone) if high incidence of gram-negative infections	IV clindamycin or IV vancomycin ± gram-negative cover (aztreonam, aminoglycoside, fluoroquinolone) if high incidence of gram-negative infections	≤ 24 hours		A
STS ^{55,56}	Cardiac surgeries	IV cefazolin 2g <u>MRSA colonised/ high MRSA prevalence/ valve surgery or vascular implants:</u> IV cefazolin + single dose IV vancomycin	IV vancomycin 1-1.5g or 15mg/kg ± single dose IV gentamicin (or other gram-negative cover)	≤ 48 hours		Class IIa, Level B
EACTS ⁵⁷	Cardiac Surgeries	IV cefazolin or IV cefuroxime <u>If MRSA colonised:</u> IV Vancomycin	IV clindamycin or IV vancomycin	24-48 hours		Class IIa, Level A
SAAGAR ⁵⁸	Coronary artery bypass graft	IV cefazolin 2g <u>If MRSA colonised:</u> IV cefazolin 2g + IV vancomycin 1g (1.5g if weight >80kg)	IV vancomycin 1g (1.5g if weight >80kg) + IV gentamicin 5mg/kg	24 hours		No grading of evidence as this guideline cited other guidelines
	Routine cardiac valve surgery	IV cefazolin 2g + IV vancomycin 1g (1.5g if weight >80kg) (regardless of MRSA status)	IV vancomycin 1g (1.5g if weight >80kg) + IV gentamicin 5mg/kg	24 hours		
	High risk cardiac valve surgery, Transcatheter aortic valve implantation	IV cefazolin 2g + IV vancomycin 1g (1.5g if weight >80kg) ± IV gentamicin 5mg/kg (regardless of MRSA status)	IV vancomycin 1g (1.5g if weight >80kg) + IV gentamicin 5mg/kg	24 hours		

***STS**: Society of Thoracic Surgeons; **EACTS**: European Association of Cardio-Thoracic Surgery; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance

Literature

Table A-6: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
59	Meta-analysis (North America, Europe, Australia)	12 RCTs 7,893 patients	Open heart cardiac surgery Any antibiotic prophylactic regimen: Compared <24 hours vs ≥24 hours	Sternal SSIs: prophylaxis ≥24 hours reduced SSI rates by 38% (RR 1.38, 95% CI 1.13–1.69, $p=0.002$)	Antibiotic regimens used varied across studies	1 ⁺	
60	RCT (Spain)	838 patients	Elective cardiac valve surgery, coronary surgery, or both by means of mean sternotomy IV cefazolin 2g once vs 2g then 1g q8h for 24 hours	SSI: 35 (8.3%) in single dose group vs 15 (3.6%) in 24-hour group But no difference in mortality or length of hospital stay was observed	Supports prophylaxis for 24 hours	1 ⁺	
61	RCT (Taiwan)	231 patients	Coronary artery bypass graft surgery IV cefazolin 1g q8h x 1 day vs 3 days	SSI: no difference	No sample size calculation, likely underpowered study	1 ⁻	
62	RCT (Switzerland)	53 patients	High risk cardiac surgery (requiring inotropes and IABP post-operatively) IV cefazolin for 24 hours then: Ticarcillin-clavulanic acid + vancomycin until removal of IABP vs none	Mortality, infections (SSI, pneumonia, sepsis): no difference	No sample size calculation, likely underpowered study	1 ⁻	
63	RCT (North America)	Not available	Cardiac surgery with cardiopulmonary bypass IV cephalothin 1g once vs once plus 20 doses	Major and minor infections, deaths, or floral changes: no differences A longer duration of prophylaxis was associated with a change in the species of organisms causing major infection	The study from 1972 may be outdated; only the abstract was available	1 ⁻	
5	Prospective cohort study	2,641 patients	Coronary artery bypass graft surgery	Prophylaxis >48 hours was not associated with	Variability in antibiotic	2 ⁺	

	(North America)		Antibiotic prophylaxis <48 hours vs >48 hours compared	decreased SSI but was associated with antibiotic resistance (adjusted OR 1.6, 95% CI 1.1-2.6)	prophylaxis regimen; included possible confounders in analysis. Supports prophylaxis for up to 48 hours	
4	Retrospective cohort study (North America)	79,058 patients	Cardiac, orthopaedic total joint replacement, colorectal, and vascular procedures Duration of prophylaxis <24 hours vs 24-48 hours vs 48-72 hours vs ≥72 hours were compared	SSI was not associated with duration of prophylaxis Increased risk of acute kidney injury and <i>C. difficile</i> infection with prophylaxis >48 hours	Predominantly male population	2 ⁺
64	Retrospective cohort study (Germany)	1,096 patients	Cardiac surgery IV cefuroxime 1.5g q8h x 32 hours vs 56 hours were compared	SSI: no difference	No sample size calculation was provided, likely underpowered study	2 ⁻
65	Prospective cohort study (North America)	5,158 patients	Cardiac surgery No intervention but prophylaxis 0-24 hours vs 24-48 hours vs >48 hours were compared	Prophylaxis >48 hours was associated with major infection risk (Hazard ratio 1.92; 95% CI 1.28-2.88) and <i>C. difficile</i> colitis risk (Hazard ratio 6.31, 95% CI 2.86-14.0) No difference between 0-24 hours and 24-48 hours	Potential confounders as study were not randomised; Supports prophylaxis for up to 48 hours	2 ⁻
FINAL GRADE						A

*IABP: Intra-aortic balloon pump

Note: So far, no good quality study has compared the outcomes between 24 vs 48 hours prophylaxis duration. The guidelines should be reviewed when new studies published: e.g. van Oostveen RB, et al. Prevention of infections in cardiac surgery study (PICS): study protocol for a pragmatic cluster-randomised factorial crossover pilot trial. Trial. 2018;19:688.

Thoracic Procedures

Guidelines

Table A-7: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of evidence/Grade
ASHP, IDSA, SIS, SHEA ¹	Thoracic	IV cefazolin or IV ampicillin-sulbactam	IV clindamycin or IV vancomycin ± gram-negative cover (aztreonam, aminoglycoside, fluoroquinolone) if high incidence of gram-negative infections	Single dose		C (for video-assisted thoroscopic surgery), A (for other thoracic procedures)
SAAGAR ⁵⁸	Thoracic	IV cefazolin 2g ± IV metronidazole 500mg	IV vancomycin 1g (1.5g if weight >80kg) ± IV metronidazole 500mg	Single dose to 24 hours		No grading of evidence provided

*SAAGAR: South Australian expert Advisory Group on Antimicrobial Resistance

Literature

Table A-8: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
⁶⁶	RCT (United Kingdom)	208 patients	Elective thoracotomy and lung resection IV cefazolin single dose vs 48 hours	SSI: none in single dose group vs 2 in 48-hour group (95% CI: -0.008 to 0.048) Chest infection: 8 in each group Empyema: 3 in each group	Likely underpowered study	1 ⁺	
⁶⁷	RCT (France)	303 patients	Lung resection IV cefuroxime peri-operative vs 48 hours	Infection rate (SSI, pneumonia, bronchopneumonia, empyema): 65% in short duration vs 46% in long duration ($p=0.005$) Empyema: 6% in short duration vs 1% in long duration ($p=0.03$)	Infection rate higher compared to other published studies Potential bias identified, e.g. some patients in short duration group, who developed empyema, also had broncho-	1 ⁺	

					pleural fistula, suggesting the outcome was likely related to surgical technique rather than antibiotic duration	
68	RCT (Spain)	127 patients	Thoracic surgery IV cefazolin 1g once vs placebo	SSI: 1.5% in cefazolin vs 14% in placebo group ($p<0.01$) Post-operative empyema: no difference	No sample size calculation, likely an underpowered study. Study did not compare the difference in prophylaxis duration. This study supports single dose prophylaxis	1 ⁻
69	RCT (Turkey)	102 patients	Elective thoracotomy IV cefuroxime vs cefepime for 24 hours	Infection rate (pneumonia, bronchopneumonia, empyema): 14.0% in cefuroxime vs 26.7% in cefepime group ($p=0.12$)	Study compared the difference in antibiotic agent and not the difference in prophylaxis duration. This study supports 24-hour duration of prophylaxis	1 ⁻
70	Prospective cohort study (Germany)	60 patients	Lobectomy and segmentectomy IV ampicillin-sulbactam single dose vs 24 hours	SSI: 3 in single dose group vs 2 in 24-hour group (no p-value reported) Empyema: none Bronchitis/pneumonia: 10 in single dose group vs 7 in 24-hour group (no p-value reported)	Likely underpowered study	1 ⁻
71	Prospective cohort study (France)	445 patients	Thoracotomy (lobectomy or pneumectomy for non-infectious disease) Cefamandole x 48 hours during phase 1 of study vs amoxicillin-clavulanic acid x 16 hours post-operative during phase 2 of study	Post-operative pneumonia: 45% reduction with amoxicillin-clavulanic acid ($p=0.0027$)	Potential confounders: type of antibiotic use, difference in time period. Study appears to support duration <24 hours	2 ⁻
72	Prospective cohort study (Italy)	346 patients	Video-assisted thoracoscopic surgery (wedge resection, pleural biopsy or biopsy of mediastinal mass)	SSI: 1.7% (low)	No comparison on duration of prophylaxis but majority received single dose and overall infection rate was low	2 ⁻

			At least 90% of the patients received single dose prophylaxis			
73	Retrospective cohort study (Japan)	1,855 patients	Surgical lung cancer resection No intervention but studied the effect of change in antibiotic prophylaxis from physician's choice to cefazolin 1g before and after surgery	Change in antibiotic prophylaxis did not change post-operative pneumonia incidence	Study appears to support single dose before and after surgery	2 ⁺
74	Retrospective cohort study (Japan)	477 patients	Radical lobectomy for lung cancer IV cefazolin 1g before surgery then 1g q12h x 72 hours vs no further doses post-operatively	Short duration antibiotic was associated with post-operative pneumonia (OR 6.82, $p < 0.001$)	No sample size calculation. Multiple confounders present despite propensity matching done (e.g. long duration prophylaxis group had shorter surgery time)	2 ⁺
FINAL GRADE						B

Vascular Procedures

Guidelines

Table A-9: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
ASHP, IDSA, SIS, and SHEA ¹	Vascular	IV cefazolin	IV clindamycin or IV vancomycin ± gram-negative cover (aztreonam, aminoglycoside, fluoroquinolone) if procedure involves abdominal aorta/groin incision to cover GI flora	≤ 24 hours		A
SAAGAR ⁵⁸	Vascular	IV cefazolin 2g	IV vancomycin 1g (1.5g if weight >80kg)	Single dose to 24 hours		No grading of evidence provided
SIR, CIRSE, CAIR ⁷⁵	Arterial endografts	IV cefazolin 1-2g	IV vancomycin	Single dose		Class IIb, Level B (SAP not)

ESVS ⁷⁶	Vascular access creation	Antibiotic with <i>S. aureus</i> coverage (e.g. cephalosporin)	No recommendation	Single dose	recommended) non-randomised study Class I, Level A
--------------------	--------------------------	----------------------------------------------------------------	-------------------	-------------	-------------------------------------------------------------

***SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance; **SIR**: Society of Interventional Radiology; **CIRSE**: Cardiovascular and Interventional Radiological Society of Europe; **CAIR**: Canadian Association for Interventional Radiology; **ESVS**: European Society for Vascular Surgery; **GI**: gastrointestinal

Literature

Table A-10: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
77	Meta-analysis (Sweden, Australia, United Kingdom)	342 patients	Lower limb reconstruction, open arterial surgery amoxicillin-clavulanic acid or ticarcillin-clavulanic acid or cefuroxime	SSIs: prophylaxis >24 hours did not reduce SSI rate (RR 1.28, 95% CI: 0.82-1.98)	Heterogeneity across studies e.g. variability in antibiotic regimens used; some studies included patients with pre-existing cellulitis, wet gangrene or recent antibiotic therapy	1 ⁺	
78	RCT (North America)	408 patients	Arteriovenous graft creation Single dose IV vancomycin	Graft infection: 2 patients (1%) in vancomycin vs 12 (6%) in no prophylaxis group ($p=0.006$)	Study did not compare duration of prophylaxis. Supports single dose pre-operative prophylaxis	1 ⁺	
79	RCT (North America)	710 patients	Aortic or infrainguinal arterial procedures IV cefamandole for 24 hours vs IV cefazolin for 24 hours	SSIs: no difference	Study did not compare duration of prophylaxis. Supports 24 hours prophylaxis	1 ⁺	
80	RCT (North America)	559 patients	Aortic and lower extremity peripheral vascular surgery IV cefuroxime for 24 hours vs IV cefazolin for 24 hours	SSIs: no difference	Study did not compare duration of prophylaxis. Supports 24 hours prophylaxis	1 ⁺	
81	RCT (Sweden)	211 patients	Peripheral vascular surgery (vascular reconstructive surgery of lower limbs, acute	SSIs: 16.7% in placebo vs 3.8% in 24 hours ($p<0.05$ vs placebo) cefuroxime vs 4.3% in	Included in meta-analysis above (reference 67)	1 ⁺	

			femoral embolectomy or thrombectomy) No prophylaxis vs IV cefuroxime for 24 hours vs IV cefuroxime for 3 days	3 days cefuroxime ($p < 0.05$ vs placebo) Graft infection: no difference; overall rate is low ($n=1$, 1% - occurred in placebo group)	No sample size calculation was provided. Likely underpowered study. 24-hour duration is sufficient for prophylaxis	
82	RCT (Australia)	302 patients	Vascular surgery IV ticarcillin-clavulanic acid single dose vs multiple doses (maximum 5 days; average 14.3 doses)	SSIs: 18% in single dose vs 10% in multiple-dose (RR 2.00, 95% CI-1.02 to 3.92)	Ticarcillin-clavulanic acid is not a routine antibiotic prophylaxis agent. Its short half-life likely contributed to poorer outcomes in single dose group	1 ⁺
83	Retrospective cohort study (North America)	304 patients	Arteriovenous fistula or graft creation Single dose pre-operative cefazolin or vancomycin vs none	SSIs: no difference Overall SSI rate is low ($n=2$, 0.68%)	Likely underpowered study. Antibiotic group had more patients with diabetes mellitus Suggests antibiotic prophylaxis may not be necessary	2 ⁺
FINAL GRADE						B

Angioplasty or Stent Insertion

Guidelines

Table A-11: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
ASHP, IDSA, SIS, SHEA ¹	Angioplasty or stent insertion	No recommendation. If prophylaxis desired, use the same prophylaxis as vascular procedures				A
SAAGAR ⁵⁸	Angioplasty or stent insertion	Prophylaxis not recommended				No grading of evidence provided
SIR, CIRSE, CAIR ⁷⁵	Angioplasty or stent insertion	Prophylaxis usually not recommended				Class III, Level B-non-randomised study for angioplasty, Class III, Level C-limited data for stent insertion

***SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance; **SIR**: Society of Interventional Radiology; **CIRSE**: Cardiovascular and Interventional Radiological Society of Europe; **CAIR**: Canadian Association for Interventional Radiology

Literature

Table A-12: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
84	Case control study (North America)	3,473 patients 4,217 procedures	PTCA No intervention as this is observational study	27 out of 4,217 PTCA (0.64%) had bacteraemia post-procedure	No analysis on role of prophylactic antibiotics. Since incidence of post-procedure bacteraemia is low, antibiotic prophylaxis may not be necessary	3	
85	Case control study (Spain)	22,006 patients	Invasive non-surgical cardiologic procedures, PTCA, cardiac catheterisation, electrophysiologic studies No intervention as this was an observational study	68 out of 22,006 patients (0.3%) had bacteraemia post-procedure	No analysis on the role of prophylactic antibiotics was done Since incidence of post-procedure bacteraemia is low, antibiotic prophylaxis may not be necessary	3	
86	Case report and systematic review (Netherlands)	77 patients with stent infection	Non-coronary and coronary bare metal stent placement No intervention as this was an observational study (13% received antibiotic prophylaxis, 40% no prophylaxis, 47% unknown)	Identified possible risk factors that may require prophylaxis; however, this study was unable to analyse the role of prophylactic antibiotics	No analysis on the role of prophylactic antibiotics was done	4	
87	Case report and systematic review (North America)	35 patients with stent infection	Non-coronary and coronary bare metal stent placement No intervention as this was an observational study (1 received antibiotic	Identified possible risk factors for stent infection. However, this study was unable to analyse the role of prophylactic antibiotics	No analysis on the role of prophylactic antibiotics was done	4	

prophylaxis, 12 no prophylaxis, 22 unknown)	
FINAL GRADE	D

*PTCA: Percutaneous Transluminal Coronary Angioplasty

GASTROINTESTINAL PROCEDURES

Guidelines

Table A-13: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
ASHP, IDSA, SIS, and SHEA ¹	Appendectomy	Cephalosporin with anaerobic activity (cefoxitin or cefotetan)	Clindamycin plus gentamicin, aztreonam, or fluoroquinolone	Single dose	Referenced Mui et al ⁸⁹ and a cohort study	-
		or First-generation cephalosporin (cefazolin) plus metronidazole	or Metronidazole plus gentamicin or fluoroquinolone (ciprofloxacin or levofloxacin)			
ASHP, IDSA, SIS, and SHEA ¹	Gastroduodenal and oesophageal	Cefazolin	Clindamycin or vancomycin plus gentamicin, aztreonam, or fluoroquinolone	Single dose	Referenced Bates et al ⁹⁰ , Mohri et al ⁹¹	-
ASHP, IDSA, SIS, and SHEA ¹	Small bowel	Cephalosporin with anaerobic activity (cefoxitin or cefotetan)	Clindamycin plus gentamicin, aztreonam, or fluoroquinolone	No post-operative dosing	Based on inferring effectiveness from other clean-contaminated procedures. No specific RCTs for small bowel surgery	-
		or First-generation cephalosporin (cefazolin) plus metronidazole	or Metronidazole plus gentamicin or fluoroquinolone (ciprofloxacin or levofloxacin)			
ASHP, IDSA, SIS, and SHEA ¹	Colorectal	Second-generation cephalosporin with both aerobic and anaerobic activities (cefoxitin or cefotetan)	Clindamycin plus aminoglycoside, aztreonam, or fluoroquinolone	Single dose		-

		or Cefazolin plus metronidazole	or Metronidazole plus aminoglycoside or fluoroquinolone			
ASHP, IDSA, SIS, and SHEA ¹	Hernioplasty Herniorrhaphy	First-generation cephalosporin	Clindamycin or Vancomycin	Single dose	Based on Yin et al ¹⁰¹ and 2012 version of Orelio et al ¹⁰²	-
CDC ³³	Clean and clean- contaminated	-	-	No additional prophylactic antimicrobial agent doses after the surgical incision is closed (1A – strong recommendation; high- quality evidence) 21 RCTs, n=14,285. Cardiac, thoracic, vascular, ear, nose and throat, gynaecologic, orthopaedic, and general surgical procedures. No benefit of continuing antimicrobial prophylaxis after the wound is closed in the operating room: OR: 1.19 (0.94-1.50); I ² =25%	Risk of Bias of the RCTs: High (7), moderate (9), low (5). No point deducted in GRADE table for study quality because <50% of studies were rated as high risk	Category IA – strong recommendat ion; high- quality evidence
ERAS Society ⁹⁶	Elective colorectal surgery	IV cephalosporin in combination with metronidazole	-	Single dose	Referenced Nelson et al ⁹⁵	Strong recommendat ion, high- quality of evidence
SAAGAR ⁵⁸	Gastroduodenal and oesophageal	Cefazolin High risk of MRSA: add vancomycin	Gentamicin plus vancomycin	Single dose	No primary literature	-
SAAGAR ⁵⁸	Herniorrhaphy	Not recommended	Not recommended	NA	No primary literature. References quoted are ASHP ¹ , Berríos-Torres et	-

al³³ and Therapeutic
Guidelines³¹⁵

***ERAS**: Enhanced Recovery After Surgery; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance

Literature

Table A-14: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations / Remarks	Level of Evidence	Final Grade
33	Meta-analysis of RCTs (International)	14,285	Cardiac, thoracic, vascular, ear, nose and throat, gynaecologic, orthopaedic, and general surgical procedures No post-operative antibiotics vs ≤24 hours	SSI: OR 1.19 (0.94-1.50); I ² =25%	No benefit of continuing antimicrobial prophylaxis after the wound is closed in the operating room Risk of Bias of the RCTs: High (7), moderate (9), low (5). No point deducted in GRADE table for study quality because <50% of studies rated as high risk	High quality (as per guideline grading system)	Category IA – strong recommendation (as per guideline grading system)
89	RCT (Hong Kong)	269	Acute appendicitis undergoing open appendectomy Single pre-operative dose vs three doses (pre-operative dose plus two additional doses) or 5-day course	<i>Three doses</i> SSI: OR 1.01; 95% CI 0.34-3.26 <i>5-day course</i> SSI: OR 0.89; 95% CI 0.46-7.79	May be underpowered - target 88 per group; 5-day group had 83 Risk of bias: Selection (moderate: sealed envelopes but how assigned not described), Performance (low), Detection (moderate/high: blinding of assessors not described), Attrition (low), Reporting (low)	1+	A
90	RCT (United Kingdom)	900	At-risk abdominal surgery which included all appendicectomies, laparotomy for intestinal obstruction, and all open gastric, oesophageal, colonic or biliary surgery	Wound infection: 10.7% vs 10.9% (95% CI -4.25% - 3.9%) 30-day mortality (septic or sepsis-related): 3.1% vs	Met the target number for each group but the outcome measure was not clearly defined Only 114/900 in upper GI	1+	B

			Single dose (on induction) vs three doses (on induction plus two additional doses)	1.6%; 95% CI -0.4% - 3% (more elderly patients, more emergency operations)	16/449 in single dose and 7/451 in 3-dose received more doses than protocol. Deep sepsis & patients requiring interval antibiotics seemed like important outcomes, but was not elaborated on. Authors only reported as having no difference Risk of bias: Selection (low), Performance (low), Detection (high: a component of patient-reported outcome), Attrition (low), Reporting (high) Extrapolation was done as majority of the studies were not for gastroduodenal surgeries		
91	RCT (Japan)	486	Elective gastric cancer surgery Single- vs multiple-dose	SSI: 9.5% vs 8.6%; difference 0.9%; 95%CI -4.3% - 5.9% (met non-inferiority target of -7%)	A total of 4 were lost to follow-up Risk of bias: Selection (low), Performance (moderate: participants unblinded after randomisation but assessors are), Detection (low), Attrition (low), Reporting (low)	1+	A
92	RCT (Japan)	325	Elective gastric cancer surgery Single- vs multiple-dose	SSI: 9.1% vs 6.2%; difference -2.9%; 95%CI -5.9% - 0.0% (met non-inferiority target of -8%)	Met target sample size Risk of bias: Selection (low), Performance (moderate: unclear if personnel are blinded), Detection (moderate: unclear if assessors are blinded), Attrition (low), Reporting (low)	1+	A
95	Meta-analysis of RCTs (International)	2005	Elective and emergency colorectal surgery. Single pre-operative vs multiple doses	SSI: RR 1.21; 95% CI 0.82-1.80	-	1++	A

98	Network meta-analysis of RCTs (International)	3562	Elective colorectal surgery. MBP + oral antibiotics vs MBP	SSI: OR 0.71; 95% equal-tail credible interval 0.57-0.88	Varied regimens of MBP and antibiotics were used among these studies, and may have contributed to lower consistency of the results reported Extrapolated evidence based on regimen of majority of studies	1++	B
101	Meta-analysis of RCTs (International)	3318	Open inguinal hernia repair; mesh repair Antibiotic prophylaxis vs no antibiotics or placebo	SSI: OR 0.61; 95% CI 0.40-0.92; I ² =0%	Based on abstracted data but not individual patient data n=9 studies. All had reporting bias as per authors Extrapolated as studies did not compare single vs multiple doses	1-	B
102	Meta-analysis of RCT (International)	6443	<i>Hernioplasty</i> Open elective inguinal or femoral hernia repair; mesh-type based Antibiotic prophylaxis vs no antibiotics or placebo	SSI: RR 0.61; 95% CI 0.48-0.78	RCTs judged to be of low to moderate quality (GRADE level) Extrapolated as studies did not compare single vs multiple doses All RCTs used single doses	1++	B
		1865	<i>Herniorrhaphy</i> Open elective inguinal or femoral hernia repair; suture-based Antibiotic prophylaxis vs no antibiotics or placebo	SSI: RR 0.86; 95% CI 0.56-1.33	RCTs judged to be of very low quality (GRADE level)	1++	A
103	RCT (Isreal)	35	Umbilical (n=19) and incisional (n=16) hernia repair Antibiotic prophylaxis (single dose given pre-operatively) vs no antibiotics	SSI: <i>Total</i> OR 0.08; 95% CI 0.008-0.72 <i>Incisional</i> OR 0.06; 95% CI 0-1.36	Only 23% (n=8) repaired with mesh; 6 out of 8 received antibiotics; patients with mesh repair higher in prophylaxis group SSI rate for mesh repair group not reported separately	1-	B

				<i>Umbilical</i> OR 0.19; 95% CI 0.02-2.14	Risk of bias: Selection (high: lack of proper randomisation - "assigned alternatively"), Performance (high: not blinded), Detection (high: not blinded), Attrition (low), Reporting (low)		
104	Retrospective pre-post intervention study (USA)	65	Laparoscopic ventral hernia repair; mesh repair Single IV pre-operative dose (first 20 patients) vs single IV pre-operative plus additional 7 days PO antibiotic (next 45 patients)	Seroma formation: 30% (6/20) vs 33% (15/45) ($p=0.74$) Seroma-related cellulitis: 100% (6/6) vs 40% (6/15) ($p=0.001$) Mesh infection: 33% (2/6) vs 0% (0/6) ($p=0.54$)	Single centre Limited description of baseline demographics. Outcome measure very specific to seroma-related complications. Mesh infection rates not significant.	2-	C

*GI: Gastrointestinal

HEPATOBIILIARY PROCEDURES

Biliary Tract Surgery

Guidelines

Table A-15: Guideline references for surgical prophylaxis recommendations

Guideline	Procedure	First line	Alternative	Duration	Level of Evidence/Grade
ASHP, IDSA, SIS, and SHEA ¹	Biliary tract (open)	Cefazolin, cefoxitin, cefotetan, ceftriaxone, ampicillin-sulbactam	Clindamycin or vancomycin + aminoglycoside or aztreonam or fluoroquinolone Metronidazole + aminoglycoside or fluoroquinolone	Single dose	NA
	Biliary tract (lap, low risk)	None	None	NA	A
	Biliary tract (lap, high risk)*	Cefazolin, cefoxitin, cefotetan, ceftriaxone, ampicillin-sulbactam	Clindamycin or vancomycin + aminoglycoside or aztreonam or fluoroquinolone Metronidazole + aminoglycoside or fluoroquinolone	Single dose	NA

*Risk factors include performance of emergency procedures, diabetes mellitus, anticipated procedure duration exceeding 120 minutes, risk of intra-operative gallbladder rupture, age of >70 years, open cholecystectomy, risk of conversion of laparoscopic to open cholecystectomy, American Society of Anesthesiologists (ASA) classification of ≥ 3 , episode of biliary colic within 30 days before the procedure, re-intervention in less than a month for noninfectious complications of prior biliary operation, acute cholecystitis, jaundice, pregnancy, and immunosuppression. Because some of these risk factors cannot be determined before the surgical intervention, it may be reasonable to give a single dose of antimicrobial prophylaxis to all patients undergoing laparoscopic cholecystectomy.

Literature

Table A-16: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations / Remarks	Level of Evidence	Overall grade
108	Randomised, controlled, double-blind multi-centre (Netherlands)	1004	High-risk biliary tract surgery Single vs multiple doses of cefuroxime	Post-operative wound infection no difference. NS		1+	
109	Prospective, double blind (USA)	81	High risk biliary surgery	Wound infection: none in both groups	Included patients with recent cholecystitis,	1-	

			Ceftriaxone one dose vs Cefazolin pre-operative and 3 post-operative dose		common duct stones, duct obstructions and age >70 years (high risk group)		
110	Prospective, double-blind, randomised, placebo-controlled (United Kingdom)	295	Elective cholecystectomy (high risk) Single 1.5g cefuroxime or total 4 doses cefazolin	Bacteriologic success 95.5% (cefuroxime) vs 98.2% (cefazolin). NS. Clinical success: 91.4% vs 94.9%, NS		1+	
111	Systematic review (RCTs)	4 RCTs (n=953)	Acute calculous cholecystitis undergoing emergency cholecystectomy Comparing extended post-operative vs no post-operative antibiotics	Post-operative infectious complications OR 0.94, $p=0.79$. SSI OR 1.13, $p=0.72$; post-operative morbidity OR 0.93, $p=0.7$	Comparable baseline characteristics	1+	
FINAL GRADE						1+	A

*NS: Non-significant

Hepatectomy

Note: Meta-analysis suggests no antibiotic for minor hepatectomy. For hepatectomy involving biliary or intestinal manipulation, two studies below showed no difference in outcomes comparing 2 days vs longer duration. Antibiotic prophylaxis of up to 24 hours is recommended in this guideline.

Table A- 17: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations / Remarks	Level of Evidence	Overall grade
113	Network meta-analysis (countries in Asia) Hirokawa 2013 Sugawara 2016 Togo 2007 Wu 1998 Zhou 2015	5 RCTs (n=701)	Hepatectomy Comparing pre-operative, post-operative (≤ 2 days), post-operative (> 2 days) antibiotics	No antibiotic has the highest possibility of best clinical effects on SSI; remote-site and global infection. Pair-wise meta-analysis showed that additional or long-duration applications had no clinical benefits	Supports no antibiotics	1+	
113	Prospective, randomised (Japan)	180	Hepatectomy without reconstruction of biliary or intestinal tract	Infection: 7.9% (2-day) vs 6.6% (5-day). NS	Author noted that if systemic inflammatory response syndrome	1-	

			Flomoxef: 2 days vs 5 days		(SIRS) was positive on post-operative day 2, it may be safer to continue antibiotics	
114	Prospective, randomised (Japan)	86	Complicated major hepatectomy with extrahepatic bile duct resection 2 days vs 4 days antibiotic (antibiotic choice based on pre-operative cultures)	Infectious complications: 30.2% (2-day) vs 32.6% (4 day)	Similar baseline and microbiological characteristics between groups	1-
115	Prospective, randomised, placebo-controlled (China)	120	Elective hepatectomy Cefuroxime IV or placebo single dose pre-operative	Post-operative infection: 23.3% (single dose) vs 20% (placebo), $p=0.658$. SSI: 13.3% vs 15%, NS. Remote site infection NS	Supports no antibiotics	1-
116	Prospective, randomised, controlled trial (Japan)	241	Liver resection Flomoxef No post-operative antibiotic vs 3-day course of antibiotics	Infections 21.3% vs 25.5% $p=0.606$. Systemic inflammatory response syndrome (SIRS) 11.7% vs 17% $p=0.406$. Infectious complications 7.5% vs 17%, $p=0.073$. SSI 10.6% vs 13.8% $p=0.657$, remote site infection 2.1% vs 8.5% $p=0.1$	Excluded patients with multiple co-morbidities Supports single dose	1+
FINAL GRADE						1+ A

*NS: Non-significant

Whipple's Procedure (Pancreaticoduodenectomy)

Guideline

Table A-18: Guideline references for surgical prophylaxis recommendations

Guideline	Procedure	First line	Alternative	Duration	Level of Evidence/Grade
ASHP, IDSA, SIS, and SHEA ¹	Pancreaticoduodenectomy	Cefazolin	Clindamycin or vancomycin + aminoglycoside or	Single dose	NA

aztreonam or
fluoroquinolone

Literature

Table A-19: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations / Remarks	Level of Evidence	Overall grade
117	Prospective cohort review (Japan)	254	Pancreaticoduodenectomy Non-PBD vs internal-PBD vs external-PBD Antibiotics peri-operative and 2-3 days. Cefazolin for non-PBD; cefazopran (internal-PBD); depends on pre-micro culture (external-PBD)	Overall morbidity and abdominal infection (13%, 17%, 14%) complication and wound infection (2%, 1%, 2%) similar and did not reach statistical significance	Only susceptibility to peri-operative antibiotic of biliary organism classified as resistant was significant independent risk factor for abdominal infectious complications	2+	C
118	Retrospective cohort study (France)	175	Pancreaticoduodenectomy in patients with periampullary malignancy (excluded patients with percutaneous transhepatic biliary drainage) Cefoxitin for low risk group; Piperacillin-tazobactam and gentamicin for high risk group Duration: if culture-negative, stopped on POD2. If culture-positive, continued until POD5	Infection complication was higher in low risk group (46.1%) vs high risk group (29.3%), $p=0.018$. No difference in SSI, infection complication mainly driven by pneumonia, bacteraemia and UTI	The authors proposed 5-day course of antibiotics in high-risk patients	2+	
119	Retrospective review (USA)	122	Pancreaticoduodenectomy Propensity score matching comparing 72 hours vs 24 hours	SSI: 2.7% (72 hours) vs 16% (24 hours), $p=0.04$		2+	
120	Controlled before and after study (France)	122	Pancreaticoduodenectomy Cefazolin single dose vs piperacillin-tazobactam until bile culture available. If culture negative, antibiotic ceased. If culture positive, continue until	Piperacillin-tazobactam group was associated with reduction in deep abdominal abscess (36% vs 10% $p=0.008$), respiratory tract infection (15% vs 3% $p=0.02$),		2-	

			POD5, streamline according to culture	bacteraemia (41% vs 6%, $p<0.001$) and shorter LOS	
122	Pre-post intervention study (USA)	Pre (n=111) Post (n=216)	Pre: cefazolin Post: ceftriaxone and metronidazole Duration: Single dose up to 24 hours	Overall SSI was reduced from 26.4% to 14.8%, $p=0.01$. Organ/space SSI 15.3% vs 8.6%, $p=0.03$. Superficial and deep SSI: no difference <i>C. difficile</i> was seen to be higher in cefazolin group (8.1% vs 1.9%, statistically significant)	2-
121	Systematic review of the impact of intra-operative bacterobilia on patient outcome after pancreaticoduodenectomy	28 studies	Pancreatoduodenectomy	Pre-operative biliary drainage was significantly associated with bacterobilia (RR 3.27, 95%CI 2.4-4.4). SSIs significantly increased in cases with bacterobilia (RR 2.84, 95% CI 2.17-3.73). Post-operative fistula, morbidity and mortality were not significantly influenced	
FINAL GRADE					2+ C

*PBD: Percutaneous biliary drainage; POD: Post-operative day; LOS: Length of stay

Endoscopic Retrograde Cholangio-Pancreatography (ERCP)

Guideline

Table A-20: Guideline references for surgical prophylaxis recommendations

Guideline	First line	Alternative	Duration	Remarks	Level of Evidence/ Grade
ASGE Standard of Practice Committee (2015) ¹²⁶	None If required: to cover enteric	None	NA	Prophylaxis is not required when obstructive biliary tract disease is not suspected or complete biliary drainage is expected	High quality evidence for the first group (further research is very unlikely to change the confidence in the estimate of effect) Moderate quality for the second group

	gram-negative, enterococci			Antibiotic prophylaxis is recommended for those who had liver transplantation; known or suspected biliary obstruction, possible incomplete biliary drainage	
ESGE Guidelines 2020 ¹²⁷	None	None	NA	Recommends antibiotic prophylaxis in the case of anticipated incomplete biliary drainage, for severely immunocompromised, and when performing cholangioscopy	High quality (moderate quality evidence)

***ASGE**: American Society for Gastrointestinal Endoscopy; **ESGE**: European Society of Gastrointestinal Endoscopy

Literature

Table A-21: Literature review of references

Reference	Study Design/Country	Sample Size	Population and Intervention	Outcome	Limitations / Remarks	Evidence Level	Overall grade
128	Meta-analysis	5 RCTs	ERCP	RR of antibiotic prophylaxis and bacteraemia was 0.39 (95% CI 0.12-1.29). RR for sepsis and cholangitis was 0.91 (95% CI 0.39-2.15)	Routine use cannot be recommended	1+	A
129	Cochrane Review until Mar 2010	9 RCTs (n=1573)	Elective ERCP without evidence of acute or chronic cholecystitis, or acute or chronic cholangitis or severe acute pancreatitis	Fixed-effect of the meta-analysis favored the use of antibiotic in preventing cholangitis (RR 0.54, 95% CI 0.33-0.91), septicemia (RR 0.35, 0.11-1.11), bacteraemia (RR 0.5, 0.33-0.78), and pancreatitis (RR 0.54, 0.29-1.0) In random-effect analysis, only the effect on bacteraemia remained significant Overall mortality was not reduced (RR 1.33, 0.32-5.44)	Majority of trials had risk of bias Authors concluded that prophylactic antibiotic seems to prevent cholangitis and septicemia. In the subgroup of patients with uncomplicated ERCP, the effect of antibiotic less evident	1+	
130	Meta-analysis	7 trials (n=1389)	Patients undergoing ERCP	Post ERCP cholangitis: 5.8% vs 3.4% (antibiotic group), RR 0.58, 0.22-1.55, NS)	Antibiotics cannot significantly prevent ERCP induced cholangitis in unselected patients and should not be routinely	1+	

recommended. More trials are required in those with incomplete biliary drainage		
	FINAL GRADE	1+ A

*NS: Non-significant

OBSTETRICS AND GYNAECOLOGY

Caesarean Section

Guidelines

Table A-22: Guideline references for surgical prophylaxis recommendations

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade	Grading System
ASHP, IDSA, SIS, and SHEA ¹	2013 [Jan 1999 to Jun 2010]	C-section	IV Cefazolin 2g, 3g for pts weighing ≥120kg	IV clindamycin 900mg WITH IV aminoglycosides (gentamicin 5 mg/kg, single dose)	Single dose	The use of single-dose prophylaxis is supported by ACOG and AAP for procedures lasting less than 2 hours	A	Agency for Healthcare Research and Quality, and ASHP, IDSA, SIS, and SHEA Category A (Levels I–III) - Level I (evidence from large, well-conducted, randomised, controlled clinical trials or a meta-analysis) - Level II (evidence from small, well-conducted, randomised, controlled clinical trials) - Level III (evidence from well-conducted cohort studies) The strength of evidence represents only support for or against prophylaxis and does not apply to the antimicrobial agent, dose, or dosage regimen
ACOG ¹³¹	2018	C-section	First-generation cephalosporin,	IV clindamycin 900mg WITH	Single dose	For cesarean delivery prophylaxis, a single dose is recommended. A meta-	A	U.S. Preventive Services Task Force

	[Jan 1990 to Apr 2018]		IV Cefazolin: 1g for <80kg, 2g if 80-120kg, 3g if ≥120kg	IV gentamicin 5mg/kg/dose		analysis of 16 studies showed no difference in single-dose vs multi-dose therapy for uncomplicated cesarean deliveries (Pinto-Lopes et al ¹³⁶) Addition of IV azithromycin to a standard antibiotic prophylaxis regimen may be considered for women undergoing a non-elective caesarean delivery (Tita et al ¹⁴⁹). No RCT to recommend this in electives		Based on the highest level of evidence found in the data Level A: Recommendations are based on good and consistent scientific evidence
						For women with a history of a significant penicillin or cephalosporin allergy (anaphylaxis, angioedema, respiratory distress, or urticaria), a single-dose combination of clindamycin with an aminoglycoside is a reasonable alternative though limited data to support this. No references quoted	B	Level B: The following recommendations are based on limited or inconsistent scientific evidence
NICE ¹³³	2011 (Updated 2019)	C-section	NA	NA	Single dose, before skin incision	Offer women prophylactic antibiotics at C-section to reduce the risk of post-operative infections. Choose antibiotics effective against endometritis, urinary tract and wound infections, which occur in about 8% of women who have had a C-section. Avoid the use amoxicillin-clavulanic acid	No grading	NA
ANZOG ¹³⁴	2012	C-section	IV cefazolin	IV clindamycin 600mg	Single dose	Studies showed that single-dose antibiotic prophylaxis	I	NHMRC Levels of Evidence

				1g for <80kg, 2g if ≥80kg		was as effective as multiple doses of antibiotic. Referenced only this RCT by McGregor et al ¹⁶² , and a systematic review (Tita et al ¹⁴⁸) of antibiotic prophylaxis timing at cesarean delivery		Level I: A systematic review of level II studies (Level II: A RCT)
SOGC ¹³⁵	2010 [Jan 1978 to Jun 2009]	C-section	First-generation cephalosporin	IV clindamycin 600mg or IV erythromycin 500mg	Single dose, 15 – 60 minutes prior to skin incision	References did not compare single vs multiple doses of antibiotics, mainly need for and timing of antibiotic (Chelmow et al ¹³⁹ , Costantine et al ¹⁵⁰). RCT showing superiority of cefazolin prior skin incision vs at cord clamping for preventing post C-section infectious morbidity (Sullivan et al ³¹⁶)	I-A	Canadian Task Force on Preventive Health Care Level I: Evidence obtained from at least one RCT Class A: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees
						Additional dose may be considered if blood loss exceeds 1500ml or at 4 hours if the procedure lasts more than 4 hours (i.e. up to 2 half-lives of the drug) Gordon ¹⁵⁸ - review on antibiotic prophylaxis	III-L	Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees Class L: There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making

***ACOG:** American College of Obstetricians and Gynecologists; **AAP:** American Academy of Pediatrics; **ANZOG:** Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC:** National Health and Medical Research Council; **SOGC:** Society of Obstetricians and Gynaecologists of Canada

Literature

Table A-23: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
136	Systematic review (Multiple countries)	2695 (16 RCTs, of which 3 are quasi- RCTs)	C-section, both elective and emergency Intervention: Multiple doses antibiotics (varied dosing regimens) Comparator: Single dose antibiotics (varied regimens)	Composite post-partum infectious morbidity (endometritis, wound infection, UTI and other causes of febrile morbidity of probably infectious origin): RR 0.95 (95% CI: 0.75 – 1.20) Urinary tract infection: RR 0.65 (95% CI: 0.34 – 1.24)	Quality of evidence is rated as very low, with low to unclear risk of bias. A trend towards a decreased risk of UTI was noted when using a multiple doses regimen but was not significant	1-	B
137	Systematic review (Multiple countries)	15000 (95 RCTs, quasi- RCTs)	C-section, both elective and emergency Intervention: Antibiotics (varied dosing regimen) Comparator: None Duration: Varied (ranges from single dose to 7 days)	Wound infection: RR 0.40 (95% CI: 0.35 – 0.46) for all, RR: 0.62 (95% CI: 0.47 – 0.82) for elective C-section Endometritis: RR 0.38 (95% CI: 0.34 – 0.42) for all, RR: 0.38 (95% CI: 0.24 – 0.61) for elective C-section Serious infectious complications: RR 0.31 (95% CI: 0.20 – 0.49) for all, RR: 1.01 (95% I: 0.04 to 24.21) for elective C-section	Varied antibiotic regimens, made no mention about the duration of antibiotic prophylaxis and impact on outcomes. Included studies dating back to 1980s, with high rates of endometritis, which may no longer be representative of the current surgical technique of C-section	1-	B
151	RCT (USA)	403	Obese women (BMI ≥30) underwent C-section Intervention: IV cefazolin 2g prior to surgical incision, then (PO cephalexin 500mg TDS PLUS PO metronidazole 500mg TDS) x 48 hours	SSI: RR 0.41 (95% CI: 0.22 - 0.77); 6.4% (Intervention) vs 15.4 % (Comparator), (difference, 9.0%, 95% CI: 2.9 – 15.0%)	Baseline rate of infection was high at 15.4% (with single dose IV cefazolin). NNT to prevent 1 SSI in all obese women undergoing C-section was 12 (95% CI: 6.7 – 33.8) Included as this explains the rationale for remark: “Continuation of antimicrobial	1+	A

			Comparator: cefazolin 2g prior to surgical incision		prophylaxis for patients with major risk factors for surgical infections, e.g. obesity (BMI≥30) may be considered"		
152	RCT (Austria)	1112	Elective C-section Intervention: IV cefazolin 2g prior to surgical incision Comparator: (1) IV cefazolin 2g after cord clamping (2) Placebo (sodium chloride 0.9%) prior to surgical incision	Post-operative infection (wound infection, endometritis, UTI): 4.9% (Intervention), vs 3.8% (Comparator 1) vs, 12.1% (Comparator 2), $p < 0.05$ Antibiotic prophylaxis: OR 0.31 (95% CI: 0.19 – 0.50)	Baseline rates of post-operative infection relatively high at 12.1% (without antibiotic prophylaxis). Balanced demographics across all 3 arms – age, BMI (approximate mean of 28), gestational diabetes mellitus (approximately 9-10%), and use of immunosuppression. Does not compare the use of single vs multiple doses of antibiotic prophylaxis, but supports evidence for antibiotic prophylaxis (as a single dose) in a high baseline post-operative infection risk setting	1+	B
155	Randomised controlled, non-inferiority trial (Africa)	176	C-section (elective and emergency) Intervention: Single dose of IV ampicillin 1g AND IV metronidazole 500mg Comparator: Day 1: IV ampicillin 1g AND IV metronidazole 500mg, followed by IV ampicillin 500mg and IV metronidazole 500mg for 2 more doses (8 hours apart) Day 2-5: PO amoxicillin 500mg TDS with PO metronidazole 400mg TDS	Wound infection: 6.7% (Intervention) vs 10.3% (Comparator), difference 3.60; 95% CI: -4.65 – 11.85)	Reported length of hospital stay at 7 days is long (LOS for elective C-section locally is shorter at 2 – 3 days). Only 1 is an elective procedure, the rest are emergency C-section; high percentage in intervention group had ruptured membranes before C-section – 70.8% vs 59.8%. Dose of IV ampicillin used lower than usual (vs those used for maternal Group B Streptococcus (GBS) prophylaxis), body weight of population studied generally lean at 50 – 60kg, compared with the local (Singapore) population	1+	B
153	Quai-randomised trial	100	Elective C-section Intervention: IV cefotaxime 1g pre-operation	Febrile morbidity (wound hematoma, superficial wound infection, deep wound infection, chest infection, UTI):	High rate of febrile morbidity at 20% even with antibiotics, reported length of hospital stay at 6 days is long (LOS for elective	2+	C

	(Pakistan)		Comparator: 3 doses IV cefotaxime 1g, given 12 hours apart, followed by PO cefuroxime for 5 days	20.0% (Intervention) vs 20.0% (Comparator), OR 1.0	C-section locally is shorter at 2 – 3 days)		
154	Quai-randomised trial (Nepal)	100	Elective C-section Intervention: Single dose of IV cefazolin AND IV metronidazole Comparator: IV cefazolin AND IV metronidazole for 7 days	Febrile morbidity: 4.0% (Intervention) vs 6.0% (Comparator), $p=1.00$	Similar BMI between both groups (approximate mean of 27 - 28). 22% in intervention arm, vs 34% in comparator arm are obese (BMI >30) but did not develop post-operative wound infection. Definition of febrile morbidity was not clearly defined, and there was no mention of antibiotic doses given	2+	C
159	Quasi-randomised trial (Sri Lanka)	369	C-section (both elective and emergency) Intervention: Single dose of IV cefuroxime 1.5g and IV metronidazole 500mg after cord clamping Comparator: IV cefuroxime 750mg q8h and IV metronidazole q8h for up to 24 hours, then PO cefuroxime 750mg q8h AND PO metronidazole 400mg q8h for 7 days	Post-operative infection (fever, wound infection, endometritis, UTI or serious infection such as bacteraemia, septic shock, septic thrombophlebitis, necrotising fasciitis and death): 1.8% (Intervention) vs 3.2% (Comparator), rate ratio 0.3 [95% CI 0.065-1.63] $p=0.284$. NS: febrile morbidity ($p=0.28$), wound infections ($p=0.123$), perinatal outcome ($p>0.05$) and median duration of hospital stay ($p=0.329$) in both arms	Non-blinded trial 1/3 were emergency C-section, generally similar baseline demographics. Median LOS at 3 – 4 days, similar to the local (Singapore) context	1-	B
160	Quasi-randomised trial (Palestine)	313	C-section Intervention: Single pre-operative dose IV cefazolin 1g Comparator: multiple post-operative doses of antibiotics (1g cefazolin, gentamicin 80mg, metronidazole 500mg TDS till discharge)	Readmission due to wound infection: 2% (Intervention) vs 1% (Comparator), $p=0.375$ Nil endometritis, UTI, or febrile morbidities in both groups	Non-blinded trial. Attempted randomisation by “manual-blocks formation based on the rolling of a die”. Mean LOS was 39.62 hours (I) AND 40.48 hours. Well-conducted case control/ cohort study with low risk of bias	2+	C

161	Quasi-randomised trial (Africa)	500	Emergency C-section Intervention: Single pre-operative dose IV gentamicin 3mg/kg AND metronidazole 500mg Comparator: IV gentamicin 3mg/kg AND metronidazole 500mg q8h for 24 hours	SSI: 4.8% (Intervention) vs 6.4% (Comparator), difference 1.6% (95% CI -2.4 – 5.6%)	2/3 high BMI, approximately half: operation time >1 hour but NS difference in both groups. A higher proportion in multiple dose group had ruptured membranes	1+	B
FINAL GRADE						1-	B

***LOS**: Length of stay; **NNT**: Number needed to treat; **NS**: Non-significant

Normal Vaginal Delivery

Guidelines

Table A-24: Guideline references for surgical prophylaxis recommendations

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade	Grading System
SOGC ¹³⁵	2010	Operative vaginal delivery	Not recommended	Not recommended	NA	NA	Level II-1C	Canadian Task Force on Preventative Health Care II-1: Evidence from well-designed controlled trials without randomisation C. The existing evidence is conflicting and does not allow a recommendation for or against the use of the clinical preventive action; however, other factors may influence decision-making
		Third or fourth-degree perineal lacerations	IV cefotetan 1g or IV ceftioxin 1g	NA	Single dose	NA Ref: Buppasiri et al. Cochrane 2005 (updated in 2014 ¹⁷¹), but quotes	I-B	Canadian Task Force on Preventative Health Care I: Evidence obtained from at least one properly randomised controlled trial

						only 1 trial: Duggal M et al ¹⁷⁵		B. There is fair evidence to recommend the clinical preventive action
ACOG ¹⁶³	2020	Operative vaginal delivery	Not recommended	Not recommended	NA	Findings from ANODE trial may not be generalisable to USA. As 89% of women received an episiotomy, mostly mediolateral (routine in the UK), hence does not recommend routine prophylaxis before delivery. May consider antibiotics in the presence of third- or fourth-degree laceration (also based on Duggal et al ¹⁷⁵)	No grading (Level I, Knight et al ¹⁷²)	U.S. Preventive Services Task Force Level I: Evidence obtained from at least one properly designed RCT
RCOG ¹⁶⁴	2020	Assisted vaginal delivery	IV amoxicillin-clavulanic acid 1.2g	NA	Single dose	Lack of evidence for the role of antibiotics at normal birth (Heitmann and Benrubi ¹⁷³) ANODE ¹⁷² trial provided evidence of benefit of prophylactic antibiotic administration after assisted vaginal birth, with few observed adverse events in relation to the intervention	Level 1++, Grade A	Level 1++ High-quality meta-analyses, systematic reviews of RCTs or randomised Grade A: At least one meta-analysis, systematic reviews or RCT rated as 1++, and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results
ANZOG ¹⁶⁵	2020	Instrumental vaginal birth	IV amoxicillin-clavulanic acid 1.2g	IV cefazolin 2g or IV clindamycin 600mg	Single dose	NA	Evidence based, Level A	NHMRC Levels of Evidence Level A: Body of evidence can be trusted to guide practice

SOGC ¹⁶⁶	2019	Assisted vaginal birth	Not recommended	Not recommended	NA	Consider single dose IV antibiotic after obstetrical anal sphincter injury repair	No grading (Liabsuetrakul et al ¹⁶⁸ - Cochrane review 2014 which was updated in 2020)	Canadian Task Force on Preventative Health Care
WHO ¹⁶⁷	2015	Uncomplicated vaginal birth	Not recommended	Not recommended	NA	NA	Strong recommendation, very low-quality evidence	Grading of Recommendations, Assessment Development and Evaluation (GRADE)
		Operative vaginal birth	Not recommended	Not recommended	NA	NA	Conditional recommendation, very low-quality evidence	
		Third- or fourth-degree perineal lacerations	Recommended	Recommended	NA	Insufficient evidence to determine clinical benefits of routine administration of prophylactic antibiotics in women with third- or fourth-degree perineal tear post-partum. However, indirect evidence of benefit exists for potentially contaminated wounds (considering the bacterial flora in the rectum).	Strong recommendation, very low-quality evidence	

***SOGC**: Society of Obstetricians and Gynaecologists of Canada; **ANODE**: Prophylactic Antibiotics for the prevention of infection following Operative Delivery; **ACOG**: American College of Obstetricians and Gynecologists; **RCOG**: Royal College of Obstetricians and Gynaecologists; **ANZOG**: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC**: National Health and Medical Research Council; **WHO**: World Health Organization

Literature

Table A-25: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
168	Systematic review (Multiple countries)	3813 (2 RCTs)	Operative vaginal delivery (vacuum or forceps delivery) Intervention: Antibiotics (IV amoxicillin-clavulanic acid 1.2g or 2g IV cefotetan immediately after cord clamping) Comparator: Placebo Duration: Single dose	Superficial perineal wound infection: RR: 0.53 (95% CI: 0.40 – 0.69) Deep perineal wound infection: RR: 0.46 (95% CI: 0.31 – 0.69) Reduction of wound breakdown: RR: 0.52 (95% CI: 0.43 – 0.63) Organ or space perineal wound infection: RR: 0.11 (95% CI: 0.01 – 2.05) Endometritis: RR: 0.32 (95% CI: -0.23 – 0.41)	Evidence was mainly derived from a single multicenter study conducted in a high-income setting (referenced ANODE trial ¹⁷²). The evidence of antibiotic prophylaxis on endometritis, organ or space perineal wound infection, maternal adverse reactions and LOS remain unclear	1+	B
169	Systematic review (Multiple countries)	1779 (1 RCT, 2 quasi-RCTs)	Normal (uncomplicated) vaginal birth Intervention: Antibiotics (IV amoxicillin-clavulanic acid 1.2g or 2g IV cefotetan immediately after) Comparator: Placebo Duration: Single dose	Endometritis: RR 0.28 (95% CI: 0.09 to 0.83) Urinary tract infection: RR 0.25 (95% CI: 0.05 – 1.19) Wound infection after episiotomy: RR: 0.78 (95% CI: 0.31 – 1.96)	Relatively low incidence of puerperal endometritis and UTI were reported. Infection prevention and control measures remain important	1-	B
172	Prospective RCT (United Kingdom)	3420	Operative vaginal delivery (vacuum or forceps delivery) Intervention: IV Amoxicillin- clavulanic acid 1.2g	Confirmed or suspected maternal infection within 6 weeks of delivery: 11.0% (Intervention) vs 19.0%	High baseline rate (>10%) of infections/ complications observed after operative vaginal delivery. Use of a composite primary outcome (including new	1++	A

			Comparator: Placebo Duration: Single dose	(Comparator), RR: 0.58 (95% CI: 0.49 – 0.69)	prescription of antibiotics for confirmed or suspected infection)		
174	Prospective RCT (France)	121	Normal (uncomplicated) vaginal birth Intervention: Antibiotics (IV Amoxicillin-clavulanic acid 1.2g) Comparator: No treatment Duration: Single dose, 1 hour after birth	Endometritis rates: 0.66% (Intervention) vs 2.38% (Comparator) ($p=0.013$, 95% CI 0.36- 3.08). NS difference in hospitalisation duration	Overall rates were low. Similar in demographics, but not blinded. High risk of bias, small numbers	1-	B
173	Prospective RCT (USA)	393	Operative vaginal delivery (vacuum or forceps delivery) Intervention: IV Cefotetan 2g Comparator: No treatment Duration: Single dose	Endomyometritis: none in intervention group vs 7 with endometritis (no antibiotic) (RR 0.07, 95% CI 0.00–1.21)	Baseline demographics were similar, NS difference in proportion with fourth-degree laceration (approximately 40% delivered by forceps, the other 60% by vacuum extraction). Baseline rate of endometritis: 3.47% (high) without prophylaxis vs normal vaginal delivery 0.83%. Patients were randomised by “randomisation table”	1-	B
175	Randomised control trial (USA)	146	Third- or fourth-degree perineal lacerations Intervention: IV Cefotetan or IV cefoxitin 1g, or IV clindamycin 900mg (if penicillin allergy) Comparator: Placebo Duration: Single dose	Perineal wound complications (wound disruption and purulent discharge) at two-week: 8.20% (intervention) vs 24.10% (comparator), RR: 0.34 (95% CI: 0.12 – 0.96)	Study has a high loss of follow- up (27.2% lost to follow-up at 2 weeks post-partum check-up); the study terminated early as it was unable to achieve the desired enrolment number	1+	B
170	Systematic review (Brazil)	73 (1 quasi-RCT)	Episiotomy repair after vaginal birth Intervention: PO Chloramphenicol 500mg QDS for 72 hours after episiotomy repair	Episiotomy wound dehiscence with infection: RR: 0.13 (95% CI: 0.01 – 2.28) Episiotomy wound dehiscence without	Only 1 quasi-RCT was included with small numbers (n=73), high risk of selection bias (non- random sequence generation and allocation concealment according to protocol number) and wide CIs	2-	C

			Comparator: No treatment	infection: RR: 0.82 (95% CI: 0.29 – 2.34)			
				No cases of other puerperal infections (e.g. endometritis) were reported			
176	Quasi-Randomised control trial (Brazil)	73	Episiotomy repair after vaginal birth Intervention: PO Chloramphenicol 500mg QDS for 72 hours after episiotomy repair Comparator: No treatment	NS difference in episiotomy wound dehiscence with and without infection, no cases of other puerperal infections reported	Assessment at day 10 post-partum. One trial - Bonet et al ¹⁷⁰ [High risk of selection bias (non-random sequence generation and allocation concealment according to protocol number), no double-blinding]	2-	C
177	Quasi-Randomised control trial (India)	300	Episiotomy repair after vaginal birth Intervention: PO cefixime 200mg BD and PO metronidazole 400mg TDS for 5 days after episiotomy repair Comparator: No treatment	Presence of infection at 5 days post-partum 0.7% (Intervention) vs 2.0% (Comparator), $p=0.622$	Nil comparison of baseline characteristics. Outcomes were assessed only at 5 days post-partum, which may be too early to draw conclusions	2-	C
Operative vaginal delivery					FINAL GRADE	1+	A
Third- or fourth-degree perineal lacerations					FINAL GRADE	1+	B
Episiotomy repair					FINAL GRADE	2-	C
OVERALL					FINAL GRADE	1-	B

***ANODE**: Prophylactic ANtibiotics for the prevention of infection following Operative Delivery; **LOS**: Length of stay; **NS**: Non-significant

Hysterectomy

Guidelines

Table A-26: Guideline references for surgical prophylaxis recommendations

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade	Grading System
ASHP, IDSA, SIS, and SHEA ¹	2013	Hysterectomy (vaginal or abdominal)	IV cefazolin or IV cefotetan or IV cefoxitin or IV ampicillin-sulbactam	[(IV clindamycin or IV vancomycin) WITH (IV aztreonam or IV fluoroquinolone)] or [IV metronidazole WITH (IV aminoglycosides or IV fluoroquinolones)]	Single dose	Limited trials involving Single dose cefazolin was used, mainly for vaginal hysterectomy. Single doses of cefotetan, ceftizoxime, or cefotaxime appeared to be as effective as multiple doses of cefoxitin. The studies were done mainly in the 1980-1990s	A	Agency for Healthcare Research and Quality, and ASHP, IDSA, SIS, and SHEA Category A (levels I–III) - Level I (evidence from large, well-conducted, randomised, controlled clinical trials or a meta-analysis) - Level II (evidence from small, well-conducted, randomised, controlled clinical trials) - Level III (evidence from well-conducted cohort studies)
ANZOG ¹³⁴	2012	Hysterectomy	IV metronidazole 500mg WITH IV cefazolin 1g (2g if weight ≥80kg)	(IV clindamycin 600mg WITH IV gentamicin) or IV cefoxitin 2g	Single dose	Multiple doses were not found to be more effective than a single dose prior to incision. Based on Chang et al ¹⁹⁴ . Single dose cefazolin was as effective as multiple doses in laparoscopic-assisted vaginal hysterectomy. Screen and treat patients for bacterial vaginosis prior to undergoing	Level I	NHMRC Levels of Evidence Level I: A systematic review of level II studies (RCTs)

						hysterectomy. Antibiotic prophylaxis should include an antibiotic with an anaerobic spectrum		
ACOG ¹⁷⁹	2018	Hysterectomy, including supracervical (vaginal, abdominal, laparoscopic, robotic)	IV cefazolin 2g (3g if weight ≥120kg)	(IV clindamycin 900mg or IV Metronidazole 500mg) PLUS (IV Gentamicin 5mg/kg or IV Aztreonam 2g)	Single dose	Single dose cefazolin is recommended, based on ASHP ¹ . Studies were mainly based on need for antibiotic prophylaxis (Mittendorf et al ¹⁸⁸ meta-analysis on antibiotic prophylaxis for abdominal hysterectomy, Ayeleke et al ¹⁸³ elective hysterectomy)	Level A	U.S. Preventive Services Task Force Level A: Recommendations are based on good and consistent scientific evidence
						Screening for bacterial vaginosis in women undergoing hysterectomy can be considered		
SOGC ¹⁸⁰	2012	Vaginal and abdominal hysterectomy Laparoscopic hysterectomy Laparoscopy not entering the uterus and/or vagina	First- or second-generation cephalosporin (IV)	IV clindamycin or IV erythromycin or IV metronidazole	Single dose	Considered Class II (clean-contaminated) Vaginal: Review by Duff et al ¹⁸⁴ , 20 studies, supports use of antibiotic prophylaxis. Abdominal: -3 meta-analyses (Tanos et al ¹⁸⁷ , Mittendorf et al ¹⁸⁸ , Wttewaall-Evelaar ¹⁸⁹ . RCT: Chongsomchai et al ¹⁹¹ , single dose vs placebo, Eckenhausen and Jonker ¹⁹² , single dose cefuroxime/ metronidazole vs 24 hours) Laparoscopic: clean contaminated procedure,	<ul style="list-style-type: none"> • Level I-A • Level III-B • Level I-E 	Canadian Task Force on Preventive Health Care Level I: Evidence obtained from at least one properly RCT Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees Class A: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

						<p>similar rates of SSI vs vaginal hysterectomy Chang et al¹⁹⁴ (single dose cefazolin as effective as multiple doses).</p> <p>Johnson et al. Cochrane 2006: laparoscopic procedures lower SSI rates vs abdominal hysterectomy (updated in 2015¹⁹³).</p> <p>Not entering uterus and/or vagina: clean procedure.</p> <p>RCT: Kocak et al²⁰¹, laparoscopy (non-hysterectomy) found no difference in SSIs in those who received 1 dose cefazolin vs without</p>		<p>Class B: There is fair evidence to recommend the clinical preventive action</p> <p>Class E: There is good evidence to recommend against the clinical preventive action</p>
SOGC ¹⁸¹	2019	Hysterectomy for benign gynaecologic conditions	First-generation cephalosporin	NA	Single dose	<p>Additional doses should be administered if an open procedure exceeds 3 hours or if blood loss is greater than 1500ml</p> <p>For need for single dose antibiotics, this guideline references the SOGC Guidelines (Van Eyk et al¹⁸⁰: The SOGC recommends a first-generation cephalosporin as a single dose given 15 to 60 minutes prior to the first incision)</p>	Strong, High	<p>Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)</p> <p>Strong: Highly confident of the balance between desirable and undesirable consequences (i.e., desirable consequences outweigh the undesirable consequences; or undesirable consequences outweigh the desirable consequences)</p> <p>High (++++): Very confident that the true effect lies close to that of the estimate of the effect</p>

ERAS Society ¹⁸²	2019 [1966 – 2018]	Hysterectomy	First-generation cephalosporin	NA	Single dose	Antibiotic prophylaxis should be adjusted according to the planned procedure, with the addition of anaerobic cover in the setting of pelvic cancer surgery or bowel surgery. (Ref: Re-dosing should be performed as indicated based on duration of surgical case and blood loss)	Strong, High	<p>Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)</p> <p>Strong recommendations: The panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects</p> <p>Recommendations are based on quality of evidence (high, moderate, low) but also on the balance between desirable and undesirable effects, and on values and preferences of practitioners. Thus, strong recommendations may be reached from low-quality data and vice versa</p>
-----------------------------	-----------------------------	--------------	--------------------------------	----	-------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

***ANZOG**: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC**: National Health and Medical Research Council; **ACOG**: American College of Obstetricians and Gynecologists; **SOGC**: Society of Obstetricians and Gynaecologists of Canada; **ERAS**: Enhanced Recovery After Surgery

Literature

Table A-27: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
200	Systematic review (Multiple countries)	13 RCTs	Intervention: Cefazolin Comparator: other first-choice antimicrobials with anti-anaerobic activity	SSI risk higher with cefazolin vs cefoxitin or cefotetan (RR 1.7; 95% CI, 1.04–2.77; $p=0.03$)	Most studies included non-standardised dosing and duration, had indeterminate or high risk of bias, did not include patients with gynecological malignancies, and/or were older RCTs not	1-	B

					reflective of current clinical practices. Did not comment on single vs multiple doses of antibiotic		
183	Systematic review (Multiple countries)	6079 (37 RCTs)	Elective hysterectomy (vaginal and abdominal, benign gynaecological conditions) Intervention: Antibiotic (varied) Comparator: None	Vaginal hysterectomy Post-operative infections: RR 0.28 (95% CI: 0.19 – 0.40) Abdominal hysterectomy Post-operative infections: RR 0.16 (95% CI: 0.06 – 0.38)	Unclear evidence on which dose regimen or route is safest or most effective. Studies included had very low to moderate quality of evidence with risk of bias such as poor reporting of randomisation, small sample sizes, low event rates, inadequate reporting of adverse effects Did not comment on single vs multiple dose antibiotic. Studies/ RCTs mostly in the 1980s	1-	B
195	Observational prospective cohort study (Finland)	5279	Hysterectomy (abdominal, laparoscopic, and vaginal) Intervention(s): A) IV cefuroxime 1.5g at induction B) IV metronidazole 500mg at induction C) Combination of IV cefuroxime with IV metronidazole	Total infections: cefuroxime OR 0.29 (95% CI: 0.22 – 0.39); metronidazole OR 0.95 (95% CI: 0.72 – 1.24)	Lack of randomisation, possible bias (single drug may have been chosen for the less challenging cases)	2-	D
196	Retrospective observational study (China)	1783	Minimally invasive endometrial staging Intervention: IV cefazolin 1g q6h PLUS IV metronidazole 500mg q8h Comparator: IV cefoxitin 2g q8h Duration: 24 hours	SSI: 3.6% (Intervention) vs 5.7% (Comparator) Higher incidence of SSI in cefoxitin vs cefazolin/ metronidazole: OR 2.213 (95% CI: 1.193 – 4.107)	No available records of bacterial vaginosis in this study (known that bacterial vaginosis may increase the incidence of vaginal cuff infections)	2-	D

198	Retrospective observational study (Taiwan)	139	Radical hysterectomy or staging operation for gynaecologic cancers Intervention: Cefazedone for 1 day Comparator: Cefazedone for >1 day	SSI: 6.4% (Intervention) vs 8.3% (Comparator)	Metronidazole was added in 3 cases (5.0%) in "Comparator" group	2-	D
199	Retrospective cohort study (USA)	18,255	Abdominal, vaginal, laparoscopic, or robotic hysterectomy for benign or malignant indications Intervention(s): 1) IV cefazolin 2) Second-generation cephalosporin 3) IV cefazolin and IV metronidazole (combination)	Unadjusted SSI rate: 1.8% (cefazolin), 2.1% (second-generation cephalosporin), 1.4% (combination) SSI higher in cefazolin group (Adjusted OR, 2.30; 95% CI 1.06-4.99) and second-generation cephalosporin (Adjusted OR 2.31, 95% CI 1.21-4.41) vs combination	Lack of randomisation, possible bias in antibiotic selection	2-	D
194	Retrospective cohort study (Taiwan)	319	Laparoscopic-assisted vaginal hysterectomy Intervention: 1g IV cefazolin, single dose Comparator: Multiple doses of IV Cefazolin	Prophylactic effect similar in single dose cefazolin group vs multiple doses (range 2-4 doses), 94.6% vs 93.9%, NS difference between operative site infection and UTI	Select population with similar baseline demographics	2+	C
192	Open study (Netherlands)	159	Abdominal hysterectomy Intervention: IV cefuroxime, IV Metronidazole single dose Comparator: IV cefuroxime, IV Metronidazole 24 hours	Post-operative wound infections, UTI similar in both groups (2/84 vs 1/75, 3/84 vs 4/75, NS). No significant differences in other parameters, e.g.: pyrexia and LOS	Lack of randomisation, information on demographics. possible bias in antibiotic selection	2-	D
202	Retrospective observational study (Japan)	Benign indication: 131	Open hysterectomy for benign indication (without lymphadenectomy) a for malignant indication (with lymphadenectomy)	For benign indication SSI: 0.0% (Intervention), vs 4.7% (Comparator) For malignant indication	Real-world study of pre- and post-guidelines implementation in Japan, but small sample size. Similar demographics between both groups (benign	2+	C

Malignant indication: 93	<p>For benign indication Intervention (post-optimisation): IV cefazolin x 1 dose, 30-60 minutes pre-skin incision Comparator (pre-optimisation): IV cefazolin, up to 1 day</p> <p>For malignant indication Intervention (post-optimisation): IV cefmetazole x 24 hours Comparator (pre-optimisation): IV cefmetazole, up to 1 day</p>	SSI: 9.5% (Intervention), vs 7.8% (Comparator)	and malignant indications), approximately 30% of those with malignant indication were abdominal radical hysterectomy. Showed no change in SSI post-national guidelines optimisation of antibiotics use (intervention arm). Cefmetazole use or malignant indications (hysterectomy with lymphadenectomy, abdominal radical hysterectomy) included anaerobic cover	FINAL GRADE	2-	C
--------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------	-----------	----------

***LOS**: Length of stay; **NS**: Non-significant

Hysteroscopy

Guidelines

Table A-28: Guideline references for surgical prophylaxis recommendations

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence / Grade	Grading System
ANZOG ¹³⁴	2012	Hysterosalpingography or hysteroscopy or chromotubation for patients with dilated tubes or a history of PID or tubal damage	PO doxycycline 100g BD for 5 days PLUS IV metronidazole 500mg single dose	PO azithromycin 1g single dose	5 days (doxycycline); Single dose (metronidazole, azithromycin)	Reported rate of infection after HSG: 1.4 – 3.4%, lower when fallopian tubes were not dilated	IV	NHMRC Level of Evidence Level IV: A case series with either post-test outcomes or pre-test/post-test outcomes
		Hysterosalpingography or hysteroscopy or chromotubation with	NA	NA	NA		IV	

		no history of PID and normal tubes on visualisation						
ACOG ¹⁷⁹	2018	Hysterosocopy	Not recommended	Not recommended	NA	Infectious complications after hysteroscopic surgery are uncommon (approx. 1–2%). A systematic review (4 RCTS), one RCT, no difference in post-operative infection after hysteroscopy between women who received antibiotic prophylaxis and those who received a placebo	Level I to II-3, Level B	U.S. Preventive Services Task Force Level I: Evidence obtained from at least one properly designed RCT. Level II-3: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence. Level B: Recommendations are based on limited or inconsistent scientific evidence
SOGC ¹⁸⁰	2012	Hysteroscopy	Not recommended	Not recommended	NA	Case series by Baggish et al ³¹⁷ suggests that infection risk is low (< 1%). References Kasius et al ²¹³ - A pseudo-randomised study of 266 women who underwent office hysteroscopy, and received PO amoxicillin-clavulanic acid and doxycycline 2 hours pre-procedure, with no difference in infection; Bhattacharya et al ²¹² - A randomised trial of amoxicillin-clavulanic acid vs placebo for hysteroscopic ablation (n=116) found a significant difference in the occurrence of bacteraemia	Level II-2D	Canadian Task Force on Preventive Health Care II-2: Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group D. There is fair evidence to recommend against the clinical preventive action

(16% vs 2%); however, isolated organisms of dubious clinical significant

***ANZOG**: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC**: National Health and Medical Research Council; **ACOG**: American College of Obstetricians and Gynecologists; **SOGC**: Society of Obstetricians and Gynaecologists of Canada

Literature

Table A-29: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
206	Meta-analysis (Multiple countries)	2327, 5 RCTs	Hysteroscopic procedures, various indications Intervention: Antibiotic prophylaxis (1106) vs none (698) vs placebo (523)	Pooled incidence of events was very low. Fever, 3.79% vs 1.8%, OR 2.17 (95% CI 0.80-5.88), infection 0.52% vs 0.58%, OR 1.66, (95% CI 0.43-6.5) Incidence of serious infections requiring treatment was very low at 0.2% (pre-treated, none in control groups)	Indications and techniques of hysteroscopies, definition and timing of prophylaxis are heterogenous, no event for some outcomes	1-	B
207	Meta-analysis (Multiple countries)	2221	Hysteroscopic procedures, various indications Intervention: Antibiotic prophylaxis vs none	Infection rate between the antibiotic prophylaxis group and control group: NS difference (OR: 0.50, 95% CI: 0.987–1.008)	As above, all were European studies, with inadequate raw data for analysis	1-	B
209	RCT (Italy)	180	Hysteroscopic procedures, various indications Intervention: IV cefazolin 2g vs no antibiotic pre-operatively	NS difference between post-operative fever 2.4% (Intervention) vs 2.3% (Comparator), infectious complications including endometritis, PID (none)	Various indications for hysteroscopy including endometrial hyperplasia, myomas, and endometrial polyps	1-	B
210	RCT (Italy)	1046	Hysteroscopy for intrauterine lesions	Post-surgical infection after 5 days: 1.0% (Intervention) vs 1.15% (Comparator), NS	Various indications for hysteroscopy in the office/ clinic setting, for endometrial	1+	B

			Intervention: IM cefazolin 1g Comparator: placebo, pre-operative		polypectomy, uterine septa, submucosal myomas and intrauterine adhesions		
211	RCT (Greece)	364	Diagnostic hysteroscopy Intervention: antibiotic prophylaxis vs no antibiotics (pre-operative)	No difference in post-procedural infection, 0.57% (Intervention) vs 0.53% (Comparator)	Various indications for diagnostic hysteroscopy such as, menometrorrhagia, post-menopausal vaginal bleeding, thickened endometrium, or as routine examination prior to 1 st in-vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI), over 8 years	1-	B
213	Quasi-Randomised control trial (Netherlands)	631	Diagnostic hysteroscopy for infertility candidates (prior to 1 st IVF or ICSI) Intervention: PO augmentin 625mg and doxycycline 200mg 2 hours pre-procedure Comparator: none	No difference in post-procedural infection, 1 in antibiotic group (0.4%)	Low risk of infectious complication at 0.4%. No randomisation	2-	C
212	RCT (United Kingdom)	116	Hysteroscopic surgery (TCRE or ELA) Intervention: IV Augmentin 1.2g at induction Comparator: Placebo Duration: once	No difference in bacteraemia (16% vs 2%, 95% CI 0.05-0.25) and women treated for presumed infection (11.4% vs 9%)	Majority of organisms were of dubious clinical significance; contamination could not be excluded in 7 of 10 cases, and none of the women were seriously ill. No objective measures for presumed infection	1-	B
FINAL GRADE						1-	B

***IVF**: in-vitro fertilization; **ICSI**: intracytoplasmic sperm injection; **TCRE**: transcervical resection of the endometrium; **ELA**: laser ablation of the endometrium; **NS**: Non-significant

Hysterosalpingography (HSG)**Guidelines***Table A-30: Guideline references for surgical prophylaxis recommendations*

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade	Grading System
ANZOG ¹³⁴	2012	Hysterosalpingography or hysteroscopy or chromotubation for patients with dilated tubes or a history of PID or tubal damage	PO doxycycline 100g BD for 5 days PLUS IV metronidazole 500mg single dose	PO azithromycin 1g single dose	5 days (doxycycline); Single dose (metronidazole, azithromycin)	Reported rate of infection after HSG: 1.4 – 3.4%, lower when fallopian tubes are not dilated	IV	NHMRC Level of Evidence Level IV: A case series with either post-test outcomes or pretest/post-test outcomes
		Hysterosalpingography or hysteroscopy or chromotubation with no history of PID and normal tubes on visualisation	NA	NA	NA		IV	
ACOG ¹⁷⁹	2018	Hysterosalpingography	NA	NA	NA	If a history of PID or abnormal tubes is noted on HSG, PO doxycycline 100mg BD for 5 days can be considered to reduce the incidence of post-procedural PID	Level II-2	U.S. Preventive Services Task Force II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or research group
SOGC ¹⁸⁰	2012	Hysterosalpingography	PO doxycycline 100g BD for 5 days (in the presence of dilated tubes)	NA	5 days (doxycycline)	Screen for STI, and treat if necessary. Antibiotics prophylaxis should be given to patients at high risk (determined by history	Level II-3B	Canadian Task Force on Preventative Health Care II-3: Evidence obtained from comparisons

	and/or as indicated by the presence of tubal obstruction at time of HSG)	between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category B: There is fair evidence to recommend the clinical preventive action
--	--------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

***ANZOG:** Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC:** National Health and Medical Research Council; **ACOG:** American College of Obstetricians and Gynecologists; **SOGC:** Society of Obstetricians and Gynaecologists of Canada; **STI:** Sexually transmitted infection

Literature

Table A-31: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade	Reference
214	Retrospective observational (case-control) (USA)	604	Group 1: 278 Group 2: 326	Hysterosalpingography with a history of tubal dilatation, or dilated tubes at time of HSG PO doxycycline 100mg BD for 5 days	PID in women with dilated tubes: 0% (doxycycline) vs 11.4% (without doxycycline), $p<0.02$	NA	2-	C
FINAL GRADE							2-	C

Endometrial Biopsy, Cervical Tissue Excision, Cervical Cone Procedures**Guidelines***Table A-32: Guideline references for surgical prophylaxis recommendations*

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade	Grading System
ANZOG ¹³⁴	2012	Endometrial biopsy	Not indicated	Not indicated	NA	NA	Level IV	NHMRC Level of Evidence Level IV: A case series with either post-test outcomes or pretest/post-test outcomes
ACOG ¹⁷⁹	2018	Endometrial biopsy	Not recommended	Not recommended	NA	Considered clean-contaminated procedures. Although, even without antimicrobial prophylaxis, the risk of infection complicating these procedures is very low. No estimates of infectious complications of endometrial biopsy was found in the review, the incidence is presumed to be negligible	NA (unclear grading)	U.S. Preventive Services Task Force
		Cervical tissue excision procedures (LEEP, biopsy, endocervical curettage)	Not recommended	Not recommended	NA	Two randomised trials of antibiotics prophylaxis undergoing LEEP with prolonged antibiotics were included, with significant limitations including prolonged duration of antibiotics and surrogate outcomes (vaginal discharge, vaginal discharge). A Cochrane review, which included an additional study, showed no evidence of	NA (unclear grading)	U.S. Preventive Services Task Force

					reduction in infection with antibiotic prophylaxis		
SOGC ¹⁸⁰	2012	Endometrial biopsy	None recommended	None recommended	There were no studies that assessed the use of prophylactic antibiotics given before an endometrial biopsy procedure. Insufficient evidence to support the use of antibiotic prophylaxis for an endometrial biopsy	Level III-L	Canadian Task Force on Preventative Health Care Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees Grade; L: There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making

***ANZOG**: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC**: National Health and Medical Research Council; **ACOG**: American College of Obstetricians and Gynecologists; **LEEP**: loop electrosurgical excision procedure; **SOGC**: Society of Obstetricians and Gynaecologists of Canada

Literature

Table A-33: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
205	Systematic review (NA)	NA	Transcervical intrauterine procedures	NA	No trials were eligible for inclusion in the systematic review, no conclusions regarding the use of prophylactic antibiotics in transcervical intrauterine procedures. A few RCTs have been conducted since for hysteroscopic procedures	4	GPP

215	Systematic review (Multiple countries)	708 (3 RCTs)	Excisional treatment to cervix (for cervical intraepithelial neoplasia) Intervention: Prophylactic antibiotics (oral or pessary), 1 trial with PO ofloxacin 400mg once daily for 5 days; 2 trials with antimicrobial pessaries (1 for 5 days, 1 for 14 days) Comparator: Placebo (oral antibiotics); No treatment (pessaries)	Incidence of prolonged vaginal discharge: 13.3% (Intervention) vs 10.3% (Comparator), RR 1.29 (95% CI: 0.72 – 2.31) No difference in incidence of fever, lower abdominal pain, unscheduled medical consultation, or additional self-medication	2 trials with antimicrobial pessary, only one with oral antibiotics (ofloxacin for 5 days). Only 1 trial (oral antibiotics) reported the outcome of prolonged vaginal discharge (presumed cervicitis), other outcomes reported were possible “surrogate” outcomes of infection (such as fever, abdominal pain), but unknown whether symptoms were due to infection (no microbiological cultures taken, self-reported symptoms). But no direct comparison of the incidence of cervicitis, endometritis, and PID	1-	B
216	Prospective, randomised, placebo controlled RCT (United Kingdom)	348	LEEP Intervention: Ofloxacin 400mg Comparator: Placebo Duration: once daily for 5 consecutive days	Post-operative vaginal loss (vaginal discharge, bleeding): 15% (Intervention) vs 11% (Comparator), $p=0.39$	Assessment was done via pictorial chart, with self-reported outcomes. Did not reach final sample size	1-	B
217	Prospective observational cohort study (Bulgaria)	92 (only 72 had follow-up outcome data)	Diagnostic and therapeutic curettage (49 were emergency, 23 had an endometrial biopsy) Intervention: PO doxycycline 200mg after procedure, then 100mg BD for 3 days	No signs of infection in all patients with endometrial biopsy; 6 patients (8.3%) of patients with emergency curettage had signs of infection and PO doxycycline was continued for 6 days	Unable to access article (in Bulgarian). There was no comparator arm, all patients received PO doxycycline, and continued use for 6 days was at physicians' discretion	2-	D

No comparator arm							
218	Prospective observational cohort study (Greece)	67	Endometrial curettage for metrorrhagia Intervention: PO doxycycline 200mg once daily for 1 week Comparator: No treatment	PID: 4 patients, 9% (Intervention), vs 3 patients, 9% (Comparator), NS	Unable to access article	2-	D
219	Prospective observational cohort study (Indonesia)	60	Curettage for indications for diagnostic and therapeutic indications Intervention: Group A: IV cefazolin 2g single dose, then PO amoxicillin 500mg TDS x 3 doses Comparator: Group B: IV cefazolin 2g single dose only Group C: PO amoxicillin 500mg TDS x 3 doses post-procedure only	Similar occurrence of PID symptoms (high leukocyte counts, high ESR, abdominal pain, fever, vaginal discharge and bleeding) between groups, except pain ($p=0.03$)	Selection bias, no mention of randomisation process. Most common reason for curettage was for abortion (65 – 70%). Small sample size, did not evaluate the need for no antibiotics but of different antibiotics regimens	2-	D
FINAL GRADE						2-	C

* **LEEP**: loop electrosurgical excision procedure; **ESR**: erythrocyte sedimentation rate; **NS**: Non-significant

Intra-Uterine Device (IUD) Insertion

Guidelines

Table A-34: Guideline references for surgical prophylaxis recommendations

Reference	Year	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade	Grading System
ANZOG ¹³⁴	2012	IUD insertion	Not recommended	Not recommended	NA	A 2001 meta-analysis of four randomised trials (Grimes et al ²²²) found no evidence that antibiotic prophylaxis reduced the risk of PID. Antibiotic prophylaxis at time of IUD insertion does not impact on the risk of future actinomycosis	Level 1	NHMRC Level of Evidence Level I: A systematic review of level II studies
ACOG ¹⁷⁹	2018	IUD insertion	Not recommended	Not recommended	NA	Considered as clean-contaminated procedures, although even without antimicrobial prophylaxis, the risk of infection complicating these procedures is very low Main reference: ACOG 2017 Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices ²²⁰	Level III, Level A	U.S. Preventive Services Task Force Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. Level A: Recommendations are based on good and consistent scientific evidence
ACOG ²²⁰	2017	IUD insertion	Not recommended	Not recommended	NA	The 1999 Cochrane meta-analysis (Grimes et al. Cochrane 1999, updated 2001 ²²²) showed that antibiotics prophylaxis at the time of IUD insertion did not reduced risk of PID, or reduce the likelihood of IUD removal within the 1 st 3 months. Risk of IUD-related infection occurs within first few weeks to months after insertion, suggesting that	Level III, Level A	U.S. Preventive Services Task Force Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. Level A: Recommendations are based on good and consistent scientific evidence

						bacterial contamination of endometrial cavity at time of insertion was the cause of infection. Absolute risk of developing PID is less than 0.5%		
SOGC ¹⁸⁰	2012	IUD insertion	Not recommended	Not recommended	NA	Consider screening for STI in high-risk populations	Level I-E	Canadian Task Force on Preventative Health Care Level I: Evidence obtained from at least one properly randomised controlled trial Level E: There is good evidence to recommend against clinical preventive action
SOGC ²²¹	2016 [Jan 1994 to Jan 2015]	IUD insertion	Not recommended	Not recommended	NA	Perform STI testing in women at high risk. If tested positive for chlamydia and/or gonorrhea, treat post-insertion, IUD can remain in-situ	Level I-B	Canadian Task Force on Preventative Health Care Level I: Evidence obtained from at least one properly randomised controlled trial Level B: There is fair evidence to recommend clinical preventive action

***ANZOG**: Royal Australian and New Zealand College of Obstetricians and Gynaecologists; **NHMRC**: National Health and Medical Research Council; **ACOG**: American College of Obstetricians and Gynecologists; **SOGC**: Society of Obstetricians and Gynaecologists of Canada; **STI**: Sexually transmitted infection

Literature

Table A-35: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
222	Meta-analysis (Multiple countries)	4119 (6 RCTs)	IUD insertion Antibiotics (either PO doxycycline 200mg before IUD insertion; 200mg before insertion followed by daily for two days; or PO azithromycin	PID: OR 0.89 (95% CI: 0.53 – 1.51) Removal of IUD within 90 days: OR 1.05 (95% CI: 0.68 – 1.63) Antibiotic prophylaxis confers little benefit, low risk of IUD-	Higher prevalence of STI among women enrolled in the African studies. But low overall prevalence of cervical infection with <i>Neisseria gonorrhoeae</i> at 3% (in	1+	B

			500mg before insertion) vs placebo	associated infection, with or without use of prophylaxis	Kenyan trial), and 1% (Nigerian trial)		
225	RCT (USA)	1985	Copper IUD insertion in women with a low self- reported risk of STIs Intervention: PO azithromycin 500mg Comparator: Placebo Duration: Single dose 1 hour prior IUD insertion	IUD removal (for reasons other than partial expulsion): 3.8% (Intervention) vs 3.4% (Comparator), RR 1.1, 95% CI 0.7-1.8), no difference in rate of unscheduled visits	Low STI risk in this population (screened for STI prior). Reasonable follow-up period of 90 days	1+	B
223	RCT (Nigeria)	1813	IUCD insertion Intervention: PO doxycycline 200mg Comparator: Placebo Duration: Single dose 1 hour prior IUD insertion	PID: 1.3% (Intervention) vs 1.9% (Comparator), RR 0.69, 95% CI 0.32-1.47. IUCD-related visits statistically significant: RR 0.69; 95% CI 0.52 to 0.91)	Ladipo et al ²²⁷ attempted to replicate this and found no difference in both outcomes	1+	B
FINAL GRADE						1+	A

***STI**: Sexually transmitted infection; **IUCD**: Intrauterine contraceptive device

ORTHOPAEDIC/SPINAL PROCEDURES

Clean Orthopaedic, Non-Spinal Procedure with No Implantation

Guidelines

Table A-36: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
ASHP, IDSA, SIS, and SHEA ¹	Clean orthopaedic surgery not involving implantation of foreign materials	Not recommended	Not recommended	NA		1+/C
SIGN ²³⁰	Orthopaedic surgery without implants	Not recommended	Not recommended	NA		4/D
SAAGAR ⁵⁸	Arthroscopic and other clean procedures not involving foreign material	Not recommended	Not recommended	NA		No grading of evidence as this guideline cited other guidelines

***SIGN**: Scottish Intercollegiate Guidelines Network; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance

Literature

Table A-37: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
231	Randomised placebo controlled trial (USA)	715 patients	General orthopaedic procedures (fractures, osteoarthritis, internal knee derangements) Cefamandole vs placebo Cefamandole given 1 dose pre-operative and 4 doses post-operative till 24 hours	SSI: 1.6% vs 4.2% (NS)	Old study: Oct 1976 to Sep 1976 There was a significant reduction in post-operative infection in the prophylaxis group. There was a significant reduction when operation time was >120 minutes	1+	
						FINAL GRADE	B

***NS**: Non-significant

Clean Orthopaedic Surgery with Implants

Guidelines

Table A-38: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
ASHP, IDSA, SIS, and SHEA ¹	Clean orthopaedic surgery with implants	Cefazolin	Vancomycin Clindamycin	24 hours		1+/A
SIGN ²³⁰	Arthroplasty	NA	NA	24 hours		2++/B
SAAGAR ⁵⁸	Orthopaedic surgery with and without joint replacement	Cefazolin If MRSA colonised: IV cefazolin + IV vancomycin	IV vancomycin	24 hours		No grading of evidence as this guideline cited other guidelines
CDC ³³	Fracture surgery and prosthetic joint arthroplasty	No recommended antibiotic choice	No recommended antibiotic choice	24 hours		1+/A

*SIGN: Scottish Intercollegiate Guidelines Network; SAAGAR: South Australian expert Advisory Group on Antimicrobial Resistance

Literature

Table A-39: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
232	Randomised placebo controlled trial (Unknown)	312 patients	Hip fracture surgery Cefazolin 4 doses vs 1 dose vs placebo	SSI: 1.6% vs 2.4% vs 3.7%, NS	Full text not available	1+	
233	Randomised placebo controlled trial (Sweden)	121 patients	Trochanteric hip fracture surgery Cefuroxime x 24 hours vs cefuroxime x 24 hours + PO cefalexin x 6 days	SSI: 7.6% vs 10.7%, NS	Sep 1982 to May 1984 - Authors concluded that there is no need for prophylaxis to be extended beyond 72 hours	1++	
234	Meta-analysis (USA)	14 RCTs 9691 patients	Orthopaedic procedures where implants are utilised	SSI: 2.0% vs 2.0%, $p=0.74$	Authors concluded that quality of evidence was low 14 RCTs: 7 arthroplasty surgeries, 1 spine surgery, 6 general	1++	

			Single dose vs multiple doses of peri-operative antibiotics	orthopaedic procedures (2 hip fractures) There were 4 studies with high bias		
235	Retrospective cohort study (USA)	2181 patients	Primary total knee and hip arthroplasty surgery Antibiotic prophylaxis ≤24 hours vs additional oral antibiotic prophylaxis x 7 days	High-risk patients without extended antibiotic prophylaxis were 4.9 ($p=0.009$) and 4.0 ($p=0.037$) times more likely to develop prosthetic joint infections after total knee arthroplasty and total hip arthroplasty	2011 to 2016 - Authors concluded that high-risk patients should receive oral antibiotics for 7 days to reduce infection	2++
236	Case-control study (USA)	418 patients	Revision total hip placement surgery Antibiotic prophylaxis ≤24 hours vs >24 hours	SSI: 2.4% vs 4.8%, NS	Retrospective review of cases between 2000 to 2015: No benefit was noted with extending antibiotic prophylaxis	2++
237	Randomised double-blinded case-control study (USA)	160 patients	ORIF of closed extremity fractures Post-operative 23 hours Cefazolin prophylaxis (1g q8h, 2 doses) vs Placebo	SSI: NS Patients treated with cefazolin prophylaxis were less likely to develop SSI either superficial or deep infection (5 SSI in treatment vs 10 in prophylaxis, NS)	Patients with diabetes mellitus and risk score ≥2 more likely to develop SSI (smoking, ≥65 years old, diabetes mellitus, BMI ≥35, surgery >3 hours, urinary catheter)	2+
238	Retrospective cohort study (USA)	20682 patients	Total knee or hip arthroplasty	SSI: 0.6% vs 0.88%, NS	There was a trend towards a lower prosthetic joint infection risk among patients who received a	2+

			Antibiotic prophylaxis (cefazolin or vancomycin) single dose vs multiple doses (24 hours)		single dose. Patients who received multiple doses of antibiotics demonstrated a trend toward higher rates of acute kidney injury compared with a single dose. <i>C. difficile</i> infections were infrequent in both groups	
239	Retrospective cohort study (Hong Kong)	887 patients	Total knee or hip arthroplasty Cefazolin x 1 peri-operative dose vs Cefuroxime x 3 doses (1 peri-operative and 2 post-operative doses)	SSI: Hip: 1.1% vs 1.1%, $p=1.00$ Knee: 1.0% vs 1.6%, $p=0.63$	887 patients with 1367 arthroplasties were included. The overall deep wound infection rate in the cefuroxime group was 1.4% and 1.0% in the cefazolin group (Fisher's exact test, $p=0.72$). The overall superficial wound infection rates of the cefuroxime group and the cefazolin group were 2.8% and 1.6% (Fisher's exact test, $p=0.26$) respectively	2++
240	Systematic review (United Kingdom)	23 studies 8447 patients	Closed fracture fixation No antibiotic prophylaxis vs single dose vs multiple dose antibiotic prophylaxis	SSI: Deep infection: 2.4% vs 2.0%, $p=0.91$ Superficial infection: 6.2% vs 10.7%, $p=0.37$	Antibiotics are effective in reducing the incidence of infection. Single dose antibiotic prophylaxis significantly reduced deep surgical site infection, superficial SSI, urinary infections, and respiratory tract infections. Multiple dose prophylaxis had an effect of similar size on deep surgical site infection, but significant effects on urinary and respiratory infections were not confirmed	1++
						FINAL GRADE A

*ORIF: Open reduction and internal fixation; NS: Non-significant

Spine Procedures with/without Implantation

Guidelines

Table A-40: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
ASHP, IDSA, SIS, SHEA ¹	Spinal Procedures with and without Instrumentation	Cefazolin	Vancomycin Clindamycin	24 hours		1+/A
SAAGAR ⁵⁸	Spinal Procedures	Cefazolin If MRSA colonised: IV cefazolin + IV vancomycin	IV Vancomycin	24 hours		No grading of evidence as this guideline cited other guidelines
NASS ²⁴¹	Spine Surgery	No recommended antibiotic choice	No recommended antibiotic choice	Single dose		1+/B

*SAAGAR: South Australian expert Advisory Group on Antimicrobial Resistance; NASS: North American Spine Society

Literature

Table A-41: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
2	Systematic review and Meta-analysis (USA)	5 studies 2824 patients	Spinal surgery Pre-operative antimicrobial prophylaxis vs extended antimicrobial prophylaxis (indefinite)	SSI: 1.28% vs 1.38% (NS)		1++	
242	Randomised case-control study (Canada)	552 patients	Posterior thoracolumbar spinal surgery managed with a closed-suction drain Post-operative antibiotic prophylaxis x 24 hours vs 24 hours after drain removal	SSI: 6.0% vs 5.2%, $p=0.714$	A complicated infection developed in 17 (6.0%) of 282 patients in the 24-hour group and in 14 (5.2%) of 270 patients in the 72-hour group; the rates did not differ between antibiotic groups ($p=0.714$) The superficial infection rate	1++	

					was 9.6% (27 of 282) among patients in the 24-hour group and 8.1% (22 of 270) among patients in the 72-hour group ($p=0.654$)	
243	Randomised double-blinded case-control study (USA)	314 patients	Multilevel thoracolumbar spinal surgery, followed by use of post-operative drain Antibiotic duration x 24 hours vs duration that drain was in place	SSI: 12.4% (24 hours) vs 13.2% (drain-duration), $p=0.48$	There were NS differences between the 24 hours and drain-duration groups with respect to demographic characteristics (except for the ASA classification), operative time, type of surgery, drain output, or length of hospital stay. Authors commented that a much larger sample size could have led to a decreased rate of infection in the 24 hours arm	2+
244	RCT (USA)	233 patients	Instrumented lumbar spinal fusion surgery Cefazolin x single dose pre-operatively vs cefazolin x 3 days + PO cefalexin x 7 days post-operatively (total 10 days)	SSI: 4.3% (single dose) vs 1.7% (10 days), NS	Study limitations were its small sample size	1-
245	Retrospective cohort study (Korea)	548 patients	Spinal surgery Antibiotics x 48 hours vs 72 hours	SSI: 1.4% (48 hours) vs 0.4% (72 hours), $p=0.325$	A subgroup analysis was performed for cases with instrumented fusion. NS differences were noted between both groups in this subgroup analysis ($p=1.0$) Study limitations were its small sample size	2+
246	Retrospective cohort study (Hong Kong)	226 patients	Posterior spinal fusion surgery Cefazolin prophylaxis x 2 post-operative doses vs continued cefazolin antibiotic prophylaxis till drain removal	SSI: 1.9% (2 doses) vs 1.4% (antibiotics till drain removal), $p=1.0$	It was also noted that shorter antibiotic prophylaxis did not negatively affect wound healing. Study limitations were small sample size and likely underpowered study. Groups	2+

					were compared across 2 time periods	
247	Prospective cohort study (Poland)	5208 patients	Spine surgery (instrumented) Single dose antibiotic prophylaxis vs 72 hours antibiotic prophylaxis	SSI: 5.3% (single-dose) vs 2.2% (72 hours prophylaxis), $p<0.01$	Both groups were compared in 2 different time periods, whereby there could have been other factors that may have affected the results e.g. new non-pharmacological interventions. Different antibiotics were also used and not clearly documented	2+
FINAL GRADE						A

*NS: Non-significant; ASA: American Society of Anesthesiologists

OTORHINOLARYNGOLOGY

Clean Head and Neck Procedures

Guidelines

Table A- 42: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
ASHP, IDSA, SIS, and SHEA ¹	Head and neck – clean	None	None	NA	Thyroidectomy, lymph node excision	B
	Head and neck – clean with placement of prosthesis	Cefazolin, cefuroxime	Clindamycin*	24 hours		C

*The addition of an aminoglycoside to clindamycin may be appropriate when there is an increased likelihood of gram-negative contamination of the surgical site.

Literature

Table A- 43: Literature review of references

Reference	Study Design/ Country	Sample Size	Population intervention	Outcome	Limitations/Remarks	Level of Evidence	Final grade
249	Randomised, double-blinded (Italy)	500	Thyroid procedure Prophylaxis vs none	SSI 0.8% (prophylaxis) vs 0.4% (none). NS	Excluded patients with diabetes mellitus, immunocompromised, patients with secondary surgeries, >80 years old	1+	
250	Systematic review	6 studies (n=4428)	Thyroidectomy Parathyroid surgery (RCT, non-RCT)	SSI 0.6% (case) vs 0.4% (control). NS	No evidence of heterogeneity (Q statistic=8.36)	1+	
251	Retrospective cohort (Israel)	464	Parotidectomy Comparing those with peri-operative antibiotic (cefazolin or clindamycin) vs none	Wound infection rates: $p=0.168$. Multivariate analysis showed female gender, neck dissection and drain output > 50ml/24hours were predictive of post-operative wound infection		2+	

						FINAL GRADE	1+ (Grade A)
Neck Dissection							
267	Retrospective cohort	192	Uncontaminated neck dissection	Wound infection – 10% (no antibiotic), 3.3% (antibiotics). NS	Low power beta greater than 0.2	2-	
268	Prospective series	57 (antibiotic group) vs 51 (no antibiotic)	Clean neck dissection Unasyn 24 hours vs no peri-operative antibiotic	Wound infection 1/57 (1.7%) in study group and 7/51 (13.3%) in control group, $p=0.02$	Baseline high infection rate Small sample size	1-	
269	Retrospective chart review	273 procedures	Uncontaminated neck dissections Group 1 – no antibiotic Group 2 – intra-operative Group 3 – Intra-operative and post-operative antibiotic	Wound infection only occurred in Group 2 and 3. 4/157 (Group 2) vs 5/75 (Group 3) ($p=0.11$). Wound infection associated with operative time and with radical or extended neck dissection	Conclusion: Antibiotic prophylaxis may be required in extended lymphadenectomy procedures	2+	
						FINAL GRADE	2+ Grade C

*NS: Non-significant

Clean-Contaminated Head and Neck

Guidelines

Table A- 44: Guideline references for surgical prophylaxis recommendations

Guideline	Type of Surgery	Fist line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
ASHP, IDSA, SIS, and SHEA ¹	Clean-contaminated cancer surgery	Cefazolin/cefuroxime + metronidazole Ampicillin-sulbactam	Clindamycin**	24 hours		A
	Other clean-contaminated procedures (except tonsillectomy and FESS)	Cefazolin/cefuroxime + metronidazole Ampicillin-sulbactam	Clindamycin**	24 hours	Parotidectomy, submandibular gland excision,	B

adenoidectomy,
rhinoplasty,
mandibular
fracture repair

* **FESS:** Functional endoscopic sinus surgery

**The addition of an aminoglycoside to clindamycin may be appropriate when there is an increased likelihood of gram-negative contamination of the surgical site.

Literature

Table A- 45: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
252	Systematic review and meta-analysis (only RCT)	4 RCTs (n=340)	Clean-contaminated head and neck surgery	Pooled relative risk of wound infection 0.98 (95% CI 0.58-1.61, NS) comparing 1 day vs 5 days	1 day vs 5 days no difference	1++	
253	Systematic review and meta-analysis (RCTs, observational studies)	15 studies compared duration	Clean-contaminated head and neck surgery	Treatment for more than 48 hours did not reduce wound infection. Increased infection with clindamycin treated patients OR 2.73	>48 hours no benefit	1+	
254	Systematic review and meta-analysis (3 retrospective, 2 prospective)	5 studies (n=861)	Clean-contaminated head and neck with microvascular free flap reconstruction (short course 24-48 hours vs long course)	SSI were higher in ≤24 hours (RR 1.56, 95% CI 1.13-2.14). Post hoc multivariate analysis based on individual level data from 697 patients showed that risk of SSI 24 hours vs > 24 hours was not significant after adjusting for antibiotic type (RR 1.09, CI 0.78- 1.55). Those who received clindamycin had higher SSIs	Risks of SSI NS between 1-2 days vs longer after adjusting for antibiotic type	1-	
255	Prospective, randomised trial (USA)	181 Antibiotic (n=81) No-Antibiotic (n=100)	Open mandibular fractures with ORIF 2.4 MU PenG +/- metronidazole, cefazolin or clindamycin with (5-7	Infection: 8/81 vs 14/100, (p=0.399)	High drop-out rate 20- 30% No difference between with or	1-	

			days) or without post-operative antibiotic		without post-operative antibiotic	
256	Prospective, randomised, double-blind (Taiwan)	53	Clean-contaminated head and neck IV clindamycin 24 hours vs 72 hours	30-day wound infections were not associated with duration of antibiotics Pre-operative haemoglobin level and surgical reconstruction with free flaps or pectoralis major myocutaneous flaps were independent factors significantly related to wound infection	Excluded diabetes mellitus patients 26 patients had reconstruction surgery including flaps	1-
257	Prospective randomised double blind study (Turkey)	60	Major head and neck surgery Cefotaxime 24 hours vs 7 days	Wound infection: 13% (24 hours) vs 10% (7 days), NS	*Unable to access full article* No difference between 1 day vs 7 days	1-
258	Prospective randomised (Iran)	90	Laryngectomy Cefazolin 2 days vs 5 days	No wound infection in either group. Mucocutaneous fistula 4.4% (2 days) vs 6.7% (5 days) NS		1-
259	Retrospective review (USA)	147	Free tissue reconstruction Short course (≤ 2 days) or long course (> 2 days)	SSI, flap dehiscence, flap loss and LOS – no difference. Those receiving long course has higher rates of pneumonia but lower UTI	No difference between ≤ 2 and > 2 days	2+
260	Retrospective multi-institution analysis (multivariate log regression) (USA)	8836	Clean-contaminated head and neck	Patients on Unasyn had OR 0.28 when used antibiotic on day of surgery +1 day (vs on day of surgery alone). This effect was not seen in the clindamycin group	Favours 2 days as compared to 1 day	2++
261	Retrospective cohort (USA)	150 (75 each arm)	Complicated and non-complicated mandibular fractures 24 hours vs up to 10 days	Infection: 10.6% (extended duration) vs 13.3% (24 hours) $p=0.8$	No difference: 24 hours vs up to 10 days	2+

262	Retrospective cohort study (USA)	427 96 (24 hours or less) 331 (prolonged)	Free flap reconstruction of head and neck defects Unasyn (53.2%), Clindamycin (36%), others (10.3%)	Clindamycin associated with post-operative infection OR 6.71, $p=0.004$; not the duration of antibiotic		2++
						FINAL GRADE 1+ (A)
Oncologic Head And Neck						
263	Prospective, randomised trial (Italy)	162 (81 on each arm)	Oncologic head and neck Clindamycin-cefonicid (1 day vs 3 days)	20-day wound infection: 2.5% (1 day) vs 3.7% (3 days), NS. Pre-operative radiotherapy associated with greater severity of infection and higher risk of late wound complications	No difference comparing 1 vs 3 days	1+
264	Prospective randomised (USA)	74	Head and neck cancer surgery with free-flap reconstruction Clindamycin (3 doses) vs (15 doses)	Wound infection: 11% (3 doses) vs 10% (15 doses), NS	No difference comparing 1 vs 5 days	1-
265	Prospective, quasi-randomised (Germany)	75 (25 in each arm)	Major oncologic head and neck Group 1: 5 day Group 2: Peri-operative Group 3: Peri-operative + local antiseptic care	SSI: Group 1 (1/25), Group 2 (9/25), Group 3 (9/25), $p=0.01$	Suggest prolonged course (5 day has lower SSI compared to peri-operative only)	1-
266	Retrospective review	100 procedures (61 free flap, 39 local flap reconstructions)	Oropharyngeal reconstruction after oncologic resection. 48 hours vs long course (>48 hours)	Duration of antibiotic is not associated with recipient-site complications. Clindamycin was associated with complications		2-
						FINAL GRADE 2+ (C)

***ORIF**: Open reduction and internal fixation; **NS**: Non-significant; **LOS**: Length of stay


Otologic procedures

Clean procedures include tympanostomy tubes, tympanoplasty, stapedectomy and mastoidectomy. Clean-contaminated procedures include cholesteotoma or drainage involved.

Literature

Table A- 46: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
270	Cochrane review (through 2002) Randomised and quasi-randomised	11 studies	Clean and clean-contaminated ear surgery	No difference between prophylaxis group (peri-operative antibiotic) vs control group (no antibiotic) for post-operative infection, graft failure, draining of outer ear and adverse drug reaction	Combined both clean and clean-contaminated	1+	
271	Prospective randomised controlled, double-blind (India)	78	Tympanoplasty with cortical mastoidectomy Group 1: Peri-operative Group 2: 8 days more	Wound infection rate – NS Graft success rate – NS LOS longer in Group 2 Higher GI adverse drug reaction in Group 2		1-	
272	Prospective, double-blind, randomised, placebo-controlled (Belgium)	750	Ear surgery Cefuroxime 1 day vs placebo	Infection rate: 3.1% (cefuroxime) vs 4.7% (placebo), NS. All infections occurred in the tympanoplasty group. $p < 0.005$	Extrapolation Risk of infection was higher in pre-operative state of wet perforation and in cases of cholesteatomas.	1+	

 <p>The authors recommend that antibiotics, when given as in the present study design, may decrease the incidence of early post-operative infections by factor 3 (which is statistically significant) in draining ears and cholesteatomas</p>						
273	Retrospective chart review (USA)	195	Tympanoplasty +/- mastoidectomy for cholesteotoma Clindamycin and ceftazidime or gentamicin	SSI: 11% (no antibiotic) vs 1% (pre-operative antibiotic), $p=0.02$	Clean-contaminated (extrapolation as no direct duration comparison)	2+
FINAL GRADE						Clean: 1+(A) Clean-contaminated: 1- (B)

*NS: Non-significant; LOS: Length of stay; GI: Gastrointestinal

Tonsillectomy

Guidelines

Table A- 47: Guideline references for surgical prophylaxis recommendations

Guideline	Type of Surgery	First line	Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
ASHP, IDSA, SIS, and SHEA ¹	Other clean-contaminated procedures (except tonsillectomy and FESS)	Cefazolin/cefuroxime + metronidazole Ampicillin-sulbactam	Clindamycin**	24 hours	Parotidectomy, submandibular gland excision, adenoidectomy,	B

rhinoplasty, mandibular
fracture repair

* **FESS**: Functional endoscopic sinus surgery

**The addition of an aminoglycoside to clindamycin may be appropriate when there is an increased likelihood of gram-negative contamination of the surgical site.

Literature

Table A- 48: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/ Remarks	Level of Evidence	Final Grade
274	Systematic review (only RCTs included)	5 trials	Tonsillectomy	Fever RR 0.62 (0.45-0.85); duration of halitosis -1.94 (-3.57, -0.3), time taken to resume normal activity -0.63 (-1.12, -0.14). No effect on pain score -0.01 or the need for analgesia. RR for antibiotic adverse drug event was 2.45 (0.45, 13.31)		1+	
275	Systematic review (RCTs)	10 trials (n=1035)	Tonsillectomy	Most did not find significant reduction in pain with antibiotics. Not associated with reduction in hemorrhage. Secondary outcome: Antibiotic reduced the proportion of patients with fever (RR 0.63, 0.46-0.85, $p=0.002$)		1+	
FINAL GRADE						1+	A

Septorhinoplasty

Literature

Table A- 49: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
276	Prospective, randomised, single- blind study (Australia)	200	Septorhinoplasty (simple) Single shot IV Augmentin vs 7-day regimen	Local wound infection (3%) in 7-day group; none (single dose), NS Side effects: 29% vs 2% ($p=0.03$)	Excluded patients with significant comorbidities (cardiovascular, diabetes mellitus, infections, malignancy, immunodeficiencies)	1+	

Nasal packing only 24 hours						
277	Prospective, randomised, single-blinded (United Kingdom)	164	Complex septorhinoplasty Augmentin 1 day vs 7-day	10 th day post-operative infection: 7% (1-day) vs 11% (7-day). NS 80% were minor	*full article not available*	1-
278	Systematic review (up to Feb 2018)	5 RCTs n=589	Rhinoplasty Post-operative vs pre-operative and peri-operative or placebo	Infectious complications – no difference Pooled RR 0.92 ($p=0.86$)	Low internal risk of bias Moderate heterogeneity in terms of surgical techniques	1+
279	Systematic review (all study types)	6 studies n=990	Nasal packing for epistaxis or septoplasty	Purulent drainage was 11.2% (no antibiotic) vs 9.9% (with antibiotic), NS. None developed toxic shock syndrome	Only 3 of the studies were prospective RCTs Study number may be too small	1-
FINAL GRADE: Simple						1- B
FINAL GRADE: Complex						1- B

*NS: Non-significant

Note: Two older RCTs (1980, 1977) showed no benefits of antibiotics for septorhinoplasty with nasal packing (n=504). Another RCT (n=100) found that 7-day course reduce infection as compared to placebo in complex rhinoplasty. (1988) – extrapolation done using these older studies.

For simple septorhinoplasty, extrapolations done based on 1+ studies. The only study that addressed this was by Lange JL (Level of evidence 1-).

Endoscopic sinus surgery (clean-contaminated)

Note: Given the lack of studies comparing intra-operative antibiotic vs no antibiotics, one dose of antibiotic is recommended to be given intra-operatively.

Guidelines

Table A- 50: Guideline references for surgical prophylaxis recommendations

Guideline	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
-----------	-----------------	------------	-------------------------------------------	----------	---------	--------------------------

ASHP, IDSA, SIS, and SHEA ¹	Other clean-contaminated procedures (except tonsillectomy and FESS)	Cefazolin/cefuroxime + metronidazole Ampicillin-sulbactam	Clindamycin**	24 hours	Parotidectomy, submandibular gland excision, adenoidectomy, rhinoplasty, mandibular fracture repair	B
----------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------	---------------	----------	-----------------------------------------------------------------------------------------------------	---

* **FESS**: Functional endoscopic sinus surgery

**The addition of an aminoglycoside to clindamycin may be appropriate when there is an increased likelihood of gram-negative contamination of the surgical site.

Literature

Table A- 51: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
280	Systematic review and meta-analysis (Through May 2011)	4 studies (all RCTs)	Endoscopic sinus surgery	Antibiotic prophylaxis associated with NS reduction of infection (RR 0.76, 95% 0.64-1.09), symptom scores -0.04 (-0.46-0.38)	Heterogeneity was significant only for the outcomes of change of symptoms	1+	
281	Randomised, double-blind, placebo (China)	97	FESS for chronic sinusitis Group 1: on Traditional Chinese Medicine Group 2: amoxicillin 4 weeks Group 3: placebo	NS difference in subjective and objective outcomes	Did not state clearly if antibiotic was given intra-operative. Patients were given antibiotic pre-surgery but instructed to stop 1 week before surgery	1-	
282	Prospective, randomised, double-blind, placebo-controlled (Romania)	75	Endoscopic sinus surgery Augmentin 2 weeks vs placebo	5 th day nasal obstruction and drainage better in antibiotic group. Endoscopic score was statistically significantly different. Use of antibiotic was able to improve outcome in early blood crust healing phase,	Favours antibiotic use for early stage outcome improvements Did not state if antibiotic was given intra-operative	1-	

				nasal obstruction and drainage	
283	Randomised, double-blind, placebo-controlled, non-inferiority trial (USA)	77	Endoscopic sinus surgery Cefazolin was given intra-operative for both groups, then amoxicillin-clavulanic acid 1 week vs placebo	Placebo was non-inferior to antibiotic in terms of - SNOT-22 score - LK score Post-operative infection rates (2.6% vs 2.4%, NS). Diarrhoea was significantly higher in the antibiotic group (24.3% vs 2.5%, $p=0.02$)	1-
				FINAL GRADE**	1- Grade B

* **FESS**: Functional endoscopic sinus surgery; **NS**: Non-significant; **SNOT-22**: Sino-nasal outcome test; **LK**: Lund-Kennedy

**Note: Extrapolation was made based on one 1+ study and mainly 1- studies.

NEUROSURGERY

Guidelines

Table A- 52: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
ASHP, IDSA, SIS, and SHEA ¹	Clean wounds e.g. Elective craniotomy, EVD, ICP monitors	IV cefazolin 2g (3g if > 120kg) <u>MRSA colonised</u> IV vancomycin 15mg/kg	IV vancomycin 15mg/kg or IV clindamycin 600mg-900mg	Single dose*		A
	Clean wounds with foreign body or instrumentation e.g. CSF shunting procedures	IV cefazolin 2g (3g if > 120kg) <u>MRSA colonised</u> IV vancomycin 15mg/kg	IV vancomycin 15mg/kg or IV clindamycin 600mg-900mg	Single dose*		A
IDSA ²⁸⁴	Clean wounds e.g. Elective craniotomy, EVD	NA	NA	Single dose*		Strong, moderate
	Clean wounds with foreign body or instrumentation e.g. CSF shunting procedures	NA	NA	Single dose*		Strong, moderate
Neurocritical Care Society ²⁸⁸	Clean wounds EVD	NA	NA	Single dose*	Prolonged prophylactic antibiotic until EVD removed may increase the risk of resistant organisms and <i>C. difficile</i> diarrhea. Most studies of ventriculostomy-related infections are prospective or retrospective large case series, only 3 RCT exist	Conditional recommendation; low quality

* While single-dose prophylaxis is usually sufficient, the duration of prophylaxis for all procedures should be less than 24 hours.

Elective Craniotomy

Table A-53: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
285	Systematic review and meta- analysis	7 studies (1 RCT, 6 case series) (n=1655)	6 craniotomies, 1 ICP monitor. Comparing the efficacy of peri- operative antibiotic (no antibiotic, penicillin family antibiotics, first- generation cephalosporins vs fluoroquinolones, lincosamides, vancomycin, third- generation cephalosporins), single vs combination antibiotics	Lincosamides, glycopeptides, third- generation cephalosporins, other combinations of antibiotics or penicillin family antibiotics alone offer better coverage against SSI than first- generation cephalosporins	The inclusion of only 1 RCT and 6 case series can present bias. High heterogeneity in the pooled studies. Included Gliadel wafer implantation (1 case, ampicillin), primary brain tumor (2 cases, ampicillin and cefazolin) associated with high risk of post-surgical infection	1-	
286	Systematic review and meta- analysis	5 RCT (n=2209)	4 studies included craniotomy and shunt procedure, 3 studies include bur- hole and spinal surgery, 2 studies included transphenoidal. Comparing the efficacy of third- generation cephalosporin with peri-operative conventional regimens (vancomycin plus gentamicin,	The pooled OR for SSI with third-generation cephalosporin was 0.94 (95% CI, 0.59-1.52; $p=0.81$) Single dose conventional antibiotic regimen is much favourable as third- generation cephalosporin failed to show superiority in reduction of SSI	This study may not have included all the conventional antibiotics as comparators during cranial surgeries in view of the strict inclusion criteria (third-generation cephalosporin). Hence, unable to infer a specific conventional antibiotic regimen that provides the best coverage from infections	1++	

			trimethoprim-sulfamethoxazole, ampicillin-sulbactam, cefazolin). End point of the RCTs was the occurrence of SSI			
287	Meta-analysis	6 prospective randomised trials (n=1729)	Craniotomies with or without a prophylactic antibiotic. Protocol specified single dose allowed additional dose if the operation lasted longer than a prescribed time Primary end point was a random effects OR meta-analysis for meningitis after craniotomy	The pooled OR for meningitis with antibiotic treatment was 0.43 (95% CI 0.20-0.92; $p=0.03$) showing a significant benefit from antibiotics Subgroup analyses showed no detectable difference in antibiotic efficacy with or without gram-negative coverage	Excluded patients with implanted shunts or hardware, transphenoidal surgeries and patients who are undergoing re-operation Bias in interpretation or selective reporting due to differences in the definitions of meningitis used in individual studies	1++
FINAL GRADE						1+ (Grade A)

External Ventricular Drain (EVD), ICP Monitors

Table A- 54: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
289	Prospective performance analysis (USA)	866	Patients who underwent intraventricular catheterisation. Patients in period 1 received 1g q8h IV	Overall incidence of ventriculitis was 0.92%. Rates of ventriculitis did not differ significantly between period 1 and period 2 (1.1% vs 0.4%, $p=0.22$)	Results may not be generalisable. A low rates of ventriculitis raised the possibility of study is not sufficiently powered to see a difference	2+	

			cefazolin until EVD removed. Patients in period 2 only received peri-operative antibiotic up to 24 hours prior to antibiotic coated EVD placement	Single dose antibiotic following placement of antibiotic coated EVD did not result into more incidence of catheter-related ventriculitis		
290	Systematic review and meta-analysis	3 RCT and 7 observational studies	Patients who received prolonged prophylactic antibiotic and antibiotic coated EVD as a preventive measures for VRI	Pooled analysis showed a protective effect of SAP and antibiotic coated EVD for VRI (RR:0.32; 95% CI: 0.18-0.56)	Moderate heterogeneity in the pooled studies. The definitions of ventriculitis were variable, the type and dose of antimicrobials were different. Pooled analysis effect was likely contributed by the majority of the retrospective studies that were prone to bias. Mixture of placebo vs SAP and peri-operative antibiotic vs SAP makes the impact on peri-operative vs SAP difficult to interpret. Study by Poon et al. demonstrated that SAP caused more drug resistant virulent pathogens and higher mortality rate. SAP use is not recommended	1-
291	Retrospective cohort (USA)	345	EVD ≥3 days. 209 patients received prophylactic antibiotic for the duration of the EVD vs 99 patients who received peri-operative antibiotic	Overall rate of ventriculitis was 3.9%. The infection rate for prophylactic group (3.8%) vs peri-operative group (4.0%) Prophylactic antibiotic did not significantly reduce the rate of ventriculitis in patients with EVD and they may select for resistant organisms	With the baseline of overall rate of ventriculitis (4%), the sample size is inadequate to achieve power (80%) to observe differences in the infection rate for both arms	2+

292	Retrospective cohort (USA)	279	Patients with ICP monitor who received narrow spectrum antibiotic, cefazolin or vancomycin or no antibiotic (n=119), broad spectrum antibiotic, ceftriaxone or ciprofloxacin (n=160) as prophylaxis	Overall CNS infection occurrence was 3.2%. Narrow spectrum or no prophylaxis was 1.7% vs broad spectrum antibiotic (4.4%) (<i>p</i> =NS) but associated with a shift to resistant gram-negative pathogens	This study was non-randomised and retrospective.	2++
293	Retrospective cohort (USA)	30	Patients with severe closed-head injury who placed on ICP monitoring. 14 patients were initiated with cefazolin 1g q8h or nafcillin 1g q6h immediately before ICP placement and was continued for the duration of ICP monitoring vs 16 patients without ICP and prophylactic antibiotic	Patients with prophylactic antibiotic demonstrated statistically higher septic morbidity rates (78.6% vs 31.3%) and statistically higher pneumonia rates (57.1% vs 18.8%) compared with patients who did not. No patients developed CNS infection	Prolonged duration of prophylactic antibiotic use is unnecessary, if given at all, should be limited to the up to 24 hours prior to ICP monitor placement	2+
FINAL GRADE						2++ (Grade B)

***VRI**: ventriculostomy-related infections; **CNS**: Central Nervous System; **NS**: Non-significant

Cerebrospinal Fluid (CSF) Shunting

Table A- 55: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
294	Randomised prospective trial (Italy)	176 (88 vancomycin, 88 cefazolin single dose)	Patients aged >16 who underwent elective placement of internal and external shunts in a high MRSA prevalence hospital. Primary end point was the rate of shunt infections	Shunt infection in vancomycin group (4%) vs cefazolin group (14%) ($p=0.03$). Mortality among patients with post-surgical infections was higher in the cefazolin group vs vancomycin (5 vs 0) ($p=0.02$)	-	1+	
295	Systematic review and meta-analysis	15 RCT (n=1736)	Patients of any age with any type of intracranial ventricular CSF shunt surgical procedure. Comparing the use of prophylactic antibiotics vs placebo/no antibiotic in intracranial shunt procedures. Primary end point was the presence of shunt infection	The use of systemic antibiotic prophylaxis (vs placebo/no antibiotic) was associated with a decrease in shunt infection (OR: 0.52, 95% CI 0.36-0.74) regardless of the type of internal shunt (VA/VP) used Prophylactic antibiotic use up to 24 hours (vs continuous antibiotic) was found to be significant different (OR: 0.53, 95% CI 0.34-0.83; OR: 0.50, 95% CI 0.36-0.74 respectively)	No conclusion could be reached regarding the administration of prophylactic antibiotics for EVD	1++	
296	Prospective, open-label study (Italy)	100	Patients with hydrocephalus underwent VP shunt and received single dose of ceftriaxone prior to surgery	No shunt infection was observed over 4 year follow-up period	Exclusion: patients who received post-operative treatment in other departments or clinics might have missed the events (shunt infection)	2+	
FINAL GRADE							1+ (Grade A)

*VA: ventriculoatrial; VP: ventriculoperitoneal

UROLOGY

Cystourethroscopy

Guidelines

Table A- 56: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
AUA ²⁹⁷	Cystourethroscopy	Not required	NA	NA	Small RCT (n=47); recruited patients underwent urethrocystoscopy or urethrocystography with clear urine. Compared antibiotic prophylaxis and no antibiotic None of the patients in either group developed pyuria, bacteriuria or a febrile infection	1+
EAU ²⁹⁹	Cystourethroscopy	Not required	NA	NA	Cited two systematic reviews (details in Table A- 57) that show benefits of antibiotic prophylaxis with high NNT and concluded as below: Given the low absolute risk of post-procedural UTI in well-resourced countries, the high numbers of procedures being performed and the high risk of increasing antimicrobial resistance, the Workgroup Panel consensus strongly recommend not using antibiotic prophylaxis in patients undergoing urethrocystoscopy (flexible or rigid)	1+

*AUA: American Urological Association; EAU: European Association of Urology; NNT: Needed number to treat

Literature

Table A- 57: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
²⁹⁸	Systematic review – meta-analysis (Cochrane) 2019	20 RCTs and 2 quasi-RCTs with 7711 participants	Adults undergoing cystoscopy Antibiotic prophylaxis vs	Primary outcomes <u>Systemic UTI</u> RR 1.12 (95% CI 0.38-3.32) from 5 RCTs, 504 participants, low quality evidence	Most of the evidence reviewed were RCT which were graded as low and very low quality by the investigators;	1+	

			placebo or no treatment	<p><u>Symptomatic UTI</u> RR 0.49 (95% CI 0.28-0.86) from 11 RCTs, 5441 participants, low quality evidence. Serious adverse events: no serious adverse events were observed in either intervention group or control group and no effect size could be calculated</p> <p>Secondary outcomes</p> <p><u>Minor adverse events</u> RR 2.82 (0.54-14.80) from 4 RCTs, 630 participants, very low quality evidence</p> <p><u>Localized UTI</u> RR 1.0 (0.06-15.77) from 1 RCT, 200 participants, very low quality evidence</p> <p><u>Bacterial resistance</u> RR 1.73 (1.04-2.87) from 2 RCTs 38 participants, very low quality evidence</p>	<p>therefore, the recommendation is not strong</p> <p>Antibiotic prophylaxis is favourable in the prevention of symptomatic UTI, although it also causes significant bacterial resistance</p>
318	Systematic review and meta-analysis	7 RCTs – 5107 patients undergoing flexible cystoscopy	RCTs compare antibiotic vs placebo or no antibiotic administration	<p><u>Confirmed bacteriuria on mid-stream urine</u> OR 0.36 (95% CI 0.27-0.48), NNT 15</p> <p><u>Asymptomatic bacteriuria</u> OR 0.40 (95% CI 0.29-0.54), NNT 32</p> <p><u>Symptomatic bacteriuria</u> OR 0.34 (95% CI 0.25-0.47), NNT 26</p>	High NNT reflects less significant clinical benefit of antibiotic prophylaxis
319	Systematic review and meta-analysis	7 RCTs – 3038 patients (Jan 1998 – Dec 2013)	RCTs compare antibiotic vs placebo or no antibiotic administration	<p>Primary outcomes</p> <p><u>UTI</u> RR 0.53 (0.31-0.90), Absolute RR 1.3% (from 2.8% to 1.5%) NNT 74 (from 5 studies with moderate quality of evidence)</p> <p>Secondary outcomes</p> <p><u>Asymptomatic bacteriuria</u> RR 0.28 (0.20-0.39) from 6 RCTs with moderate quality of evidence</p>	High NNT for prevention of UTI reflects a low clinical benefit of antibiotic prophylaxis
FINAL GRADE A					

*NNT: Number needed to treat

Transurethral Procedures

Guidelines

Table A- 58: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
AUA ²⁹⁷	Transurethral procedures	Cefazolin or cotrimoxazole	Aminoglycosides	Single dose	<p>Cited</p> <p>1) systematic review (2005) showed any antibiotic prophylaxis (cephalosporins, fluoroquinolones, cotrimoxazole, aminoglycosides etc.) were effective in reducing the incidence of post-operative bacteriuria and fever (duration of antibiotic varied in each trial included in the systematic review)</p> <p>2) RCTs compared single dose ciprofloxacin and cefazolin and ciprofloxacin vs cefotaxime show no statistical difference in post-operative UTI</p> <p>Lack of large RCTs or systematic reviews to compare the effectiveness of a single-dose to multiple-dose of antibiotic</p>	1+
EAU ²⁹⁹	Transurethral procedure	Aminopenicillin + beta-lactamase inhibitor or cotrimoxazole or second- /third-generation cephalosporins	Non-penicillins agents in the first line	NA	<p>Cited systematic review (published in 2010) that showed benefit of antibiotic prophylaxis</p> <p>Does not specify type of antibiotic but recommends urologists to give antibiotics according to local susceptibility data for the common uropathogens</p>	1+
SAAGAR ⁵⁸	Transurethral procedure	Cefazolin or gentamicin		Single dose	No reference provided	
ASHP/IDSA ¹	Transurethral procedure	Fluoroquinolones or cotrimoxazole or cefazolin	Aminoglycoside with or without clindamycin	Single dose or less than 24 hours	Cited systematic reviews showed benefit of antibiotic prophylaxis for TURP in reducing post-operative infectious complication. Effective antibiotic included aminoglycosides, fluoroquinolones, cotrimoxazole and cephalosporins. Treatment protocols of any duration were effective	1+

***AUA**: American Urological Association; **EAU**: European Association of Urology; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance; **TURP**: Transurethral resection of the prostate

Literature

Table A- 59: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
300	RCT, multicentre	n=203, (Jan 2015 – Dec 2018 in Japan)	Patients with benign prostatic hyperplasia (without pyuria or bacteriuria) underwent transurethral enucleation of the prostate Single dose cefazolin (n=101) vs multiple dose cefazolin (n=102)	Primary outcome <u>Rate of genitourinary tract infection</u> : single dose (1.0%) vs multiple dose (2.0%), $p=1.00$ Secondary outcome <u>Antibiotic related adverse effect</u> 1 case in the multiple dose group No mention about this outcome in the single dose	Small sample size (did not indicate how sample size was calculated; this may have affected the power of the study)	1+	
FINAL GRADE							B

Transrectal Procedure

Guidelines

Table A- 60: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
AUA ²⁹⁷	Transrectal procedure	Fluoroquinolones or cephalosporins (commonly use third-generation) + aminoglycosides	NA	Single dose	Cited 1) RCT (1992-1993, n=537) compared single dose PO ciprofloxacin to placebo. The study showed benefit of PO ciprofloxacin in prevention of bacteriuria and UTI 2) RCT (1996-1998, n=231) compared single dose PO ciprofloxacin + tinidazole vs 3-day dose vs placebo. The study found antibiotic lowers the incidence of UTI post procedure compared to placebo. There was no difference in UTI in the single dose and 3-day group	1+
EAU ²⁹⁹	Transrectal procedure	Fluoroquinolones or cephalosporins or fosfomycin or aminoglycosides	NA	NA	Cited 1) RCT (1998-2001, n=192 in China) compared single dose ciprofloxacin + metronidazole vs 3-day dose of ciprofloxacin + metronidazole BD vs placebo. Study showed higher incidence of	1+

					<p>infection in the placebo group. There was no difference in infection rate in the antibiotic groups</p> <p>2) RCT (1996-1997, n=110) compared single dose ofloxacin vs single dose cotrimoxazole vs no antibiotic. The study showed higher frequency of bacteriuria in the non-prophylactic group (26.08%) while there was no difference in the antibiotic group 4.76% vs 6.66% (ofloxacin vs cotrimoxazole). There were 3 patients in non-prophylactic group required hospitalisation for pyelonephritis and prostatitis while there was no patient in the antibiotic group required hospitalisation</p> <p>EAU recommended fluoroquinolones but also emphasised on the issue of drug resistance for urologists to consider using targeted therapy or using alternatives such as cephalosporins</p>	
ASHP/IDSA ¹	Transrectal procedure	Fluoroquinolone or cotrimoxazole or cefazolin	Aminoglycoside +/- clindamycin	Single dose or less than 24 hours	Cited RCTs compared single dose and 3-day antibiotic prophylaxis and found no difference in infectious complication between the 2 groups	1+

***AUA**: American Urological Association; **EAU**: European Association of Urology

Literature

Table A- 61: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitation/Remarks	Level of Evidence	Final Grade
301	Systematic review – meta-analysis (Cochrane)	19 RCTs (total 3599 patients) Including studies from 1966 to 2010	<p>Patients underwent transrectal prostate biopsy</p> <p>Antibiotic prophylaxis vs placebo/no treatment</p> <p>Short-course (one day) treatment vs long-course (3 days) treatment</p> <p>Single dose vs multiple dose</p>	<p>Primary outcomes</p> <p><u>Bacteriuria</u> – RR 0.25 (0.15-0.42) – benefit of antibiotic prophylaxis regardless the drug class (quinolones, sulfonamides and other classes)</p> <p><u>Bacteraemia</u> – RR 0.67 (0.49-0.92)</p> <p><u>Fever</u> – RR 0.39 (0.23-0.64)</p> <p><u>UTI</u> – RR 0.37 (0.22-0.62)</p> <p><u>Sepsis</u> – 0.36 (0.04-3.24)</p> <p>Secondary outcomes</p>	Several classes of antibiotic were effective while fluoroquinolones were used in the highest number of studies and patients; however, this meta-analysis does not show the difference in outcomes from different antibiotic classes	1+	

				<p><u>Mortality</u> – no case of mortality reported</p> <p><u>Hospitalisation due to infection</u> – RR 0.13 (0.03-0.55)</p> <p><u>Adverse effects of antibiotic</u> – RR 1.62 (0.23-11.56)</p> <p>Short-course vs long-course Data shows favor long-course for bacteriuria only (RR 2.09, 1.17-3.73)</p> <p>Single dose vs multiple dose Data shows favor multiple dose for bacteriuria only (RR 1.98, 1.18-3.33)</p>		
302	Non-RCT (SGH study) – compared prospective intervention with retrospective control	367 vs 374	<p>Patient underwent transrectal ultrasound guided prostate biopsy from Sep 2003 to Aug 2004, who received ciprofloxacin only (n=367), were classified as the control group (ciprofloxacin-only). Patient underwent TRPB from Sep 2004 to Aug 2005 would be added 80mg IM gentamicin to the regimen (n=374) and classified as the intervention group (ciprofloxacin + gentamicin)</p> <p>Ciprofloxacin was given at 500mg BD x 3 days, started 24 hours prior to the procedure</p>	<p>Primary endpoint <u>Hospitalisation secondary to sepsis</u> – 12 cases in ciprofloxacin-only vs 5 cases in ciprofloxacin+gentamicin ($p=0.0458$)</p> <p>Secondary endpoint <u>Isolated bacteria and antibiotic susceptibility</u> – 9 cases of ciprofloxacin resistant <i>E. coli</i> were isolated in the control group while there was 1 case in the intervention group</p>	The investigators matched samples with underlying conditions and characteristics like diabetes mellitus, age, prostate size and prostate-specific antigen but did not match the history of antibiotic exposure and hospitalisation which potentially affect resistance and clinical infection	2*

			Gentamicin was given IM over the gluteal muscle 30 minutes prior to the procedure			
303	Retrospective cohort study (Jan 2011 to Oct 2013)	n=487 (455 for evaluation)	Ciprofloxacin vs alternative regimens – ciprofloxacin + cephalosporin (cefodoxime) vs ciprofloxacin + additional agent vs IM gentamicin	Infection related complication Ciprofloxacin 7.5% vs ciprofloxacin + cephalosporin 1.1% OR 7.29 (1.65-32.37) Ciprofloxacin 7.5% vs ciprofloxacin + additional agent 2.3% ($p=0.014$) Ciprofloxacin vs gentamicin – OR 0.39 (0.13-1.17, $p=0.08$) Gentamicin vs any alternative regimen – OR 4.23 (1.5-12.2, $p=0.004$)	Sample size was calculated to achieve the power of test Baseline demographic data were collected and analysed by univariate and multivariate analysis to determine the influence of infection; however, there was no mention of distribution of these factors to each group	2 ⁺
304	Systematic review Articles were recruited from 1946 to Nov 2015 All studies were comparing infective outcomes of patients undergoing TRUS-guided biopsy with either fluoroquinolone or culture-based targeted antimicrobial prophylaxis	9 studies	Patients underwent TRUS received either fluoroquinolone or culture-based targeted antimicrobial prophylaxis	Primary outcome <u>Post TRUS biopsy infective complication</u> – empiric prophylaxis vs targeted prophylaxis – 4.55% vs 0.72% $p<0.001$ Secondary outcome <u>Baseline prevalence of fluoroquinolone-resistance before TRUS</u> – 505/2219 (22.8%)		2 ⁺⁺
305	Systematic review	19 Trials (published in English from 2005 -2015, 10 RCTs, 7 prospective trials and 2 retrospective trials) were reviewed	Clinical trials compared the effect of antibiotic prophylaxis between active treatment (different agents or different duration)	Post biopsy infectious complication – 5 RCTs as follow, 1) tosufloxacin vs levofloxacin, 2) single dose IM ceftriaxone vs single dose PO ciprofloxacin vs 3-day PO ciprofloxacin 3) single dose ciprofloxacin vs single dose levofloxacin vs 3-day ciprofloxacin vs 3-day levofloxacin 4) ciprofloxacin vs ciprofloxacin + cephalosporin	This systemic review did not include a placebo controlled study. So the results cannot be used solely to determine the effective of using ciprofloxacin as a prophylactic choice especially in the era of high fluoroquinolone-resistant <i>E. coli</i> and <i>K. pneumoniae</i> . However, it did show that the duration of prophylaxis should be limited to no more than 3	1 ⁺

				<p>None of the trials demonstrated any differences in infectious or non-infectious complication rates following TRUS</p> <p>5) single dose PO ciprofloxacin vs 3-day PO ciprofloxacin vs 3-day PO chloramphenicol vs 3-day PO norfloxacin – significant reduction in the risk of post-biopsy infection favoring ciprofloxacin both as single-dose and 3-day regimen compared to chloramphenicol ($p=0.0003$) and norfloxacin ($p=0.03$)</p> <p>Duration of prophylaxis – none of the studies were able to show a benefit of continuing prophylaxis for more than a single dose (5 studies) or a 3-day regimen (1 study)</p>	days and ideally to a single dose	
306	Observational prospective study (2 phases of 5 years between 2001 and 2010)	300 vs 897	<p>First phase (Group 1, 2001 to 2005) - 300 patients were given ciprofloxacin 500 mg BD 1 day prior to the procedure, on the day of biopsy and 2 days after biopsy</p> <p>Second phase (Group 2, 2006 to 2010) - 897 patients were given additional IV amikacin 500 mg 30 minutes prior to biopsy (added to ciprofloxacin regimen)</p>	<p>Septicemia</p> <p>Group 1 vs Group 2 – 24/300 (8%) vs 15/897 (1.7%) ($p<0.001$)</p> <p>There was an increase in the incidence of post-procedural septicemia in Group 1, while the incidence was steady in the Group 2</p> <p>In 39 cases of septicemia, ciprofloxacin resistant <i>E.coli</i> is responsible for 33 cases</p>	Ciprofloxacin-resistant pathogens (<i>E. coli</i> , <i>K. pneumoniae</i> and <i>E. faecalis</i>) are a major concern of post-procedural infection	2 ⁺
						FINAL GRADE A

*SGH: Singapore General Hospital; TRUS: Transrectal ultrasonography

Transperineal Procedures

Guidelines

Table A- 62: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/Grade
AUA ²⁹⁷	Transperineal procedure (prostate brachytherapy)	Cefazolin	Clindamycin	Single dose	Cited RCT (conducted in 1998 to 2001) in which patients underwent prostate brachytherapy and were randomised to receive peri-operative antibiotic (n=258), either cefazolin or ciprofloxacin or no antibiotic prophylaxis (n=259). The author did not provide details on dose and duration. 1/258 (0.4%) in the antibiotic group developed epididymitis while 4/259 (1.5%) in no prophylaxis group developed epididymitis The number of cases was too small for statistical analysis regarding antibiotic use	1 ⁺

*AUA: American Urological Association

Literature

Table A- 63: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
307	Retrospective case review	n=485	Patients underwent a transperineal prostate biopsy between 2014 to 2016. Cefazolin (1g twice daily for 1 day at induction and 4 hours later) was used for antimicrobial prophylaxis	Infectious complications up to post-operative day 30 The rate of an infectious complications was 0.82% (4/485)	The rate of post-operative infection was very low. This was not an RCT so it is not certain that antibiotic prophylaxis is truly needed	2 ⁻	
308	Multicenter cohort study (retrospective chart review) conducted in Japan	n=826	Patients who underwent transperineal ¹²⁵ brachytherapy and	Peri-operative infection up to post-operative day 30 6/826 (0.73%) had infection received antibiotic prophylaxis for 1 or more days	The rate of peri-operative infection was very low. This was a chart review therefore it cannot be	2 ⁻	

	between Jan 2009 to Dec 2010		were evaluated for the relationships between various antimicrobial prophylaxis protocols and the incidence of post-implant infection	(4 patients received 1-day regimen of second-generation cephem). None of the patients who received single dose antibiotic prophylaxis (first-generation cephem, penicillin with beta-lactamase inhibitor and quinolone) had infection	used to recommend antibiotic prophylaxis. However, the benefit of using antibiotic prophylaxis is questionable	
320	Pooled prospective databases (from Sep 2009 to 2011) on transperineal prostate biopsy from multiple centres in Melbourne, and systematic literature review from PubMed and Embase	244 patients were reviewed	<p>Case review: Patients underwent transperineal biopsy. All patients received antibiotic prophylaxis – type of antibiotic as follows: cephalosporin alone (6%), cephalosporin + gentamicin (16%), cephalosporin + quinolone + gentamicin (45%), Quinolone alone (25%), Not specified (8%)</p> <p>Systematic review: from PubMed and Embase from 2003 to the time of study conducted (using search terms: transperineal, prostate biopsy, fever, infection, sepsis, septicemia and complications)</p>	<p>Case review: 245 transperineal biopsies were taken from 244 patients – no patient was re-admitted for infective complications. Ten patients (4%) developed acute urinary retention and 3 (1%) patients had clot retention</p> <p>Systematic review: There were 4 studies that did not use antibiotic prophylaxis. There were 5/6609 (0.076%) patients re-admitted to hospital for sepsis</p>	<p>Due to very low rate of infection, the author suggested antibiotic prophylaxis is probably not required for transperineal biopsy</p> <p>The author did not mention on the type of studies included in the systematic review. It is difficult to determine biases</p>	2 ⁺⁺
309	Retrospective review	242 cases of transperineal prostate biopsy by Precision	212/242 cases (88%) received no antibiotic prophylaxis. 30/242 (12%) cases received IM ceftriaxone or PO	No report of sepsis (0/242, 0.0%) and 1 report of late onset perianal abscess in the group of no antibiotic prophylaxis (1/212, 0.5%)		3

Percutaneous Renal Surgery

Table A- 64: Guideline references for surgical prophylaxis recommendations

Page | 123

SAAGAR ⁵⁸	Percutaneous renal surgery	Cefazolin + gentamicin (+metronidazole if risk of entering GI tract is present)	Vancomycin + gentamicin	Single dose	No reference was provided, but recommendations in the Australian guideline was assessed to be reasonable. The chances of entering the GI tract secondary to this procedure was deemed to be very rare	4
ASHP/IDSA ¹	Percutaneous renal surgery	Cefazolin + metronidazole or cefoxitin	Fluoroquinolone or aminoglycoside + metronidazole or clindamycin	Single dose or less than 24 hours	Cited a small RCT which recruited 81 patients with large stones, who underwent PCNL. Patients were randomised to receive single-dose ofloxacin or short-course ofloxacin until removal of the nephrostomy catheter. There was no difference in infectious complication between the two groups	1+

***AUA**: American Urological Association; **EAU**: European Association of Urology; **SIRS**: Systemic inflammatory response syndrome; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance; **GI**: Gastrointestinal

Literature

Table A- 65: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
321	RCT	n=86	Low risk patients (negative pre-operative urine cultures and without urinary drains) underwent PCNL Nitrofurantoin 100mg twice daily for 7 days preceding surgery vs no antibiotic All patients received peri-operative doses of ampicillin + gentamicin	Primary outcome: <u>Sepsis</u> 12% vs 14% ($p=1.0$) No benefit of giving one week of pre-operative oral antibiotic in low risk patients. Peri-operative antibiotic appears sufficient	Randomised trial distributed confounding factors equally to both groups	1+	
FINAL GRADE							A

Ureteroscopy

Guidelines

Table A- 66: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
AUA ²⁹⁷	Ureteroscopy	Cotrimoxazole or first-/second- generation cephalosporin		Single dose	<p>RCT, n=113, Patients underwent ureteroscopy</p> <p>Intervention: PO levofloxacin 250 mg 60 minutes prior to the procedure (n=57)</p> <p>Comparator: no antibiotic (n=56)</p> <p>Post-operative symptomatic UTI – no report in both groups</p> <p>Post-operative bacteriuria – without prophylaxis vs prophylaxis – 12.5% vs 1.8%, $p=0.026$</p> <p>Antibiotic showed benefit in prevention of post-operative bacteriuria and single dose is sufficient</p>	1+
EAU ²⁹⁹	Ureteroscopy	Cotrimoxazole or second-/third- generation cephalosporins or aminopenicillin + beta-lactamase inhibitor		NA	Cited single systematic review and two meta-analysis of RCTs showed low-grade evidence that antibiotic prophylaxis reduced risk of bacteriuria but not clinical UTI	1+
SAAGAR ⁵⁸	Ureteroscopy	Gentamicin or cefazolin		Single dose	No reference provided	4
ASHP/IDSA ¹	Ureteroscopy	Cefazolin + metronidazole	Fluoroquinolone or aminoglycoside	Single dose or less than 24 hours	Cited an RCT of 113 patients who underwent ureteroscopy (received single dose PO levofloxacin or no prophylaxis) and found rate of post-operative bacteriuria of 1.8% and 12.5% respectively $p=0.0026$	1+

***AUA**: American Urological Association; **EAU**: European Association of Urology; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance

Literature

Table A- 67: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
321	Retrospective review (at the University of British Columbia, Canada and Massachusetts General Hospital, USA), included patients from Feb 2009 to Aug 2011	n=81	All patients with renal calculi received single dose of antibiotic (cefazolin, cotrimoxazole or quinolone) prior to ureteroscopic stone treatment. 42 patients received only pre-operative antibiotic (Group 1) and 39 patients received both pre-operative and post-operative antibiotics at the surgeon's discretion (Group 2)	Post-operative UTI (total 8 patients (9.9%)) Group1 vs Group 2 – 2 vs 6, $p=0.1457$	Retrospective review cannot control biases	2 ⁻	
311	Systematic review and meta-analysis the last search was conducted on 23 Jan 2017	11 studies (5 RCTs + 1 prospective comparative study + 5 retrospective comparative studies) in a total of 4591 patients	Comparative studies investigating the efficacy of different antibiotic prophylaxis in ureteroscopic lithotripsy in patients without pre-operative infection Antibiotic prophylaxis vs no antibiotic Single dose of PO vs IV antibiotic Timing of dosing (single dose), ≤ 1 hour vs >1 hour	Outcomes: Post-operative infections Post-operative UTI <u>Antibiotic vs no antibiotic</u> : OR 0.82 (95% CI 0.40-1.67) <u>≤ 1 hour vs >1 hour</u> : OR 0.93 (95% CI 0.20-4.34) <u>PO vs IV</u> : OR 1.00 (95% CI 0.26-3.88) <u>Single dose vs multiple dose</u> : OR 0.98 (95% CI 0.06-16.12) Post-operative fever <u>Antibiotic vs no antibiotic</u> : OR 1.75 (95% CI 1.22-2.50) Pyuria	Included RCTs with high quality and low risk of biases and non-RCTs of high quality	1 ⁺⁺	

Single dose vs multiple dose	<p><u>Antibiotic (single dose) vs no antibiotic</u>: OR 0.42 (95% CI 0.25-0.69)</p> <p><u>≤1 hour vs >1 hour</u>: OR 0.81 (95% CI 0.41-1.59)</p> <p><u>PO vs IV</u>: OR 1.24 (95% CI 0.63-2.43)</p> <p><u>Single dose vs multiple dose</u>: OR 0.44 (95% CI 0.08-2.54)</p> <p>Post-operative bacteriuria</p> <p><u>Antibiotic (single dose) vs no antibiotic</u>: OR 0.25 (95% CI 0.11-0.58)</p> <p><u>≤1 hour vs >1 hour</u>: OR 2.97 (95% CI 0.35-25.35)</p> <p><u>PO vs IV</u>: OR 0.34 (95% CI 0.04-2.87)</p> <p><u>Single dose vs multiple dose</u>: OR 5.11 (95% CI 0.24-109.17)</p>
FINAL GRADE A	

Open/Laparoscopic Surgery

Guidelines

Table A- 68: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
AUA ²⁹⁷	Open/laparoscopic surgery	cefazolin		Single dose	<p>Extrapolated from systematic review of general surgery and obstetrics and gynaecology surgery antibiotic prophylaxis</p> <p>Cited retrospective review (2006) cases of radical retropubic prostatectomy which compared the incidence of surgical site infection and remote site infection between 1-day and 4-day antibiotic regimen for surgical prophylaxis. The studies found</p>	2 ⁺ and 4

					no difference in the outcomes between the two groups	
SAAGAR ⁵⁸	Open/laparoscopic surgery (urinary tract entered)	Cefazolin + gentamicin	Vancomycin + gentamicin (+metronidazole when there is risk of entry into the GI tract lumen)	Single dose	No reference provided	4
ASHP/IDSA ¹	Open/laparoscopic surgery	cefazolin	Fluoroquinolone or aminoglycoside with or without clindamycin	Single dose or less than 24 hours	Mentioned that there was no clinical trial in this type of surgery but extrapolated results from other major intra-abdominal procedures	4

***AUA**: American Urological Association; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance; **GI**: Gastrointestinal

Literature

Table A- 69: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
322	Prospective registry database review (between Jan 2010 and Oct 2015)	n=229	All patients underwent laparoscopic robot-assisted radical prostatectomy Group1 (n=60): antibiotic prophylaxis according to AUA guideline (single dose cephalosporin; cefamezine 2g + aminoglycoside; gentamicin 240 mg) and continued with PO ofloxacin 200mg or ciprofloxacin 250 mg twice daily until urethral catheter removal vs Group2 (n=169): pre-operative antibiotic (according to AUA guideline) only	Rate of CAUTI – 8.3% vs 8.9%, $p=0.89$ LOS – 5.8 vs 4.5 days, $p<0.001$	The number of subjects who received a single dose of antibiotic were more than 2 times the subjects received prolong antibiotic. The results favoured giving a single dose of antibiotic prophylaxis	2+	
						FINAL GRADE	B

* **CAUTI**: Catheter-associated urinary tract; **LOS**: Length of stay; **AUA**: American Urological Association

Urinary Diversion

Guidelines

Table A- 70: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
AUA ²⁹⁷	Urinary diversion	Cefazolin + metronidazole	Clindamycin + aminoglycoside	Single dose	Extrapolated from GI surgery antibiotic prophylaxis (colorectal surgery and appendectomy) Systematic review and meta-analysis	4
ASHP/IDSA ¹	Urinary diversion	Cefazolin + metronidazole	Fluoroquinolone or aminoglycoside +/- clindamycin or metronidazole	Single dose or less than 24 hours	Cited study (in Japan) which compared prospective intervention using 1 day antibiotic prophylaxis (piperacillin, n=38) to retrospective review using 3 days or more antibiotic prophylaxis (n=46). Patients' demographics were matched. All possible post-operative complications within 30 days were measured. There were no differences in the occurrence rate of infections listed below: Total SSI (18.1% vs 20.5%) Superficial incisional SSI (12.1% vs 13.6%) Deep incisional SSI (12.1% vs 13.6%) Space SSI (12.1% vs 11.4%) Post-operative ileus (18.2% vs 11.4%) Febrile UTI (15.2% vs 15.9%) Pneumonia (3.0% vs 4.3%)	2 ⁻

*AUA: American Urological Association; GI: gastrointestinal

Literature

Table A- 71: Literature review of references

Reference	Study Design/ Country	Sample Size	Population and Intervention	Outcome	Limitations/Remarks	Level of Evidence	Final Grade
312	Chart review (in 3 centres, University Medical Centre Regensburg)	n=217	Patients with urothelial bladder cancer underwent open radical cystectomy and created urinary diversion either incontinent (ileal, colon conduit or	Primary outcome In-hospital incidence of UTI after radical cystectomy within 30 days – 42 patients (19.4%)	This was not an RCT, therefore it could not be used for determining the antibiotic of choice and duration. However, the	2 ⁻	

<p>Germany, Laval University Quebec Canada and general hospital of Bolsano Italy) between 2009 and 2015</p>	<p>ureterocutaneostomy) or continent (neobladder or continent cutaneous reservoir)</p> <p>Risk factors of infections were recorded</p> <p>Urine samples were collected for antimicrobial susceptibility prior to the procedure. Patients with positive urine culture were treated accordingly at least 24 hours prior to the procedure. Patients with negative urine culture were given antibiotic at the induction of anaesthesia and continued according to the respective institution guidelines</p> <p>The most frequent used antibiotic prophylaxis was a combination of metronidazole (98.2%) and cephalosporin (89.9%)</p> <p>Median duration of antibiotic - 7 days (IQR 5-14) – 56 patients (25.8%) received antibiotic for only 24 hours</p>	<p>Identification of risk factors of UTI (using binary univariable and multivariable logistic regression analysis)</p> <p>Continent diversion was associated with the occurrence of UTI (OR = 5.027, 95% CI 2.119-11.923)</p> <p>The duration of antibiotic prophylaxis was not a protective factor against UTI</p>	<p>multivariate logistic regression analysis did not show an association of duration of antibiotic with the occurrence of UTI</p> <p>There was no RCT/systematic review/meta-analysis based on a search of articles up until Dec 2020 using Medline (PubMed)</p>
			<p>FINAL GRADE B</p>

Other Procedures

Table A- 72: Guideline references for surgical prophylaxis recommendations

Reference	Type of Surgery	First line	Alternative for Severe Penicillin Allergy	Duration	Remarks	Level of Evidence/ Grade
AUA ²⁹⁷	Implanted prosthesis	Aminoglycoside + first- /second-generation cephalosporin	Aminoglycoside + vancomycin	Single dose	Extrapolated from orthopaedic surgery (hip fracture surgery) and obstetric-gynecologic surgery (Mesh Inguinal Hernioplasty) – systematic review and meta-analysis	4
SAAGAR ⁵⁸	Implanted prosthesis	Cefazolin + gentamicin	Vancomycin + gentamicin	Single dose	No reference provided	4
ASHP/IDSA ¹	Implanted prosthesis	Cefazolin + aminoglycoside	Clindamycin or vancomycin +/- aminoglycoside or aztreonam	Single dose or less than 24 hours	No reference provided	4
EAU ²⁹⁹	Urodynamic study	Not required			Cited Cochrane review (search date of Dec 2009) and 2 later RCTs: the meta-analysis found no benefit of antibiotic prophylaxis vs placebo in terms of clinical UTI (RR 0.73, 95% CI 0.52-1.03). The antibiotic reduced the rate of post-procedural bacteriuria (RR 0.35, 95% CI 0.22-0.56) The 2 RCTs did not report the incidence of clinical UTI and had conflicting findings in terms of the risk of bacteriuria	1+
ASHP/IDSA ¹	Urodynamic study	Cefazolin	Fluoroquinolone or aminoglycoside with or without clindamycin	Single dose or less than 24 hours	Cited meta-analysis of 8 RCTs (methodologically poor, searched up to Jan 2007) with 995 patients who underwent urodynamic study. The study found a decrease in bacteriuria with antibiotic prophylaxis (OR 0.39; 95 CI 0.24-0.61), NNT was 13. The antibiotic use was different in type, dose and duration. There were reports of 1 mild allergy and 1 anaphylaxis in the treatment group	1+
EAU ²⁹⁹	Shockwave lithotripsy	Not required		NA	For patients without bacteriuria undergoing ESWL, EAU cited a systematic review and meta-analysis (2012), the Canadian guidelines (2015) and 1 RCT	1+

					<p>The systematic review and meta-analysis found no evidence of benefit in terms of reducing the rate of post-procedural fever or bacteriuria</p> <p>One trial in 2017 with 274 patients with a severe risk of bias found no difference in the rate of bacteriuria and no reduction in fever</p> <p>For patients with bacteriuria or deemed at high risk of complication, one RCT compared the use of ofloxacin or trimethoprim-sulphamethoxazole for 3 days prior and 4 days subsequent to ESWL in 56 patients. They found no difference in the rate of clinical UTI at 7 days and no difference in post-ESWL bacteriuria</p>	
AUA ²⁹⁷	Shockwave lithotripsy	Not required antibiotic unless there are risk factors			Cited the same systematic review (2012) as EAU	1+
EAU ²⁹⁹	Shockwave lithotripsy	Not required unless with high risk of infection (large stone burden, associated pyuria, history of pyelonephritis and adjunctive procedure including stent, nephrostomy insertion, PCNL or ureteroscopy)			Conducted a systematic review (8 studies included for meta-analysis) – the incidence of UTI and fever were 4.2% and 3.4% respectively. Antibiotic prophylaxis was not associated with a significant difference in the risk of post-procedural UTI (RR 0.76, 95% CI 0.39-1.48)	1+
ASHP/IDSA ¹	Shockwave lithotripsy	Cefazolin	Fluoroquinolone or aminoglycoside	Single dose or less than 24 hours	Cited meta-analysis of 8 RCTs and 6 clinical case series. The overall rate of UTI in the RCTs ranged from 0-7.7% with antimicrobial prophylaxis and from 0%-28% in the control group (RR 0.45, 95% CI 0.22-0.91)	1 ⁻

***AUA**: American Urological Association; **SAAGAR**: South Australian expert Advisory Group on Antimicrobial Resistance; **EAU**: European Association of Urology; **NNT**: Number needed to treat; **ESWL**: Extracorporeal shock wave lithotripsy

Note: ASHP guidelines do not specify antimicrobial prophylaxis to specific procedures but did recommend antimicrobial prophylaxis to procedures that are considered clean and clean-contaminated.

References

1. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm.* 2013;70(3):195-283. doi:10.2146/ajhp120568
2. Phillips BT, Sheldon ES, Orhurhu V, et al. Preoperative Versus Extended Postoperative Antimicrobial Prophylaxis of Surgical Site Infection During Spinal Surgery: A Comprehensive Systematic Review and Meta-Analysis. *Adv Ther.* 2020;37(6):2710-2733. doi:10.1007/s12325-020-01371-5
3. McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. *Aust N Z J Surg.* 1998;68(6):388-396. doi:10.1111/j.1445-2197.1998.tb04785.x
4. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. *JAMA Surg.* 2019;154(7):590-598. doi:10.1001/jamasurg.2019.0569
5. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. *Circulation.* 2000;101(25):2916-2921. doi:10.1161/01.cir.101.25.2916
6. Cai Y, Venkatachalam I, Tee NW, et al. Prevalence of Healthcare-Associated Infections and Antimicrobial Use Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National Point Prevalence Survey. *Clin Infect Dis.* 2017;64(suppl_2):S61-S67. doi:10.1093/cid/cix103
7. Surgical site infection prevention and treatment: NICE guideline. Accessed December 9, 2020. www.nice.org.uk/guidance/ng125
8. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. *Clin Infect Dis.* 2004;38 Suppl 4:S341-345. doi:10.1086/382690
9. Cho SM, Lee JJ, Yoon HJ. Clinical risk factors for *Clostridium difficile*-associated diseases. *Braz J Infect Dis.* 2012;16(3):256-261. doi:10.1590/s1413-86702012000300007
10. van Kasteren MEE, Manniën J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. *Clin Infect Dis.* 2007;44(7):921-927. doi:10.1086/512192
11. Steinberg JP, Braun BI, Hellinger WC, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. *Ann Surg.* 2009;250(1):10-16. doi:10.1097/SLA.0b013e3181ad5fca
12. Vardakas KZ, Soteriades ES, Chrysanthopoulou SA, Papagelopoulos PJ, Falagas ME. Perioperative anti-infective prophylaxis with teicoplanin compared to cephalosporins in orthopaedic and vascular surgery involving prosthetic material. *Clinical Microbiology and Infection.* 2005;11(10):775-777. doi:10.1111/j.1469-0691.2005.01177.x
13. Periti P, Stringa G, Mini E. Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for

- Antimicrobial Prophylaxis in Orthopedic Surgery. *Eur J Clin Microbiol Infect Dis*. 1999;18(2):113-119. doi:10.1007/s100960050238
14. Humphreys H, Becker K, Dohmen PM, et al. Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. *J Hosp Infect*. 2016;94(3):295-304. doi:10.1016/j.jhin.2016.06.011
 15. Kim DH, Spencer M, Davidson SM, et al. Institutional prescreening for detection and eradication of methicillin-resistant Staphylococcus aureus in patients undergoing elective orthopaedic surgery. *J Bone Joint Surg Am*. 2010;92(9):1820-1826. doi:10.2106/JBJS.I.01050
 16. Lee AS, Cooper BS, Malhotra-Kumar S, et al. Comparison of strategies to reduce methicillin-resistant Staphylococcus aureus rates in surgical patients: a controlled multicentre intervention trial. *BMJ Open*. 2013;3(9):e003126. doi:10.1136/bmjopen-2013-003126
 17. Schweizer ML, Chiang HY, Septimus E, et al. Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. *JAMA*. 2015;313(21):2162-2171. doi:10.1001/jama.2015.5387
 18. Edmiston CE, Ledebor NA, Buchan BW, Spencer M, Seabrook GR, Leaper D. Is Staphylococcal Screening and Suppression an Effective Interventional Strategy for Reduction of Surgical Site Infection? *Surg Infect (Larchmt)*. 2016;17(2):158-166. doi:10.1089/sur.2015.257
 19. Schelenz S, Tucker D, Georgeu C, et al. Significant reduction of endemic MRSA acquisition and infection in cardiothoracic patients by means of an enhanced targeted infection control programme. *J Hosp Infect*. 2005;60(2):104-110. doi:10.1016/j.jhin.2004.11.020
 20. Lopez WY, Rider SM, Nwosu K, et al. The Impact of Vancomycin and Cefazolin as Standard Preoperative Antibiotic Prophylaxis on Surgical Site Infections Following Instrumented Spinal Fusion. *Spine (Phila Pa 1976)*. 2019;44(6):E366-E371. doi:10.1097/BRS.0000000000002839
 21. Ponce B, Raines BT, Reed RD, Vick C, Richman J, Hawn M. Surgical Site Infection After Arthroplasty: Comparative Effectiveness of Prophylactic Antibiotics: Do Surgical Care Improvement Project Guidelines Need to Be Updated? *J Bone Joint Surg Am*. 2014;96(12):970-977. doi:10.2106/JBJS.M.00663
 22. Burger JR, Hansen BJ, Leary EV, Aggarwal A, Keeney JA. Dual-Agent Antibiotic Prophylaxis Using a Single Preoperative Vancomycin Dose Effectively Reduces Prosthetic Joint Infection Rates With Minimal Renal Toxicity Risk. *J Arthroplasty*. 2018;33(7S):S213-S218. doi:10.1016/j.arth.2018.03.009
 23. Branch-Elliman W, Ripollone JE, O'Brien WJ, et al. Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: A national propensity-score-adjusted retrospective cohort study. *PLoS Med*. 2017;14(7):e1002340. doi:10.1371/journal.pmed.1002340
 24. Courtney PM, Melnic CM, Zimmer Z, Anari J, Lee GC. Addition of Vancomycin to Cefazolin Prophylaxis Is Associated With Acute Kidney Injury After Primary Joint Arthroplasty. *Clin Orthop Relat Res*. 2015;473(7):2197-2203. doi:10.1007/s11999-014-4062-3

-
25. Zelenitsky SA, Silverman RE, Duckworth H, Harding GK. A prospective, randomized, double-blind study of single high dose versus multiple standard dose gentamicin both in combination with metronidazole for colorectal surgical prophylaxis. *J Hosp Infect*. 2000;46(2):135-140. doi:10.1053/jhin.2000.0814
 26. Dubrovskaya Y, Tejada R, Bosco J, et al. Single high dose gentamicin for perioperative prophylaxis in orthopedic surgery: Evaluation of nephrotoxicity. *SAGE Open Med*. 2015;3:2050312115612803. doi:10.1177/2050312115612803
 27. Zelenitsky SA, Ariano RE, Harding GKM, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. *Antimicrob Agents Chemother*. 2002;46(9):3026-3030. doi:10.1128/aac.46.9.3026-3030.2002
 28. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. *Emerg Infect Dis*. 2001;7(5):828-831. doi:10.3201/eid0705.017509
 29. Markantonis SL, Kostopanagiotou G, Panidis D, Smirniotis V, Voros D. Effects of blood loss and fluid volume replacement on serum and tissue gentamicin concentrations during colorectal surgery. *Clin Ther*. 2004;26(2):271-281. doi:10.1016/s0149-2918(04)90025-2
 30. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intraoperative blood loss affect antibiotic serum and tissue concentrations? *Arch Surg*. 1996;131(11):1165-1171; discussion 1171-1172. doi:10.1001/archsurg.1996.01430230047009
 31. Anaya DA, Dellinger EP. The obese surgical patient: a susceptible host for infection. *Surg Infect (Larchmt)*. 2006;7(5):473-480. doi:10.1089/sur.2006.7.473
 32. Winfield RD, Reese S, Bochicchio K, Mazuski JE, Bochicchio GV. Obesity and the Risk for Surgical Site Infection in Abdominal Surgery. *Am Surg*. 2016;82(4):331-336.
 33. Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. *JAMA Surg*. 2017;152(8):784-791. doi:10.1001/jamasurg.2017.0904
 34. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. *Eur J Clin Pharmacol*. 1983;24(5):643-647. doi:10.1007/BF00542215
 35. Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis? *Clin Infect Dis*. 2012;54(10):1474-1479. doi:10.1093/cid/cis027
 36. Hafermann MJ, Kiser TH, Lyda C, et al. Weight-based versus set dosing of vancomycin for coronary artery bypass grafting or aortic valve surgery. *J Thorac Cardiovasc Surg*. 2014;147(6):1925-1930. doi:10.1016/j.jtcvs.2013.12.037
 37. Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: less is more. *J Antimicrob Chemother*. 2018;73(11):3081-3086. doi:10.1093/jac/dky310
 38. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious

- Diseases Pharmacists. *Am J Health Syst Pharm.* 2020;77(11):835-864. doi:10.1093/ajhp/zxaa036
39. Lam PW, Tarighi P, Elligsen M, et al. Self-reported beta-lactam allergy and the risk of surgical site infection: A retrospective cohort study. *Infect Control Hosp Epidemiol.* 2020;41(4):438-443. doi:10.1017/ice.2019.374
 40. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk. *Clin Infect Dis.* 2018;66(3):329-336. doi:10.1093/cid/cix794
 41. Zagursky RJ, Pichichero ME. Cross-reactivity in β -Lactam Allergy. *J Allergy Clin Immunol Pract.* 2018;6(1):72-81.e1. doi:10.1016/j.jaip.2017.08.027
 42. Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quarantino D, Gaeta F. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. *The Journal of Allergy and Clinical Immunology: In Practice.* 2018;6(5):1662-1672. doi:10.1016/j.jaip.2018.01.020
 43. de Jonge SW, Boldingh QJJ, Solomkin JS, et al. Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis. *Lancet Infect Dis.* 2020;20(10):1182-1192. doi:10.1016/S1473-3099(20)30084-0
 44. The American Society of Breast Surgeons. Consensus Guideline on Preoperative Antibiotics and Surgical Site Infection in Breast Surgery. Published online June 2017:6.
 45. Gallagher M, Jones DJ, Bell-Syer SV. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Wounds Group, ed. *Cochrane Database of Systematic Reviews.* Published online September 26, 2019. doi:10.1002/14651858.CD005360.pub5
 46. Alderman A, Gutowski K, Ahuja A, Gray D, Postmastectomy Expander/Implant Breast Reconstruction Guideline Work Group. ASPS clinical practice guideline summary on breast reconstruction with expanders and implants. *Plast Reconstr Surg.* 2014;134(4):648e-655e. doi:10.1097/PRS.0000000000000541
 47. Phillips BT, Halvorson EG. Antibiotic Prophylaxis following Implant-Based Breast Reconstruction: What Is the Evidence? *Plast Reconstr Surg.* 2016;138(4):751-757. doi:10.1097/PRS.00000000000002530
 48. Wang F, Chin R, Piper M, Esserman L, Sbitany H. Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction? *Plast Reconstr Surg.* 2016;138(6):1141-1149. doi:10.1097/PRS.00000000000002737
 49. Phillips BT, Fourman MS, Bishawi M, et al. Are Prophylactic Postoperative Antibiotics Necessary for Immediate Breast Reconstruction? Results of a Prospective Randomized Clinical Trial. *J Am Coll Surg.* 2016;222(6):1116-1124. doi:10.1016/j.jamcollsurg.2016.02.018
 50. Drury KE, Lanier ST, Khavanin N, et al. Impact of Postoperative Antibiotic Prophylaxis Duration on Surgical Site Infections in Autologous Breast Reconstruction. *Ann Plast Surg.* 2016;76(2):174-179. doi:10.1097/SAP.0000000000000514

-
51. Lanckohr C, Horn D, Voeller S, et al. Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. *J Thorac Cardiovasc Surg.* 2016;152(2):603-610. doi:10.1016/j.jtcvs.2016.04.024
 52. Fellingner EK, Leavitt BJ, Hebert JC. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. *Ann Thorac Surg.* 2002;74(4):1187-1190. doi:10.1016/s0003-4975(02)03916-4
 53. Caffarelli AD, Holden JP, Baron EJ, et al. Plasma cefazolin levels during cardiovascular surgery: effects of cardiopulmonary bypass and profound hypothermic circulatory arrest. *J Thorac Cardiovasc Surg.* 2006;131(6):1338-1343. doi:10.1016/j.jtcvs.2005.11.047
 54. Zelenitsky SA, Calic D, Arora RC, et al. Antimicrobial Prophylaxis for Patients Undergoing Cardiac Surgery: Intraoperative Cefazolin Concentrations and Sternal Wound Infections. *Antimicrob Agents Chemother.* 2018;62(11). doi:10.1128/AAC.01360-18
 55. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR, Society of Thoracic Surgeons. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration. *Ann Thorac Surg.* 2006;81(1):397-404. doi:10.1016/j.athoracsur.2005.06.034
 56. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. *Ann Thorac Surg.* 2007;83(4):1569-1576. doi:10.1016/j.athoracsur.2006.09.046
 57. Sousa-Uva M, Head SJ, Milojevic M, et al. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. *Eur J Cardiothorac Surg.* 2018;53(1):5-33. doi:10.1093/ejcts/ezx314
 58. South Australian expert Advisory Group on Antimicrobial Resistance (SAAGAR). Surgical Antimicrobial Prophylaxis Clinical Guideline Version 2.0 Policy No.: CG269. Published November 2, 2017. Accessed April 8, 2021. <https://www.sahealth.sa.gov.au/wps/wcm/connect/Public+Content/SA+Health+Internet/Resources/Policies/Surgical+Antimicrobial+Prophylaxis+Clinical+Guideline>
 59. Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. *Ann Surg.* 2011;254(1):48-54. doi:10.1097/SLA.0b013e318214b7e4
 60. Tamayo E, Gualis J, Flórez S, Castrodeza J, Eiros Bouza JM, Alvarez FJ. Comparative study of single-dose and 24-hour multiple-dose antibiotic prophylaxis for cardiac surgery. *J Thorac Cardiovasc Surg.* 2008;136(6):1522-1527. doi:10.1016/j.jtcvs.2008.05.013
 61. Lin MH, Pan SC, Wang JL, et al. Prospective randomized study of efficacy of 1-day versus 3-day antibiotic prophylaxis for preventing surgical site infection after coronary artery bypass graft. *J Formos Med Assoc.* 2011;110(10):619-626. doi:10.1016/j.jfma.2011.08.003
 62. Niederhäuser U, Vogt M, Vogt P, Genoni M, Künzli A, Turina MI. Cardiac surgery in a high-risk group of patients: is prolonged postoperative antibiotic prophylaxis effective? *J Thorac Cardiovasc Surg.* 1997;114(2):162-168. doi:10.1016/S0022-5223(97)70140-5

-
63. Conte JE, Cohen SN, Roe BB, Elashoff RM. Antibiotic prophylaxis and cardiac surgery. A prospective double-blind comparison of single-dose versus multiple-dose regimens. *Ann Intern Med.* 1972;76(6):943-949. doi:10.7326/0003-4819-76-6-943
 64. Hamouda K, Oezkur M, Sinha B, et al. Different duration strategies of perioperative antibiotic prophylaxis in adult patients undergoing cardiac surgery: an observational study. *J Cardiothorac Surg.* 2015;10:25. doi:10.1186/s13019-015-0225-x
 65. Gelijns AC, Moskowitz AJ, Acker MA, et al. Management practices and major infections after cardiac surgery. *J Am Coll Cardiol.* 2014;64(4):372-381. doi:10.1016/j.jacc.2014.04.052
 66. Olak J, Jeyasingham K, Forrester-Wood C, Hutter J, al-Zeerah M, Brown E. Randomized trial of one-dose versus six-dose cefazolin prophylaxis in elective general thoracic surgery. *Ann Thorac Surg.* 1991;51(6):956-958. doi:10.1016/0003-4975(91)91014-m
 67. Bernard A, Pillet M, Goudet P, Viard H. Antibiotic prophylaxis in pulmonary surgery. A prospective randomized double-blind trial of flash cefuroxime versus forty-eight-hour cefuroxime. *J Thorac Cardiovasc Surg.* 1994;107(3):896-900.
 68. Aznar R, Mateu M, Miró JM, et al. Antibiotic prophylaxis in non-cardiac thoracic surgery: cefazolin versus placebo. *Eur J Cardiothorac Surg.* 1991;5(10):515-518. doi:10.1016/1010-7940(91)90103-q
 69. Turna A, Kutlu CA, Ozalp T, Karamustafaoglu A, Mulazimoğlu L, Bedirhan MA. Antibiotic prophylaxis in elective thoracic surgery: cefuroxime versus cefepime. *Thorac Cardiovasc Surg.* 2003;51(2):84-88. doi:10.1055/s-2003-38991
 70. Wertzel H, Swoboda L, Joos-Würtemberger A, Frank U, Hasse J. Perioperative antibiotic prophylaxis in general thoracic surgery. *Thorac Cardiovasc Surg.* 1992;40(6):326-329. doi:10.1055/s-2007-1020174
 71. Schussler O, Dermine H, Alifano M, et al. Should we change antibiotic prophylaxis for lung surgery? Postoperative pneumonia is the critical issue. *Ann Thorac Surg.* 2008;86(6):1727-1733. doi:10.1016/j.athoracsur.2008.08.005
 72. Rovera F, Imperatori A, Militello P, et al. Infections in 346 consecutive video-assisted thoracoscopic procedures. *Surg Infect (Larchmt).* 2003;4(1):45-51. doi:10.1089/109629603764655272
 73. Shiono S, Yoshida J, Nishimura M, et al. Risk factors of postoperative respiratory infections in lung cancer surgery. *J Thorac Oncol.* 2007;2(1):34-38. doi:10.1097/JTO.0b013e31802bafb6
 74. Deguchi H, Tomoyasu M, Shigeeda W, Kaneko Y, Kanno H, Saito H. Influence of prophylactic antibiotic duration on postoperative pneumonia following pulmonary lobectomy for non-small cell lung cancer. *J Thorac Dis.* 2019;11(4):1155-1164. doi:10.21037/jtd.2019.04.43
 75. Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. *J Vasc Interv Radiol.* 2018;29(11):1483-1501.e2. doi:10.1016/j.jvir.2018.06.007
-

-
76. Schmidli J, Widmer MK, Basile C, et al. Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg*. 2018;55(6):757-818. doi:10.1016/j.ejvs.2018.02.001
 77. Stewart AH, Evers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. *J Vasc Surg*. 2007;46(1):148-155. doi:10.1016/j.jvs.2007.02.065
 78. Zibari GB, Gadallah MF, Landreneau M, et al. Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections. *Am J Kidney Dis*. 1997;30(3):343-348. doi:10.1016/s0272-6386(97)90277-8
 79. Edwards WH, Kaiser AB, Tapper S, et al. Cefamandole versus cefazolin in vascular surgical wound infection prophylaxis: cost-effectiveness and risk factors. *J Vasc Surg*. 1993;18(3):470-475; discussion 475-476. doi:10.1067/mva.1993.48123
 80. Edwards WH, Kaiser AB, Kernodle DS, et al. Cefuroxime versus cefazolin as prophylaxis in vascular surgery. *J Vasc Surg*. 1992;15(1):35-41; discussion 41-42. doi:10.1067/mva.1992.33841
 81. Hasselgren PO, Ivarsson L, Risberg B, Seeman T. Effects of prophylactic antibiotics in vascular surgery. A prospective, randomized, double-blind study. *Ann Surg*. 1984;200(1):86-92. doi:10.1097/00000658-198407000-00016
 82. Hall JC, Christiansen KJ, Goodman M, et al. Duration of antimicrobial prophylaxis in vascular surgery. *Am J Surg*. 1998;175(2):87-90. doi:10.1016/S0002-9610(97)00270-5
 83. Gray K, Korn A, Zane J, et al. Preoperative Antibiotics for Dialysis Access Surgery: Are They Necessary? *Ann Vasc Surg*. 2018;49:277-280. doi:10.1016/j.avsg.2018.02.004
 84. Samore MH, Wessolossky MA, Lewis SM, Shubrooks SJ, Karchmer AW. Frequency, risk factors, and outcome for bacteremia after percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1997;79(7):873-877. doi:10.1016/s0002-9149(97)00006-4
 85. Muñoz P, Blanco JR, Rodríguez-Creixéms M, García E, Delcan JL, Bouza E. Bloodstream infections after invasive nonsurgical cardiologic procedures. *Arch Intern Med*. 2001;161(17):2110-2115. doi:10.1001/archinte.161.17.2110
 86. Bosman WMPF, Borger van der Burg BLS, Schuttevaer HM, Thoma S, Hedeman Joosten PP. Infections of intravascular bare metal stents: a case report and review of literature. *Eur J Vasc Endovasc Surg*. 2014;47(1):87-99. doi:10.1016/j.ejvs.2013.10.006
 87. Hogg ME, Peterson BG, Pearce WH, Morasch MD, Kibbe MR. Bare metal stent infections: case report and review of the literature. *J Vasc Surg*. 2007;46(4):813-820. doi:10.1016/j.jvs.2007.05.043
 88. Andersen BR, Kallehave FL, Andersen HK. Antibiotics versus placebo for prevention of postoperative infection after appendectomy. *Cochrane Database Syst Rev*. 2005;(3):CD001439. doi:10.1002/14651858.CD001439.pub2
 89. Mui LM, Ng CSH, Wong SKH, et al. Optimum duration of prophylactic antibiotics in acute non-perforated appendicitis. *ANZ J Surg*. 2005;75(6):425-428. doi:10.1111/j.1445-2197.2005.03397.x

-
90. Bates T, Roberts JV, Smith K, German KA. A randomized trial of one versus three doses of Augmentin as wound prophylaxis in at-risk abdominal surgery. *Postgrad Med J*. 1992;68(804):811-816. doi:10.1136/pgmj.68.804.811
 91. Mohri Y, Tonouchi H, Kobayashi M, Nakai K, Kusunoki M, Mie Surgical Infection Research Group. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. *Br J Surg*. 2007;94(6):683-688. doi:10.1002/bjs.5837
 92. Haga N, Ishida H, Ishiguro T, et al. A prospective randomized study to assess the optimal duration of intravenous antimicrobial prophylaxis in elective gastric cancer surgery. *Int Surg*. 2012;97(2):169-176. doi:10.9738/CC91.1
 93. Ruol A, Bertiato G, Boscarin S, et al. Short-Term prophylaxis with ceftriaxone plus metronidazole in esophageal cancer surgery. *J Chemother*. 2000;12 Suppl 3:23-28. doi:10.1080/1120009x.2000.11782304
 94. Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. *Cochrane Database Syst Rev*. 2013;(11):CD005571. doi:10.1002/14651858.CD005571.pub3
 95. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. Cochrane Colorectal Cancer Group, ed. *Cochrane Database of Systematic Reviews*. Published online May 9, 2014. doi:10.1002/14651858.CD001181.pub4
 96. Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. *World J Surg*. 2019;43(3):659-695. doi:10.1007/s00268-018-4844-y
 97. Morris DL, Wilson SR, Pain J, et al. A comparison of aztreonam/metronidazole and cefotaxime/metronidazole in elective colorectal surgery: antimicrobial prophylaxis must include gram-positive cover. *J Antimicrob Chemother*. 1990;25(4):673-678. doi:10.1093/jac/25.4.673
 98. Toh JWT, Phan K, Hitos K, et al. Association of Mechanical Bowel Preparation and Oral Antibiotics Before Elective Colorectal Surgery With Surgical Site Infection: A Network Meta-analysis. *JAMA Netw Open*. 2018;1(6):e183226. doi:10.1001/jamanetworkopen.2018.3226
 99. WHO Surgical Site Infection Prevention Guidelines. Web Appendix 6: Summary of a systematic review on mechanical bowel preparation and the use of oral antibiotics. Accessed December 19, 2020. <https://www.who.int/gpsc/appendix6.pdf?ua=1>
 100. Güenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev*. 2011;(9):CD001544. doi:10.1002/14651858.CD001544.pub4
 101. Yin Y, Song T, Liao B, Luo Q, Zhou Z. Antibiotic prophylaxis in patients undergoing open mesh repair of inguinal hernia: a meta-analysis. *Am Surg*. 2012;78(3):359-365.
 102. Orelia CC, van Hessen C, Sanchez-Manuel FJ, Aufenacker TJ, Scholten RJ. Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair. *Cochrane Database Syst Rev*. 2020;4:CD003769. doi:10.1002/14651858.CD003769.pub5

-
103. Abramov D, Jeroukhimov I, Yinnon AM, et al. Antibiotic prophylaxis in umbilical and incisional hernia repair: a prospective randomised study. *Eur J Surg*. 1996;162(12):945-948; discussion 949.
 104. Edwards C, Angstadt J, Whipple O, Grau R. Laparoscopic ventral hernia repair: postoperative antibiotics decrease incidence of seroma-related cellulitis. *Am Surg*. 2005;71(11):931-935; discussion 935-936.
 105. Mehrabi Bahar M, Jabbari Nooghabi A, Jabbari Nooghabi M, Jangjoo A. The role of prophylactic cefazolin in the prevention of infection after various types of abdominal wall hernia repair with mesh. *Asian J Surg*. 2015;38(3):139-144. doi:10.1016/j.asjsur.2015.01.006
 106. Ríos A, Rodríguez JM, Munitiz V, Alcaraz P, Pérez Flores D, Parrilla P. Antibiotic prophylaxis in incisional hernia repair using a prosthesis. *Hernia*. 2001;5(3):148-152. doi:10.1007/s100290100026
 107. Köckerling F, Bittner R, Jacob D, et al. Do we need antibiotic prophylaxis in endoscopic inguinal hernia repair? Results of the Herniated Registry. *Surg Endosc*. 2015;29(12):3741-3749. doi:10.1007/s00464-015-4149-2
 108. Meijer WS, Schmitz PIM, Galant Trial Study Group. Prophylactic use of cefuroxime in biliary tract surgery: Randomized controlled trial of single versus multiple dose in high-risk patients. *Br J Surg*. 1993;80(7):917-921. doi:10.1002/bjs.1800800742
 109. Kellum JM, Gargano S, Gorbach SL, et al. Antibiotic prophylaxis in high-risk biliary operations: multicenter trial of single preoperative ceftriaxone versus multidose cefazolin. *Am J Surg*. 1984;148(4A):15-18.
 110. Sirinek KR, Schauer PR, Yellin AE, et al. Single-dose cefuroxime versus multiple-dose cefazolin as prophylactic therapy for high-risk cholecystectomy. *J Am Coll Surg*. 1994;178(4):321-325.
 111. Hajibandeh S, Popova P, Rehman S. Extended Postoperative Antibiotics Versus No Postoperative Antibiotics in Patients Undergoing Emergency Cholecystectomy for Acute Calculous Cholecystitis: A Systematic Review and Meta-Analysis. *Surg Innov*. 2019;26(4):485-496. doi:10.1177/1553350619835347
 112. Guo T, Ding R, Yang J, et al. Evaluation of different antibiotic prophylaxis strategies for hepatectomy: A network meta-analysis. *Medicine (Baltimore)*. 2019;98(26):e16241. doi:10.1097/MD.00000000000016241
 113. Togo S, Tanaka K, Matsuo K, et al. Duration of antimicrobial prophylaxis in patients undergoing hepatectomy: a prospective randomized controlled trial using flomoxef. *J Antimicrob Chemother*. 2007;59(5):964-970. doi:10.1093/jac/dkm028
 114. Sugawara G, Yokoyama Y, Ebata T, et al. Duration of Antimicrobial Prophylaxis in Patients Undergoing Major Hepatectomy With Extrahepatic Bile Duct Resection: A Randomized Controlled Trial. *Ann Surg*. 2018;267(1):142-148. doi:10.1097/SLA.0000000000002049
 115. Zhou YM, Chen ZY, Li XD, Xu DH, Su X, Li B. Preoperative Antibiotic Prophylaxis Does Not Reduce the Risk of Postoperative Infectious Complications in Patients Undergoing Elective Hepatectomy. *Dig Dis Sci*. 2016;61(6):1707-1713. doi:10.1007/s10620-015-4008-y
-

-
116. Hirokawa F, Hayashi M, Miyamoto Y, et al. Evaluation of postoperative antibiotic prophylaxis after liver resection: a randomized controlled trial. *Am J Surg*. 2013;206(1):8-15. doi:10.1016/j.amjsurg.2012.08.016
 117. Sudo T, Murakami Y, Uemura K, et al. Perioperative antibiotics covering bile contamination prevent abdominal infectious complications after pancreatoduodenectomy in patients with preoperative biliary drainage. *World J Surg*. 2014;38(11):2952-2959. doi:10.1007/s00268-014-2688-7
 118. Sourrouille I, Gaujoux S, Lacave G, et al. Five days of postoperative antimicrobial therapy decreases infectious complications following pancreaticoduodenectomy in patients at risk for bile contamination. *HPB (Oxford)*. 2013;15(6):473-480. doi:10.1111/hpb.12012
 119. Fathi AH, Jackson T, Barati M, Eghbalieh B, Siegel KA, Siegel CT. Extended Perioperative Antibiotic Coverage in Conjunction with Intraoperative Bile Cultures Decreases Infectious Complications after Pancreaticoduodenectomy. *HPB Surg*. 2016;2016:3031749. doi:10.1155/2016/3031749
 120. Degrandi O, Buscail E, Martellotto S, et al. Perioperative antibiotherapy should replace prophylactic antibiotics in patients undergoing pancreaticoduodenectomy preceded by preoperative biliary drainage. *J Surg Oncol*. 2019;120(4):639-645. doi:10.1002/jso.25622
 121. Müsle B, Hempel S, Kahlert C, Distler M, Weitz J, Welsch T. Prognostic Impact of Bacterobilia on Morbidity and Postoperative Management After Pancreatoduodenectomy: A Systematic Review and Meta-analysis. *World J Surg*. 2018;42(9):2951-2962. doi:10.1007/s00268-018-4546-5
 122. Cengiz TB, Jarrar A, Power C, Joyce D, Anzlovar N, Morris-Stiff G. Antimicrobial Stewardship Reduces Surgical Site Infection Rate, as well as Number and Severity of Pancreatic Fistulae after Pancreatoduodenectomy. *Surg Infect (Larchmt)*. 2020;21(3):212-217. doi:10.1089/sur.2019.108
 123. Minami T, Sasaki T, Serikawa M, Ishigaki T, Murakami Y, Chayama K. Antibiotic prophylaxis for endoscopic retrograde cholangiopancreatography increases the detection rate of drug-resistant bacteria in bile. *J Hepatobiliary Pancreat Sci*. 2014;21(9):712-718. doi:10.1002/jhbp.129
 124. Masadeh M, Chandra S, Livorsi D, Johlin F, Silverman W. Evaluation of Biliary Bacterial Resistance in Patients with Frequent Biliary Instrumentation, One Size Does Not Fit All. *Dig Dis Sci*. 2018;63(12):3474-3479. doi:10.1007/s10620-018-5263-5
 125. Du M, Suo J, Liu B, Xing Y, Chen L, Liu Y. Post-ERCP infection and its epidemiological and clinical characteristics in a large Chinese tertiary hospital: a 4-year surveillance study. *Antimicrob Resist Infect Control*. 2017;6:131. doi:10.1186/s13756-017-0290-0
 126. ASGE Standards of Practice Committee, Khashab MA, Chithadi KV, et al. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc*. 2015;81(1):81-89. doi:10.1016/j.gie.2014.08.008
 127. Dumonceau JM, Kapral C, Aabakken L, et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*. 2020;52(2):127-149. doi:10.1055/a-1075-4080

128. Harris A, Chan AC, Torres-Viera C, Hammett R, Carr-Locke D. Meta-analysis of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography (ERCP). *Endoscopy*. 1999;31(9):718-724. doi:10.1055/s-1999-153
129. Brand M, Bizo D, O'Farrell P. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. *Cochrane Database Syst Rev*. 2010;(10):CD007345. doi:10.1002/14651858.CD007345.pub2
130. Bai Y, Gao F, Gao J, Zou DW, Li ZS. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis: a meta-analysis. *Pancreas*. 2009;38(2):126-130. doi:10.1097/MPA.0b013e318189f16d
131. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. *Obstet Gynecol*. 2018;132(3):e103-e119. doi:10.1097/AOG.0000000000002833
132. National Health Service (NHS) Heart of England Foundation Trust. Clinical Guideline for the Management of Caesarean Section: Elective and Emergency. Version 10. Published online 2019. Accessed March 1, 2021. <https://hgs.uhb.nhs.uk/wp-content/uploads/Caesarean-Section.pdf>
133. National Institute for Health and Care Excellence (NICE). Caesarean section (Clinical guideline CG132). Published November 23, 2011. <https://www.nice.org.uk/guidance/cg132>
134. Clifford V, Daley A. Antibiotic prophylaxis in obstetric and gynaecological procedures: a review. *Aust N Z J Obstet Gynaecol*. 2012;52(5):412-419. doi:10.1111/j.1479-828X.2012.01460.x
135. van Schalkwyk J, Van Eyk N, Yudin MH, et al. Antibiotic Prophylaxis in Obstetric Procedures. *Journal of Obstetrics and Gynaecology Canada*. 2010;32(9):878-884. doi:10.1016/S1701-2163(16)34662-X
136. Pinto-Lopes R, Sousa-Pinto B, Azevedo LF. Single dose versus multiple dose of antibiotic prophylaxis in caesarean section: a systematic review and meta-analysis. *BJOG*. 2017;124(4):595-605. doi:10.1111/1471-0528.14373
137. Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. *Cochrane Database Syst Rev*. 2014;(10):CD007482. doi:10.1002/14651858.CD007482.pub3
138. Gyte GMI, Dou L, Vazquez JC. Different classes of antibiotics given to women routinely for preventing infection at caesarean section. *Cochrane Database Syst Rev*. 2014;(11):CD008726. doi:10.1002/14651858.CD008726.pub2
139. Chelmow D, Ruehli MS, Huang E. Prophylactic use of antibiotics for nonlaboring patients undergoing cesarean delivery with intact membranes: a meta-analysis. *Am J Obstet Gynecol*. 2001;184(4):656-661. doi:10.1067/mob.2001.111303
140. Apuzzio JJ, Reyelt C, Pelosi M, Sen P, Louria DB. Prophylactic antibiotics for cesarean section: comparison of high- and low-risk patients for endomyometritis. *Obstet Gynecol*. 1982;59(6):693-698.

-
141. Duff P. Prophylactic antibiotics for cesarean delivery: a simple cost-effective strategy for prevention of postoperative morbidity. *Am J Obstet Gynecol*. 1987;157(4 Pt 1):794-798. doi:10.1016/s0002-9378(87)80057-1
142. Jakobi P, Weissman A, Sigler E, Margolis K, Zimmer EZ. Post-cesarean section febrile morbidity. Antibiotic prophylaxis in low-risk patients. *J Reprod Med*. 1994;39(9):707-710.
143. Rizk DE, Nsanze H, Mabrouk MH, Mustafa N, Thomas L, Kumar M. Systemic antibiotic prophylaxis in elective cesarean delivery. *Int J Gynaecol Obstet*. 1998;61(3):245-251. doi:10.1016/s0020-7292(98)00062-9
144. Rouzi AA, Khalifa F, Ba'aqueel H, Al-Hamdan HS, Bondagji N. The routine use of cefazolin in cesarean section. *Int J Gynaecol Obstet*. 2000;69(2):107-112. doi:10.1016/s0020-7292(99)00225-8
145. Bagratee JS, Moodley J, Kleinschmidt I, Zawilski W. A randomised controlled trial of antibiotic prophylaxis in elective caesarean delivery. *BJOG*. 2001;108(2):143-148. doi:10.1111/j.1471-0528.2001.00042.x
146. Dinsmoor MJ, Gilbert S, Landon MB, et al. Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery. *Obstet Gynecol*. 2009;114(4):752-756. doi:10.1097/AOG.0b013e3181b8f28f
147. Currier JS, Tosteson TD, Platt R. Cefazolin compared with cefoxitin for cesarean section prophylaxis: the use of a two-stage study design. *J Clin Epidemiol*. 1993;46(7):625-630. doi:10.1016/0895-4356(93)90035-y
148. Tita ATN, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. *Obstet Gynecol*. 2009;113(3):675-682. doi:10.1097/AOG.0b013e318197c3b6
149. Tita ATN, Szychowski JM, Boggess K, et al. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. *N Engl J Med*. 2016;375(13):1231-1241. doi:10.1056/NEJMoa1602044
150. Costantine MM, Rahman M, Ghulmiyah L, et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. *American Journal of Obstetrics and Gynecology*. 2008;199(3):301.e1-301.e6. doi:10.1016/j.ajog.2008.06.077
151. Valent AM, DeArmond C, Houston JM, et al. Effect of Post-Cesarean Delivery Oral Cephalexin and Metronidazole on Surgical Site Infection Among Obese Women: A Randomized Clinical Trial. *JAMA*. 2017;318(11):1026-1034. doi:10.1001/jama.2017.10567
152. Witt A, Döner M, Petricevic L, et al. Antibiotic prophylaxis before surgery vs after cord clamping in elective cesarean delivery: a double-blind, prospective, randomized, placebo-controlled trial. *Arch Surg*. 2011;146(12):1404-1409. doi:10.1001/archsurg.2011.725
153. Shaheen S, Akhtar S. Comparison of single dose versus multiple doses of antibiotic prophylaxis in elective caesarian section. *J Postgrad Med Inst*. 2014;28(1):83-86.
154. Shakya A, Sharma J. Comparison of single versus multiple doses of antibiotic prophylaxis in reducing post-elective Caesarean section infectious morbidity. *Kathmandu Univ Med J (KUMJ)*. 2010;8(30):179-184. doi:10.3126/kumj.v8i2.3554
-

-
155. Westen EHMN, Kolk PR, van Velzen CL, et al. Single-dose compared with multiple day antibiotic prophylaxis for cesarean section in low-resource settings, a randomized controlled, noninferiority trial. *Acta Obstet Gynecol Scand*. 2015;94(1):43-49. doi:10.1111/aogs.12517
156. Maggio L, Nicolau DP, DaCosta M, Rouse DJ, Hughes BL. Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. *Obstet Gynecol*. 2015;125(5):1205-1210. doi:10.1097/AOG.0000000000000789
157. Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. *Obstet Gynecol*. 2011;117(4):877-882. doi:10.1097/AOG.0b013e31820b95e4
158. Gordon SM. Antibiotic prophylaxis against postoperative wound infections. *Cleve Clin J Med*. 2006;73 Suppl 1:S42-45. doi:10.3949/ccjm.73.suppl_1.s42
159. Vathana M, Muhunthan K. A randomized control trial of single dose versus multiple doses of IV antibiotic prophylaxis in caesarean delivery. *Sri Lanka Journal of Obstetrics and Gynaecology*. 2018;40(4):92-100. doi:10.4038/sljpg.v40i4.7871
160. Aish KAE, Zourob H, Madi W, Hams SE. Cefazolin alone versus cefazolin, gentamicin, and metronidazole for prophylaxis in women undergoing caesarean section: a randomised controlled trial. *The Lancet*. 2018;391:S15. doi:10.1016/S0140-6736(18)30340-4
161. Lyimo FM, Massinde AN, Kidenya BR, Konje ET, Mshana SE. Single dose of gentamicin in combination with metronidazole versus multiple doses for prevention of post-caesarean infection at Bugando Medical Centre in Mwanza, Tanzania: a randomized, equivalence, controlled trial. *BMC Pregnancy Childbirth*. 2013;13:123. doi:10.1186/1471-2393-13-123
162. McGregor JA, French JI, Makowski E. Single-dose cefotetan versus multidose cefoxitin for prophylaxis in cesarean section in high-risk patients. *Am J Obstet Gynecol*. 1986;154(4):955-960. doi:10.1016/0002-9378(86)90497-7
163. Operative Vaginal Birth: ACOG Practice Bulletin, Number 219. *Obstet Gynecol*. 2020;135(4):e149-e159. doi:10.1097/AOG.0000000000003764
164. Murphy DJ, Strachan BK, Bahl R, Royal College of Obstetricians and Gynaecologists. Assisted Vaginal Birth: Green-top Guideline No. 26. *BJOG*. 2020;127(9):e70-e112. doi:10.1111/1471-0528.16092
165. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Instrumental Vaginal Birth (C-Obs 16). Published online March 2020. [https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Instrumental-vaginal-birth-\(C-Obs-16\)-Review-March-2020.pdf?ext=.pdf](https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Instrumental-vaginal-birth-(C-Obs-16)-Review-March-2020.pdf?ext=.pdf)
166. Hobson S, Cassell K, Windrim R, Cargill Y. No. 381-Assisted Vaginal Birth. *J Obstet Gynaecol Can*. 2019;41(6):870-882. doi:10.1016/j.jogc.2018.10.020
167. *WHO Recommendations for Prevention and Treatment of Maternal Peripartum Infections*. World Health Organization; 2015. Accessed April 21, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK327079/>
-

-
168. Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Antibiotic prophylaxis for operative vaginal delivery. Cochrane Pregnancy and Childbirth Group, ed. *Cochrane Database of Systematic Reviews*. Published online March 26, 2020. doi:10.1002/14651858.CD004455.pub5
169. Bonet M, Ota E, Chibueze CE, Oladapo OT. Routine antibiotic prophylaxis after normal vaginal birth for reducing maternal infectious morbidity. *Cochrane Database Syst Rev*. 2017;11:CD012137. doi:10.1002/14651858.CD012137.pub2
170. Bonet M, Ota E, Chibueze CE, Oladapo OT. Antibiotic prophylaxis for episiotomy repair following vaginal birth. Cochrane Pregnancy and Childbirth Group, ed. *Cochrane Database of Systematic Reviews*. Published online November 2, 2017. doi:10.1002/14651858.CD012136.pub2
171. Buppasiri P, Lumbiganon P, Thinkhamrop J, Thinkhamrop B. Antibiotic prophylaxis for third- and fourth-degree perineal tear during vaginal birth. *Cochrane Database Syst Rev*. 2014;(10):CD005125. doi:10.1002/14651858.CD005125.pub4
172. Knight M, Chiochia V, Partlett C, et al. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. *The Lancet*. 2019;393(10189):2395-2403. doi:10.1016/S0140-6736(19)30773-1
173. Heitmann JA, Benrubi GI. Efficacy of prophylactic antibiotics for the prevention of endomyometritis after forceps delivery. *South Med J*. 1989;82(8):960-962. doi:10.1097/00007611-198908000-00007
174. Fernandez H, Gagnepain A, Bourget P, et al. Antibiotic prophylaxis against postpartum endometritis after vaginal delivery: a prospective randomized comparison between Amox-CA (Augmentin®) and abstention. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 1993;50(3):169-175. doi:10.1016/0028-2243(93)90197-K
175. Duggal N, Mercado C, Daniels K, Bujor A, Caughey AB, El-Sayed YY. Antibiotic Prophylaxis for Prevention of Postpartum Perineal Wound Complications: A Randomized Controlled Trial. *Obstetrics & Gynecology*. 2008;111(6):1268-1273. doi:10.1097/AOG.0b013e31816de8ad
176. Neto S, Goncalves JA, De Andrade LF. Clinical evaluation of the chloramphenicol use as a prophylactic antibiotic in the vaginal delivery with episiotomy. *ACM: Arquivos Catarinenses de Medicina*. 1990;19(2):97-102.
177. Tandon AN, Dalal AR. A Randomized, Open-labelled, Interventional Study to Evaluate the Incidence of Infection with or Without Use of Prophylactic Antibiotics in Patients of Episiotomy in a Normal Vaginal Delivery. *J Obstet Gynecol India*. 2018;68(4):294-299. doi:10.1007/s13224-017-1041-0
178. World Health Organization. *WHO Recommendation on Routine Antibiotic Prophylaxis for Women Undergoing Operative Vaginal Birth*. World Health Organization; 2021. Accessed December 8, 2021. <https://apps.who.int/iris/handle/10665/341862>
179. ACOG Practice Bulletin No. 195: Prevention of Infection After Gynecologic Procedures. *Obstet Gynecol*. 2018;131(6):e172-e189. doi:10.1097/AOG.0000000000002670
-

-
180. Van Eyk N, van Schalkwyk J, INFECTIOUS DISEASES COMMITTEE. Antibiotic prophylaxis in gynaecologic procedures. *J Obstet Gynaecol Can.* 2012;34(4):382-391. doi:10.1016/S1701-2163(16)35222-7
181. Thurston J, Murji A, Scattolon S, et al. No. 377-Hysterectomy for Benign Gynaecologic Indications. *J Obstet Gynaecol Can.* 2019;41(4):543-557. doi:10.1016/j.jogc.2018.12.006
182. Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update. *Int J Gynecol Cancer.* 2019;29(4):651-668. doi:10.1136/ijgc-2019-000356
183. Ayeleke RO, Mourad SM, Marjoribanks J, Calis KA, Jordan V. Antibiotic prophylaxis for elective hysterectomy. Cochrane Gynaecology and Fertility Group, ed. *Cochrane Database of Systematic Reviews.* Published online June 18, 2017. doi:10.1002/14651858.CD004637.pub2
184. Duff P, Park RC. Antibiotic Prophylaxis in Vaginal Hysterectomy: A Review. *Obstetrics & Gynecology.* 1980;55(Supplement):193S-202S. doi:10.1097/00006250-198003001-00049
185. Cormio G, Vicino M, Loizzi V, Tangari D, Selvaggi L. Antimicrobial prophylaxis in vaginal gynecologic surgery: a prospective randomized study comparing amoxicillin-clavulanic acid with cefazolin. *J Chemother.* 2007;19(2):193-197. doi:10.1179/joc.2007.19.2.193
186. Kauer FM, Wijma J, Manson WL. Vaginal hysterectomy: cefuroxime, metronidazole or both? *Pharmaceutisch Weekblad Scientific Edition.* 1990;12(6):284-288. doi:10.1007/BF01967834
187. Tanos V, Rojansky N. Prophylactic antibiotics in abdominal hysterectomy. *J Am Coll Surg.* 1994;179(5):593-600.
188. Mittendorf R, Aronson MP, Berry RE, et al. Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis. *Am J Obstet Gynecol.* 1993;169(5):1119-1124. doi:10.1016/0002-9378(93)90266-I
189. Wttewaall-Evelaar EW. Meta-analysis of randomized controlled trials of antibiotic prophylaxis in abdominal hysterectomy. *Pharm Weekbl Sci.* 1990;12(6A):296-298; discussion 299. doi:10.1007/BF01967837
190. Cormio G, fazio FD, Lorusso F, et al. Antimicrobial Prophylaxis in Laparotomic Gynecologic Surgery: a Prospective Randomized Study Comparing Amoxicillin-Clavulanic Acid with Cefazolin. *Journal of Chemotherapy.* 2002;14(6):618-622. doi:10.1179/joc.2002.14.6.618
191. Chongsomchai C, Lumbiganon P, Thinkhamrop J, Ounchai J, Vudhikamraksa N. Placebo-controlled, double-blind, randomized study of prophylactic antibiotics in elective abdominal hysterectomy. *Journal of Hospital Infection.* 2002;52(4):302-306. doi:10.1053/jhin.2002.1312
192. Eckenhausen FW, Jonker PL. Antibiotic prophylaxis in abdominal hysterectomy, with special reference to the duration of the prophylaxis. *Pharmaceutisch Weekblad Scientific Edition.* 1990;12(6):289-291. doi:10.1007/BF01967835
-

-
193. Aarts JW, Nieboer TE, Johnson N, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Gynaecology and Fertility Group, ed. *Cochrane Database of Systematic Reviews*. Published online August 12, 2015. doi:10.1002/14651858.CD003677.pub5
194. Chang WC, Lee MC, Yeh LS, Hung YC, Lin CC, Lin LY. Quality-initiated prophylactic antibiotic use in laparoscopic-assisted vaginal hysterectomy. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2008;48(6):592-595. doi:10.1111/j.1479-828X.2008.00908.x
195. Brummer T, Heikkinen AM, Jalkanen J, et al. Antibiotic prophylaxis for hysterectomy, a prospective cohort study: cefuroxime, metronidazole, or both? *BJOG*. 2013;120(10):1269-1276. doi:10.1111/1471-0528.12178
196. Song N, Gao M, Tian J, Gao Y. Choice for prophylactic antibiotics: Cefazolin plus metronidazole or cefoxitin alone for endometrial cancer surgical staging. *J Obstet Gynaecol Res*. 2020;46(9):1864-1870. doi:10.1111/jog.14348
197. Bouma J, Dankert J. Infection after radical abdominal hysterectomy and pelvic lymphadenectomy: prevention of infection with a two-dose peri-operative antibiotic prophylaxis. *Int J Gynecol Cancer*. 1993;3(2):94-102. doi:10.1046/j.1525-1438.1993.03020094.x
198. Byun JM, Jeong DH. Antibiotic prophylaxis for gynecologic cancer surgery. *Taiwanese Journal of Obstetrics and Gynecology*. 2020;59(4):514-519. doi:10.1016/j.tjog.2020.05.008
199. Till SR, Morgan DM, Bazzi AA, et al. Reducing surgical site infections after hysterectomy: metronidazole plus cefazolin compared with cephalosporin alone. *American Journal of Obstetrics and Gynecology*. 2017;217(2):187.e1-187.e11. doi:10.1016/j.ajog.2017.03.019
200. Pop-Vicas A, Johnson S, Safdar N. Cefazolin as surgical antimicrobial prophylaxis in hysterectomy: A systematic review and meta-analysis of randomized controlled trials. *Infect Control Hosp Epidemiol*. 2019;40(2):142-149. doi:10.1017/ice.2018.286
201. Kocak I, Ustün C, Emre B, Uzel A. Antibiotics prophylaxis in laparoscopy. *Ceska Gynkol*. 2005;70(4):269-272.
202. Toba M, Moriwaki M, Oshima N, et al. Prevention of surgical site infection via antibiotic administration according to guidelines after gynecological surgery: Use of antibiotics to prevent SSI. *J Obstet Gynaecol Res*. 2018;44(9):1800-1807. doi:10.1111/jog.13714
203. Pereira N, Hutchinson AP, Lekovich JP, Hobeika E, Elias RT. Antibiotic Prophylaxis for Gynecologic Procedures prior to and during the Utilization of Assisted Reproductive Technologies: A Systematic Review. *Journal of Pathogens*. 2016;2016:4698314. doi:10.1155/2016/4698314
204. Morrill MY, Schimpf MO, Abed H, et al. Antibiotic prophylaxis for selected gynecologic surgeries. *International Journal of Gynecology & Obstetrics*. 2013;120(1):10-15. doi:10.1016/j.ijgo.2012.06.023
205. Thinkhamrop J, Laopaiboon M, Lumbiganon P. Prophylactic antibiotics for transcervical intrauterine procedures. Cochrane Gynaecology and Fertility Group, ed.
-

- Cochrane Database of Systematic Reviews*. Published online May 31, 2013. doi:10.1002/14651858.CD005637.pub3
206. Muzii L, Donato VD, Tucci CD, et al. Efficacy of Antibiotic Prophylaxis for Hysteroscopy: A Meta-Analysis of Randomized Trials. *Journal of Minimally Invasive Gynecology*. 2020;27(1):29-37. doi:10.1016/j.jmig.2019.07.006
207. Guo T, Zeng N, Yang J, et al. The clinical effects of antibiotic prophylaxis for hysteroscopic procedures: A meta-analysis. *Medicine*. 2019;98(34):e16964. doi:10.1097/MD.00000000000016964
208. McCausland VM, Fields GA, McCausland AM, Townsend DE. Tuboovarian abscesses after operative hysteroscopy. *J Reprod Med*. 1993;38(3):198-200.
209. Muzii L, Di Donato V, Boni T, et al. Antibiotics Prophylaxis for Operative Hysteroscopy: A Multicenter Randomized Controlled Clinical Study. *Reprod Sci*. 2017;24(4):534-538. doi:10.1177/1933719116660848
210. Nappi L, Sardo ADS, Spinelli M, et al. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess Whether Antibiotic Administration Should Be Recommended During Office Operative Hysteroscopy. *Reprod Sci*. 2013;20(7):755-761. doi:10.1177/1933719112466308
211. Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Sofoudis C, Creatsas G. Antibiotic prophylaxis in diagnostic hysteroscopy: is it necessary or not? *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2012;163(2):190-192. doi:10.1016/j.ejogrb.2012.03.027
212. Bhattacharya S, Parkin DE, Reid TMS, Abramovich DR, Mollison J, Kitchener HC. A prospective randomised study of the effects of prophylactic antibiotics on the incidence of bacteraemia following hysteroscopic surgery. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 1995;63(1):37-40. doi:10.1016/0301-2115(95)02218-V
213. Kasius JC, Broekmans FJ, Fauser BC, Devroey P, Fatemi HM. Antibiotic prophylaxis for hysteroscopy evaluation of the uterine cavity. *Fertility and Sterility*. 2011;95(2):792-794. doi:10.1016/j.fertnstert.2010.08.031
214. Pittaway DE, Winfield AC, Maxson W, Daniell J, Herbert C, Wentz AC. Prevention of acute pelvic inflammatory disease after hysterosalpingography: Efficacy of doxycycline prophylaxis. *American Journal of Obstetrics and Gynecology*. 1983;147(6):623-626. doi:10.1016/0002-9378(83)90438-6
215. Kietpeerakool C, Chumworathayi B, Thinkhamrop J, Ussahgij B, Lumbiganon P. Antibiotics for infection prevention after excision of the cervical transformation zone. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, ed. *Cochrane Database of Systematic Reviews*. 2017;1(1):CD009957. doi:10.1002/14651858.CD009957.pub2
216. Foden-Shroff J, Redman CWE, Tucker H, et al. Do routine antibiotics after loop diathermy excision reduce morbidity? *BJOG:An international journal of O&G*. 1998;105(9):1022-1025. doi:10.1111/j.1471-0528.1998.tb10268.x
217. Pūnevskā M, Arsenova B. [Results of treatment with doxycycline after diagnostic and therapeutic curettage]. *Akush Ginekol (Sofia)*. 2006;45(6):58-60.

-
218. Makris N, Iatrakis G, Sakellaropoulos G, Rodolakis A, Michalas S. The role of antibiotics after dilatation and curettage in women with metrorrhagia in the prevention of pelvic inflammatory disease. *Clin Exp Obstet Gynecol*. 2000;27(1):27-28.
219. Herawati F, Rahem A, Handayani D, Yulia R. Antibiotic prophylaxis on curettage for preventing pelvic inflammatory disease events: is it necessary? *Asian Journal of Pharmaceutical and Clinical Research*. 2018;11(11):267-269. doi:10.22159/ajpcr.2018.v11i11.27817
220. Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. *Obstet Gynecol*. 2017;130(5):e251-e269. doi:10.1097/AOG.0000000000002400
221. Black A, Guilbert E, Costescu D, et al. Canadian Contraception Consensus (Part 3 of 4): Chapter 7-Intrauterine Contraception. *J Obstet Gynaecol Can*. 2016;38(2):182-222. doi:10.1016/j.jogc.2015.12.002
222. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. *Cochrane Database of Systematic Reviews*. 2001;2:CD001327. doi:10.1002/14651858.CD001327
223. Sinei SKA, Schulz KF, Lamptey PR, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. *BJOG:An international journal of O&G*. 1990;97(5):412-419. doi:10.1111/j.1471-0528.1990.tb01828.x
224. Walsh TL, Bernstein GS, Grimes DA, Frezieres R, Bernstein L, Coulson AH. Effect of prophylactic antibiotics on morbidity associated with IUD insertion: Results of a pilot randomized controlled trial. *Contraception*. 1994;50(4):319-327. doi:10.1016/0010-7824(94)90019-1
225. Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. *Lancet*. 1998;351(9108):1005-1008. doi:10.1016/s0140-6736(97)09086-7
226. Zorlu CG, Aral K, Cobanoglu O, Gürler S, Gokmen O. Pelvic inflammatory disease and intrauterine devices: Prophylactic antibiotics to reduce febrile complications. *Adv Contracept*. 1993;9(4):299-302. doi:10.1007/BF01983207
227. Ladipo OA, Farr G, Otolorin E, et al. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. *Adv Contracept*. 1991;7(1):43-54. doi:10.1007/BF01850718
228. Centers for Disease Control and Prevention. Surgical Site Infection (SSI) Event. Accessed September 24, 2020. <https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscscssicurrent.pdf>
229. Anderson K, Hamm RL. Factors That Impair Wound Healing. *J Am Coll Clin Wound Spec*. 2012;4(4):84-91. doi:10.1016/j.jccw.2014.03.001
230. Scottish Intercollegiate Guidelines Network. *Antibiotic Prophylaxis in Surgery*. SIGN; 2008.
-

-
231. Henley MB, Jones RE, Wyatt RW, Hofmann A, Cohen RL. Prophylaxis with cefamandole nafate in elective orthopedic surgery. *Clin Orthop Relat Res*. 1986;(209):249-254.
232. Buckley R, Hughes GN, Snodgrass T, Huchcroft SA. Perioperative cefazolin prophylaxis in hip fracture surgery. *Can J Surg*. 1990;33(2):122-127.
233. Hedström SA, Lidgren L, Sernbo I, Törholm C, Onnerfält R. Cefuroxime prophylaxis in trochanteric hip fracture operations. *Acta Orthop Scand*. 1987;58(4):361-364. doi:10.3109/17453678709146355
234. Ryan SP, Kildow BJ, Tan TL, et al. Is There a Difference in Infection Risk Between Single and Multiple Doses of Prophylactic Antibiotics? A Meta-analysis. *Clin Orthop Relat Res*. 2019;477(7):1577-1590. doi:10.1097/CORR.0000000000000619
235. Inabathula A, Dilley JE, Ziemba-Davis M, et al. Extended Oral Antibiotic Prophylaxis in High-Risk Patients Substantially Reduces Primary Total Hip and Knee Arthroplasty 90-Day Infection Rate. *J Bone Joint Surg Am*. 2018;100(24):2103-2109. doi:10.2106/JBJS.17.01485
236. Kuo FC, Aalirezaie A, Goswami K, Shohat N, Blevins K, Parvizi J. Extended Antibiotic Prophylaxis Confers No Benefit Following Aseptic Revision Total Hip Arthroplasty: A Matched Case-Controlled Study. *J Arthroplasty*. 2019;34(11):2724-2729. doi:10.1016/j.arth.2019.06.012
237. Crist BD, Oladeji LO, Della Rocca GJ, Volgas DA, Stannard JP, Greenberg DD. Evaluating the Duration of Prophylactic Post-Operative Antibiotic Agents after Open Reduction Internal Fixation for Closed Fractures. *Surg Infect (Larchmt)*. 2018;19(5):535-540. doi:10.1089/sur.2018.018
238. Tan TL, Shohat N, Rondon AJ, et al. Perioperative Antibiotic Prophylaxis in Total Joint Arthroplasty: A Single Dose Is as Effective as Multiple Doses. *J Bone Joint Surg Am*. 2019;101(5):429-437. doi:10.2106/JBJS.18.00336
239. Tang WM, Chiu KY, Ng TP, Yau WP, Ching PTY, Seto WH. Efficacy of a single dose of cefazolin as a prophylactic antibiotic in primary arthroplasty. *J Arthroplasty*. 2003;18(6):714-718. doi:10.1016/s0883-5403(03)00201-8
240. Gillespie WJ, Walenkamp GH. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. *Cochrane Database Syst Rev*. 2010;(3):CD000244. doi:10.1002/14651858.CD000244.pub2
241. North America Spine Society. *Clinical Guidelines for Multidisciplinary Spine Care: Antibiotic Prophylaxis in Spine Surgery*. North American Spine Society; 2013.
242. Urquhart JC, Collings D, Nutt L, et al. The Effect of Prolonged Postoperative Antibiotic Administration on the Rate of Infection in Patients Undergoing Posterior Spinal Surgery Requiring a Closed-Suction Drain: A Randomized Controlled Trial. *J Bone Joint Surg Am*. 2019;101(19):1732-1740. doi:10.2106/JBJS.19.00009
243. Takemoto RC, Lonner B, Andres T, et al. Appropriateness of Twenty-four-Hour Antibiotic Prophylaxis After Spinal Surgery in Which a Drain Is Utilized: A Prospective Randomized Study. *J Bone Joint Surg Am*. 2015;97(12):979-986. doi:10.2106/JBJS.L.00782
-

-
244. Hellbusch LC, Helzer-Julin M, Doran SE, et al. Single-dose vs multiple-dose antibiotic prophylaxis in instrumented lumbar fusion--a prospective study. *Surg Neurol*. 2008;70(6):622-627; discussion 627. doi:10.1016/j.surneu.2007.08.017
245. Kim B, Moon SH, Moon ES, et al. Antibiotic Microbial Prophylaxis for Spinal Surgery: Comparison between 48 and 72-Hour AMP Protocols. *Asian Spine J*. 2010;4(2):71-76. doi:10.4184/asj.2010.4.2.71
246. Kamath VHD, Cheung JPY, Mak KC, et al. Antimicrobial prophylaxis to prevent surgical site infection in adolescent idiopathic scoliosis patients undergoing posterior spinal fusion: 2 doses versus antibiotics till drain removal. *Eur Spine J*. 2016;25(10):3242-3248. doi:10.1007/s00586-016-4491-7
247. Maciejczak A, Wolan-Nieroda A, Wałaszek M, Kołpa M, Wolak Z. Antibiotic prophylaxis in spine surgery: a comparison of single-dose and 72-hour protocols. *J Hosp Infect*. 2019;103(3):303-310. doi:10.1016/j.jhin.2019.04.017
248. Patel PN, Jayawardena ADL, Walden RL, Penn EB, Francis DO. Evidence-Based Use of Perioperative Antibiotics in Otolaryngology. *Otolaryngol Head Neck Surg*. 2018;158(5):783-800. doi:10.1177/0194599817753610
249. Avenia N, Sanguinetti A, Cirocchi R, et al. Antibiotic prophylaxis in thyroid surgery: a preliminary multicentric Italian experience. *Ann Surg Innov Res*. 2009;3:10. doi:10.1186/1750-1164-3-10
250. Medas F, Canu GL, Cappellacci F, et al. Antibiotic Prophylaxis for Thyroid and Parathyroid Surgery: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg*. 2021;164(3):482-488. doi:10.1177/0194599820947700
251. Shkedy Y, Alkan U, Roman BR, et al. Role of perioperative antibiotic treatment in parotid gland surgery. *Head Neck*. 2016;38 Suppl 1:E1876-1880. doi:10.1002/hed.24339
252. Vila PM, Zenga J, Jackson RS. Antibiotic Prophylaxis in Clean-Contaminated Head and Neck Surgery: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg*. 2017;157(4):580-588. doi:10.1177/0194599817712215
253. Vander Poorten V, Uyttebroek S, Robbins KT, et al. Perioperative Antibiotics in Clean-Contaminated Head and Neck Surgery: A Systematic Review and Meta-Analysis. *Adv Ther*. 2020;37(4):1360-1380. doi:10.1007/s12325-020-01269-2
254. Haidar YM, Tripathi PB, Tjoa T, et al. Antibiotic prophylaxis in clean-contaminated head and neck cases with microvascular free flap reconstruction: A systematic review and meta-analysis. *Head Neck*. 2018;40(2):417-427. doi:10.1002/hed.24988
255. Miles BA, Potter JK, Ellis E. The efficacy of postoperative antibiotic regimens in the open treatment of mandibular fractures: a prospective randomized trial. *J Oral Maxillofac Surg*. 2006;64(4):576-582. doi:10.1016/j.joms.2006.01.003
256. Liu SA, Tung KC, Shiao JY, Chiu YT. Preliminary report of associated factors in wound infection after major head and neck neoplasm operations--does the duration of prophylactic antibiotic matter? *J Laryngol Otol*. 2008;122(4):403-408. doi:10.1017/S0022215107007529
-

-
257. Mustafa E, Tahsin A. Cefotaxime prophylaxis in major non-contaminated head and neck surgery: one-day vs. seven-day therapy. *J Laryngol Otol.* 1993;107(1):30-32. doi:10.1017/s0022215100122054
258. Taghy M, Ashtiani K, Sadeghi M, Saedi B, Givechi G. Comparative study of two cefazolin prophylactic protocols in oncologic surgery of the larynx: A randomized trial. *Indian J Otolaryngol Head Neck Surg.* 2010;62(1):55-59. doi:10.1007/s12070-010-0002-z
259. Khariwala SS, Le B, Pierce BHG, Vogel RI, Chipman JG. Antibiotic Use after Free Tissue Reconstruction of Head and Neck Defects: Short Course vs. Long Course. *Surg Infect (Larchmt).* 2016;17(1):100-105. doi:10.1089/sur.2015.131
260. Langerman A, Thisted R, Hohmann S, Howell M. Antibiotic and Duration of Perioperative Prophylaxis Predicts Surgical Site Infection in Head and Neck Surgery. *Otolaryngol Head Neck Surg.* 2016;154(6):1054-1063. doi:10.1177/0194599816634303
261. Lovato C, Wagner JD. Infection rates following perioperative prophylactic antibiotics versus postoperative extended regimen prophylactic antibiotics in surgical management of mandibular fractures. *J Oral Maxillofac Surg.* 2009;67(4):827-832. doi:10.1016/j.joms.2008.06.093
262. Mitchell RM, Mendez E, Schmitt NC, Bhrany AD, Futran ND. Antibiotic Prophylaxis in Patients Undergoing Head and Neck Free Flap Reconstruction. *JAMA Otolaryngol Head Neck Surg.* 2015;141(12):1096-1103. doi:10.1001/jamaoto.2015.0513
263. Righi M, Manfredi R, Farneti G, Pasquini E, Cenacchi V. Short-term versus long-term antimicrobial prophylaxis in oncologic head and neck surgery. *Head Neck.* 1996;18(5):399-404. doi:10.1002/(SICI)1097-0347(199609/10)18:5<399::AID-HED2>3.0.CO;2-0
264. Carroll WR, Rosenstiel D, Fix JR, et al. Three-dose vs extended-course clindamycin prophylaxis for free-flap reconstruction of the head and neck. *Arch Otolaryngol Head Neck Surg.* 2003;129(7):771-774. doi:10.1001/archotol.129.7.771
265. Bartella AK, Kamal M, Teichmann J, et al. Prospective comparison of perioperative antibiotic management protocols in oncological head and neck surgery. *J Craniomaxillofac Surg.* 2017;45(7):1078-1082. doi:10.1016/j.jcms.2017.04.001
266. Cohen LE, Finnerty BM, Golas AR, et al. Perioperative Antibiotics in the Setting of Oropharyngeal Reconstruction: Less Is More. *Ann Plast Surg.* 2016;76(6):663-667. doi:10.1097/SAP.0000000000000291
267. Carrau RL, Byzakis J, Wagner RL, Johnson JT. Role of prophylactic antibiotics in uncontaminated neck dissections. *Arch Otolaryngol Head Neck Surg.* 1991;117(2):194-195. doi:10.1001/archotol.1991.01870140082011
268. Seven H, Sayin I, Turgut S. Antibiotic prophylaxis in clean neck dissections. *J Laryngol Otol.* 2004;118(3):213-216. doi:10.1258/002221504322927991
269. Man LX, Beswick DM, Johnson JT. Antibiotic prophylaxis in uncontaminated neck dissection. *Laryngoscope.* 2011;121(7):1473-1477. doi:10.1002/lary.21815
-

-
270. Verschuur HP, de Wever WWH, van Benthem PPG. Antibiotic prophylaxis in clean and clean-contaminated ear surgery. *Cochrane Database Syst Rev.* 2004;(3):CD003996. doi:10.1002/14651858.CD003996.pub2
271. Bidkar VG, Jalisatigi RR, Naik AS, et al. Perioperative only versus extended antimicrobial usage in tympanomastoid surgery: a randomized trial. *Laryngoscope.* 2014;124(6):1459-1463. doi:10.1002/lary.24544
272. Govaerts PJ, Raemaekers J, Verlinden A, Kalai M, Somers T, Offeciers FE. Use of antibiotic prophylaxis in ear surgery. *Laryngoscope.* 1998;108(1 Pt 1):107-110. doi:10.1097/00005537-199801000-00020
273. Pierce NE, Antonelli PJ. Efficacy of antibiotic prophylaxis prior to tympanoplasty for contaminated cholesteatoma. *Laryngoscope.* 2016;126(10):2363-2366. doi:10.1002/lary.26192
274. Dhiwakar M, Eng CY, Selvaraj S, McKerrow WS. Antibiotics to improve recovery following tonsillectomy: a systematic review. *Otolaryngol Head Neck Surg.* 2006;134(3):357-364. doi:10.1016/j.otohns.2005.12.016
275. Dhiwakar M, Clement WA, Supriya M, McKerrow W. Antibiotics to reduce post-tonsillectomy morbidity. *Cochrane Database Syst Rev.* 2012;12:CD005607. doi:10.1002/14651858.CD005607.pub4
276. Rajan GP, Fergie N, Fischer U, Romer M, Radivojevic V, Hee GK. Antibiotic prophylaxis in septorhinoplasty? A prospective, randomized study. *Plast Reconstr Surg.* 2005;116(7):1995-1998. doi:10.1097/01.prs.0000191181.73298.b3
277. Andrews PJ, East CA, Jayaraj SM, Badia L, Panagamuwa C, Harding L. Prophylactic vs postoperative antibiotic use in complex septorhinoplasty surgery: a prospective, randomized, single-blind trial comparing efficacy. *Arch Facial Plast Surg.* 2006;8(2):84-87. doi:10.1001/archfaci.8.2.84
278. Nuyen B, Kandathil CK, Laimi K, Rudy SF, Most SP, Saltychev M. Evaluation of Antibiotic Prophylaxis in Rhinoplasty: A Systematic Review and Meta-analysis. *JAMA Facial Plast Surg.* 2019;21(1):12-17. doi:10.1001/jamafacial.2018.1187
279. Lange JL, Peeden EH, Stringer SP. Are prophylactic systemic antibiotics necessary with nasal packing? A systematic review. *Am J Rhinol Allergy.* 2017;31(4):240-247. doi:10.2500/ajra.2017.31.4454
280. Saleh AM, Torres KM, Murad MH, Erwin PJ, Driscoll CLW. Prophylactic perioperative antibiotic use in endoscopic sinus surgery: a systematic review and meta-analysis. *Otolaryngol Head Neck Surg.* 2012;146(4):533-538. doi:10.1177/0194599811434117
281. Liang KL, Su YC, Tsai CC, Lin JS, Jiang RS, Su MC. Postoperative care with Chinese herbal medicine or amoxicillin after functional endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. *Am J Rhinol Allergy.* 2011;25(3):170-175. doi:10.2500/ajra.2011.25.3610
282. Albu S, Lucaciu R. Prophylactic antibiotics in endoscopic sinus surgery: a short follow-up study. *Am J Rhinol Allergy.* 2010;24(4):306-309. doi:10.2500/ajra.2010.24.3475
283. Lehmann AE, Raquib AR, Siddiqi SH, et al. Prophylactic antibiotics after endoscopic sinus surgery for chronic rhinosinusitis: a randomized, double-blind, placebo-controlled
-

- noninferiority clinical trial. *Int Forum Allergy Rhinol*. Published online December 19, 2020. doi:10.1002/alr.22756
284. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis*. 2004;39(9):1267-1284. doi:10.1086/425368
285. Abraham P, Lamba N, Acosta M, et al. Antibacterial prophylaxis for gram-positive and gram-negative infections in cranial surgery: A meta-analysis. *J Clin Neurosci*. 2017;45:24-32. doi:10.1016/j.jocn.2017.07.039
286. Liu W, Neidert MC, Groen RJM, Woernle CM, Grundmann H. Third-generation cephalosporins as antibiotic prophylaxis in neurosurgery: what's the evidence? *Clin Neurol Neurosurg*. 2014;116:13-19. doi:10.1016/j.clineuro.2013.10.015
287. Barker FG. Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. *Neurosurgery*. 2007;60(5):887-894; discussion 887-894. doi:10.1227/01.NEU.0000255425.31797.23
288. Fried HI, Nathan BR, Rowe AS, et al. The Insertion and Management of External Ventricular Drains: An Evidence-Based Consensus Statement: A Statement for Healthcare Professionals from the Neurocritical Care Society. *Neurocrit Care*. 2016;24(1):61-81. doi:10.1007/s12028-015-0224-8
289. Murphy RKJ, Liu B, Srinath A, et al. No additional protection against ventriculitis with prolonged systemic antibiotic prophylaxis for patients treated with antibiotic-coated external ventricular drains. *J Neurosurg*. 2015;122(5):1120-1126. doi:10.3171/2014.9.JNS132882
290. Sonabend AM, Korenfeld Y, Crisman C, Badjatia N, Mayer SA, Connolly ES. Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review. *Neurosurgery*. 2011;68(4):996-1005. doi:10.1227/NEU.0b013e3182096d84
291. Alleyne CH, Hassan M, Zabramski JM. The efficacy and cost of prophylactic and perioperative antibiotics in patients with external ventricular drains. *Neurosurgery*. 2000;47(5):1124-1127; discussion 1127-1129. doi:10.1097/00006123-200011000-00020
292. May AK, Fleming SB, Carpenter RO, et al. Influence of broad-spectrum antibiotic prophylaxis on intracranial pressure monitor infections and subsequent infectious complications in head-injured patients. *Surg Infect (Larchmt)*. 2006;7(5):409-417. doi:10.1089/sur.2006.7.409
293. Jacobs DG, Westerband A. Antibiotic prophylaxis for intracranial pressure monitors. *J Natl Med Assoc*. 1998;90(7):417-423.
294. Tacconelli E, Cataldo MA, Albanese A, et al. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of methicillin-resistant *Staphylococcus aureus*. *J Hosp Infect*. 2008;69(4):337-344. doi:10.1016/j.jhin.2008.04.032
295. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. *Cochrane Database Syst Rev*. 2006;(3):CD005365. doi:10.1002/14651858.CD005365.pub2

-
296. Arnaboldi L. Antimicrobial prophylaxis with ceftriaxone in neurosurgical procedures. A prospective study of 100 patients undergoing shunt operations. *Chemotherapy*. 1996;42(5):384-390. doi:10.1159/000239470
297. Lightner DJ KL. Urologic Procedures and Antimicrobial Prophylaxis (2019) - American Urological Association. Accessed April 28, 2021. [https://www.auanet.org/guidelines/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-\(2019\)](https://www.auanet.org/guidelines/guidelines/urologic-procedures-and-antimicrobial-prophylaxis-(2019))
298. Zeng S, Zhang Z, Bai Y, Sun Y, Xu C. Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy. *Cochrane Database Syst Rev*. 2019;2:CD012305. doi:10.1002/14651858.CD012305.pub2
299. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan Italy 2021. ISBN 978-94-92671-13-4. Accessed September 1, 2020. <https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urological-infections-2021.pdf>
300. Togo Y, Fukui K, Ueda Y, et al. Comparison of single- and multiple-dose cefazolin as prophylaxis for transurethral enucleation of prostate: A multicenter, prospective, randomized controlled trial by the Japanese Research Group for Urinary Tract Infection. *Int J Urol*. 2020;27(3):244-248. doi:10.1111/iju.14181
301. Zani EL, Clark OAC, Rodrigues Netto N. Antibiotic prophylaxis for transrectal prostate biopsy. *Cochrane Database Syst Rev*. 2011;(5):CD006576. doi:10.1002/14651858.CD006576.pub2
302. Ho HSS, Ng LG, Tan YH, Yeo M, Cheng CWS. Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. *Ann Acad Med Singap*. 2009;38(3):212-216.
303. Marino K, Parlee A, Orlando R, Lerner L, Strymish J, Gupta K. Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. *Antimicrob Agents Chemother*. 2015;59(12):7273-7275. doi:10.1128/AAC.01457-15
304. Cussans A, Somani BK, Basarab A, Dudderidge TJ. The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. *BJU Int*. 2016;117(5):725-731. doi:10.1111/bju.13402
305. Klemann N, Helgstrand JT, Brasso K, Vainer B, Iversen P, Røder MA. Antibiotic prophylaxis and complications following prostate biopsies - a systematic review. *Dan Med J*. 2017;64(1).
306. Kehinde EO, Al-Maghrebi M, Sheikh M, Anim JT. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. *J Urol*. 2013;189(3):911-915. doi:10.1016/j.juro.2012.08.237
307. Baba K, Sekine Y, Miyazawa Y, et al. Assessment of antimicrobial prophylaxis in transperineal prostate biopsy: A single-center retrospective study of 485 cases. *J Infect Chemother*. 2018;24(8):637-640. doi:10.1016/j.jiac.2018.03.014
308. Taoka R, Togo Y, Kubo T, et al. Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: multicenter cohort study. *J Infect Chemother*. 2013;19(5):926-930. doi:10.1007/s10156-013-0610-0
-

-
309. Szabo RJ. Free-Hand Transperineal Prostate Biopsy Under Local Anesthesia in the Office Without Antibiotic Prophylaxis: Experience with 304 Cases. *J Endourol*. Published online March 31, 2021. doi:10.1089/end.2020.1086
310. Chew BH, Flannigan R, Kurtz M, et al. A Single Dose of Intraoperative Antibiotics Is Sufficient to Prevent Urinary Tract Infection During Ureteroscopy. *J Endourol*. 2016;30(1):63-68. doi:10.1089/end.2015.0511
311. Deng T, Liu B, Duan X, et al. Antibiotic prophylaxis in ureteroscopic lithotripsy: a systematic review and meta-analysis of comparative studies. *BJU Int*. 2018;122(1):29-39. doi:10.1111/bju.14101
312. Haider M, Ladurner C, Mayr R, et al. Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. *Urol Oncol*. 2019;37(5):300.e9-300.e15. doi:10.1016/j.urolonc.2019.01.017
313. Mrkobrada M, Ying I, Mokrycke S, et al. CUA Guidelines on antibiotic prophylaxis for urologic procedures. *Can Urol Assoc J*. 2015;9(1-2):13-22. doi:10.5489/cuaj.2382
314. The ADAPTE Collaboration (2009). The ADAPTE Process: Resource Toolkit for Guideline Adaptation. Version 2.0.
315. Antibiotic Expert Groups. *Therapeutic Guidelines: Antibiotic. Version 15*. Therapeutic Guidelines Limited; 2014.
316. Sullivan SA, Smith T, Chang E, Hulse T, Vandorsten JP, Soper D. Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized, controlled trial. *Am J Obstet Gynecol*. 2007;196(5):455.e1-5. doi:10.1016/j.ajog.2007.03.022
317. Baggish MS, Sze EH. Endometrial ablation: a series of 568 patients treated over an 11-year period. *Am J Obstet Gynecol*. 1996;174(3):908-913. doi:10.1016/s0002-9378(96)70324-1
318. Carey MM, Zreik A, Fenn NJ, Chlosta PL, Aboumarzouk OM. Should We Use Antibiotic Prophylaxis for Flexible Cystoscopy? A Systematic Review and Meta-Analysis. *Urol Int*. 2015;95(3):249-259. doi:10.1159/000381882
319. García-Perdomo HA, López H, Carbonell J, Castillo D, Cataño JG, Serón P. Efficacy of antibiotic prophylaxis in patients undergoing cystoscopy: a randomized clinical trial. *World J Urol*. 2013;31(6):1433-1439. doi:10.1007/s00345-013-1034-2
320. Grummet JP, Weerakoon M, Huang S, et al. Sepsis and “superbugs”: should we favour the transperineal over the transrectal approach for prostate biopsy? *BJU Int*. 2014;114(3):384-388. doi:10.1111/bju.12536
321. Chew BH, Miller NL, Abbott JE, et al. A Randomized Controlled Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy in a Low Infectious Risk Population: A Report from the EDGE Consortium. *J Urol*. 2018;200(4):801-808. doi:10.1016/j.juro.2018.04.062
322. Haifler M, Mor Y, Dotan Z, Ramon J, Zilberman DE. Prophylactic antibiotic treatment following laparoscopic robot-assisted radical prostatectomy for the prevention of catheter-
-

associated urinary tract infections: did the AUA guidelines make a difference? *J Robot Surg.* 2017;11(3):367-371. doi:10.1007/s11701-016-0667-8